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Abstract
Gestational diabetes mellitus (GDM) is an increasingly prevalent form of diabetes that
first appears during pregnancy, and reverses after parturition in most cases. Nonetheless,
GDM is associated with adverse maternal and fetal health outcomes. There is currently
no reliable method of intervention for GDM and a limited understanding of the
mechanisms of impaired endocrine adaptability in GDM. In this thesis, I aimed to address
these knowledge gaps by establishing a mouse model for the study of suboptimal
endocrine adaptations during pregnancy. This was accomplished using a dietary low
protein (LP) insult during fetal and neonatal development, which programs for
suboptimal pancreas development in the offspring, and performing histomorphometric
analyses on fixed pancreas tissues. Female offspring displayed glucose intolerance during
their own pregnancy that was apparent by gestational day (GD) 18.5 and characterized by
reduced β-cell mass (BCM) and α-cell mass (ACM) relative to control-fed animals. Using
this model, I provided evidence that pancreatic maladaptations at GD18.5 persisted at
postpartum day 7.5, contributing to glucose intolerance until 1 month after parturition. To
provide mechanistic insights of reduced BCM expansion in GDM, I investigated the
contribution of α- to β-cell transdifferentiation via immunofluorescence cell counting
analysis of fixed pancreas tissues. I identified maladaptations of α-cell plasticity in
glucose-intolerant mice, as demonstrated by reduced α-cell proliferation, leading to
reduced ACM expansion relative to controls. Additionally, these animals presented with
hyperglucagonemia. These findings demonstrated that, in addition to β-cells, insufficient
pancreatic α-cell adaptations can also contribute to GDM pathogenesis. Although there
were differences in the percentages of bihormonal (Insulin+Glucagon+) cells in LP vs.
control pregnancy, genetic lineage tracing in control pregnancy using GlucagonCre/Rosa26-eYFP mice revealed a negligible amount of α- to β-cell transdifferentiation
contributing to BCM expansion. Finally, I used the animal model to test a therapeutic
intervention for GDM through the attempted manipulation of BCM using the artemisinin,
artesunate. Artesunate-treated animals had improved glucose tolerance, although the
glucose-lowering effect was attributed to the acetone vehicle. Collectively, this thesis has
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identified mechanisms of impaired endocrine pancreas adaptability in GDM and has
established a mouse model that can be used to explore novel therapeutics.
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Summary for Lay Audience
Diabetes occurs when there is a loss or dysfunction of insulin-producing β-cells in the
pancreas, leading to elevated blood sugar levels. Diabetes is often classified as either
being type 1 or type 2. However, gestational diabetes mellitus (GDM) is another type of
diabetes that first presents during pregnancy and is becoming increasingly prevalent.
Although human pancreas samples during GDM are scarce, it is believed that β-cell
dysfunction is a major driver of GDM pathogenesis. In this thesis, I sought to develop a
mouse model that can be used to better understand the reasons for suboptimal pancreas
adaptations in GDM. First, I established the mouse model using a dietary insult (low
protein) during early life, which results in suboptimal pancreas development in the
offspring. As is diagnosed in humans, these animals presented with GDM identified
during late gestation (which in mice is around gestational day 18.5) due to impairments in
β-cell number and the capacity for insulin release. Since many women go on to develop
type 2 diabetes mellitus after delivery, I also presented evidence that these impairments in
the pancreas are still present following birth and contribute to high blood sugar levels
until at least one month postpartum. Using our mouse model, I demonstrated that diabetes
develops not only due to impairments in β-cells, but also due to abnormalities in
pancreatic α-cells, which work antagonistically with β-cells to secrete glucagon. Finally, I
identified a therapeutic effect in GDM where there was a reversal of diabetes in animals
treated with a chemical that likely damages the gut equivalent to transient fasting. This
thesis characterized a novel mouse model of GDM and provides new information about
mechanisms of suboptimal pancreas adaptations that can be used to explore methods of
treatment.
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Chapter 1

Sections of this chapter have been published:

S.K. Szlapinski, D. Hill. Metabolic Adaptations To Pregnancy In Healthy And
Gestational Diabetic Pregnancies: The Pancreas – Placenta Axis, Curr. Vasc. Pharmacol.
18 (2020). https://doi.org/10.2174/1570161118666200320111209.
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1

Introduction

The disease report conducted by the World Health Organization from 2000 to 2015 lists
diabetes mellitus (DM), which was not on the report previously, as the top 6th leading
cause of death in 2015 killing 1.6 million people worldwide [1]. DM is a metabolic
disorder characterized by increased levels of glucose in the blood (hyperglycemia). When
left uncontrolled, DM can result in multiple adverse health complications such as damage
to the nerves and blood vessels increasing the risk of cardiovascular disease [2],
nephropathy [3] and retinopathy [4].

1.1

Diabetes

There are two main types of diabetes, Type I diabetes mellitus (T1DM) and Type II
diabetes mellitus (T2DM). T1DM is characterized by insufficient insulin production
while T2DM occurs when the body is unable to effectively use insulin. Insulin is a
hormone produced by pancreatic beta (β)-cells, which are cells located in the endocrine
portion of the pancreas called the islets of Langerhans. Insulin binds the insulin receptor,
a tyrosine kinase, on target tissues (liver, adipose, muscle) resulting in
autophosphorylation and subsequent phosphorylation of downstream targets [5]. This
ultimately leads to translocation of vesicles containing glucose transporters (i.e. Glut1,
Glut4) to the cell membrane and regulates glucose uptake in target tissues [5].
Insulin was first isolated by Sir Frederick Banting and colleagues Charles Best, James
Collip and John Macleod in 1922 which revolutionized treatment for individuals with
T1DM [6]. This life-saving treatment is now given via exogenous insulin therapy. The
protein, insulin, was isolated from pancreas extract samples and injected into dogs with
pancreatectomy-induced diabetes, which resulted in lowering of blood glucose levels.
In individuals with T1DM, insulin deficiency occurs due to autoimmune destruction of
insulin producing β-cells [5]. Autoimmune destruction of β-cells is mediated by T-cell
activation through direct cell toxicity and β-cell specific autoantibodies [7]. T1DM is the
less common form of diabetes as it accounts for only 5-10% of all cases of diabetes.
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Symptoms include fatigue, weight loss, polyuria and dehydration. Individuals with
T1DM require exogenous insulin therapy to maintain euglycemia. Transplantation of
cadaveric human islets or whole pancreas as a strategy for diabetes reversal has also been
undertaken but is limited by the shortage of organ supply from deceased donors which
does not meet the demand for islet transplantations [8]. A combination of predispositions
for T1DM have been suggested including viral exposure and genetic susceptibility [9].
T2DM is the more common form of diabetes (>90% of patients with diabetes) and occurs
when insulin secretion is suboptimal [10]. T2DM often includes peripheral insulin
resistance, meaning that target tissues are unable to respond to insulin resulting in
hyperglycemia. However, the major driver of T2DM is suggested to be β-cell dysfunction
with particularly a marked reduction of first-phase insulin secretion [11]. Individuals with
T2DM can manage blood glucose levels with lifestyle changes including diet and
exercise. Antihyperglycemic therapeutics can also be used, such as glucagon-like peptide
1 (GLP-1) receptor agonists, metformin and sodium-glucose cotransporter 2 (SGLT2)
inhibitors. Each therapeutic works to either decrease blood glucose levels or increase
insulin secretion in effort to attain euglycemia. Metformin reduces gluconeogenesis in the
liver, GLP-1 receptor agonists enhance glucose-stimulated insulin secretion (GSIS), and
SGLT2 inhibitors block the reabsorption of filtered glucose in the kidney [12]. The
prevalence of T2DM is drastically increasing as the susceptibility is influenced by
lifestyle factors such as obesity, age and a sedentary lifestyle [13]. This is concerning due
to the various health risks associated with T2DM including cardiovascular disease,
neuropathy and nephropathy [12].
Both T1DM and T2DM show the vital role that pancreatic β-cells play in maintaining
euglycemia which demonstrates the important role of the pancreas in the physiology of
regulating glucose homeostasis.
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1.2

Pancreas Anatomy and Development

The pancreas is an organ located in the abdominal cavity. In humans, the head of the
pancreas is attached at the initial curve of the duodenum of the small intestine, while the
tail is attached to the spleen (Fig. 1.1). The body of the pancreas is found between the tail
and head. This organization differs from that observed in mice, where 3 less defined
lobes (duodenal, gastric and splenic) are present. The pancreas has both endocrine and
exocrine functions, with only ~1-2% of the pancreas being endocrine despite its critical
role in glucose homeostasis. Endocrine cells of the pancreas are congregated in the islets
of Langerhans and secrete various hormones. Exocrine cells comprise the remaining
~98% of the pancreas including acinar and duct cells which secrete pancreatic fluids
containing digestive enzymes into the small intestine.
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Figure 1.1. Anatomical location of the pancreas
The pancreas is located behind the stomach in the upper left abdomen. The endocrine
portion, the islets of Langerhans, are found dispersed throughout the head and tail of the
pancreas and function to regulate glucose metabolism. The exocrine portion is
characterized as a highly branched ductal system, which secretes digestive enzymes into
the small intestine through the pancreatic duct. Reproduced from Human Anatomy and
Physiology, an OpenStax College resource [14].
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All pancreatic progenitor cells express the transcription factor pancreatic duodenal
homeobox-1 (Pdx1) [15], which is a key regulator of pancreas development, β-cell
differentiation and maintenance of β-cell function in mature β-cells [16]. In mice,
development of pancreatic tissue begins at embryonic day (E) 8.5 when expression of
Pdx1 is induced in the endodermal epithelium of the foregut [17]. This is followed by
formation of the dorsal and ventral pancreatic buds from the foregut endoderm at E9.5.
Expression of pancreas associated transcription factor 1a (Ptf1), the key transcriptional
regulator promoting exocrine cell specification [18], is initiated at E9.5, with Pdx1 coexpression from E9.5-12.5 [19]. Both Pdx1 and Ptf1a are essential for appropriate
endocrine and exocrine pancreas lineage specification, as animal models lacking these
transcription factors demonstrate pancreatic defects such as incomplete branching,
expansion and differentiation [18,20]. Each pancreatic bud develops into a highly
branched ductal-tree structure of undifferentiated ductal epithelium [21]. By E14.5, both
pancreatic buds rotate and fuse into a single organ [21]. Contained within the dorsal and
ventral pancreatic buds are multipotent progenitor cells (MPC) forming a multilayered
epithelium. The MPCs are able to give rise to endocrine, acinar and duct cells. From
E12.5-15.5, the MPCs in the dorsal bud proliferate causing pancreatic bud expansion.
Endocrine cells are present from the beginning of pancreatic development arising from
MPCs in the gut endoderm by E9.5, while acinar cell clusters differentiate from ductal
epithelium and are visible by E14.5 [22,23]. The differentiation of MPCs into either
endocrine/ductal or acinar exocrine lineages occurs as MPCs are segregated into either
the trunk or tip domains, respectively. The allocation of MPCs to either domain is
regulated by the balance of the transcription factors Ptf1a, which favors tip formation,
and homeobox protein Nkx6.1, which induces trunk formation [23,24]. Thus, both
endocrine and exocrine compartments in the mouse and human fetus arise from
endodermal pancreatic epithelium during development. However, the expression of the
transcription factor neurogenin3 (Ngn3) plays a major role in the lineage switch that is
required for development of all endocrine cell types [25,26].
Expression of the pancreatic hormone, glucagon, occurs as early as E9.5 and is followed
by insulin co-expression by E10.5 [21]. Studies have demonstrated an increase in
messenger ribonucleic acid (mRNA) encoding endocrine hormones between E14.5-
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E20.5, indicating endocrine cell morphological development [27]. On E16.5 the
endocrine cells that were previously organized as single cells within the ductal
epithelium, become organized as clusters [21]. By E19.5, the endocrine clusters, termed
the islets of Langerhans, become regulated by specific transcription factors to produce
either alpha (α), β, epsilon (), delta () or pancreatic polypeptide/gamma (γ) cells. In
both mice and humans, the majority of the islet is composed of α- and β-cells, while the
remaining minority of composition of the islet contain , γ and -cells. Nonetheless, islet
composition and architecture vary between these species. In mice, β-cells are localized to
the core of the islet, encompassing 60-80% of the islet, while α-cells are contained within
the mantle and compose only 10-20%. In contrast, human islets do not display this coremantle arrangement, with most islet cell types being dispersed throughout the islet.
Additionally, in humans, 50-70% of the islet is composed of β-cells while α-cells account
for 20-40% [28]. These two endocrine cell types play a critical role in maintaining
glucose homeostasis by functioning in an antagonistic manner, whereby the intra-islet
hypothesis states that insulin inhibits glucagon secretion [29]. β-cells secrete insulin in
response to high blood glucose levels (i.e. fed state), resulting in glycolysis or glucose
uptake in peripheral organs and initiating a decrease in blood glucose levels. On the other
hand, α-cells secrete glucagon in response to fasting conditions to increase blood glucose
levels via glycogenolysis in the liver and muscle. In order to maintain glucose
homeostasis, islet cells receive information about neighbouring cells through paracrine
interactions [29,30]. For example, studies have shown that paracrine intra-islet glucagon
signaling is essential for maintaining appropriate secretion of insulin from β-cells [29].
An additional study showed that the pancreatic islet establishes the ‘glycemic set-point’
in the body [30]. This process relies on paracrine input of neighbouring α-cells in the islet
to regulate insulin secretion from β-cells. The transcriptional balance of α- and β-cells is
regulated by changes in the expression of V-maf musculoaponeurotic fibrosarcoma
oncogene homolog A (MafA) and MafB transcription factors. MafA levels increase in
mature β-cells while MafB expression becomes restricted to α-cells [31]. In addition to
MafA, mature β-cells express multiple transcription factors including neurogenic
differentiation 1 (NeuroD), paired box gene4 (Pax4), Homeobox protein Nkx2.2
(Nkx2.2), and Nkx6.1 [19,32]. A transcriptional network listing some of the key
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transcription factors involved in endocrine cell lineage development is shown in Figure
1.2. Together with α- and β-cells, islets also contain hormone-producing -, γ- and cells. -cells produce somatostatin which acts as an important regulator of paracrine
inhibition of insulin and glucagon secretion while also controlling gastric emptying [33].
Novel studies have started to explore the mechanisms involved in -cell secretion in
regulating blood glucose levels in more detail [34–36]. -cells have filopodia that enable
interaction with many islet cell types despite their low prevalence (~5% of islet cell
types) [36]. Somatostatin is released via adenosine triphosphate (ATP)-sensitive
potassium channels (K+ATP channels) but can also be released in response to glucose
stimulation via K+ATP channel-independent mechanisms [35]. It is postulated that
defective somatostatin secretion can occur in diabetes, warranting continued research
efforts to understanding the integrative communication between the multiple islet cell
types [35]. Lastly, -cells release ghrelin, stimulating appetite and γ-cells produce
pancreatic polypeptide in response to food intake proportional to calorie intake, inhibiting
pancreas secretions [37,38].
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Figure 1.2. Transcriptional pathways involved in endocrine cell specification
Progenitor cells expressing Ngn3 give rise to all islet cell types. A simplified list of some
of the key transcription factors involved in endocrine islet subtype specification are
depicted. The expression of different transcription factors ultimately delineates the
differentiation of the distinct endocrine cell types. Figure was created in Biorender.

10

In addition to differences in islet architecture between humans and mice, differences also
exist in islet development. While in humans islet development is complete at birth, this
process continues in mice from E15.5 to postnatally at the end of lactation [39,40]. Islet
maturation occurs via increased β-cell replication and neogenesis, both of which slow
extensively by adulthood [41]. Pancreatic β-cells are considered to be a slowly renewed
cell with low turnover in healthy adults. The steady state β-cell replication rate in an adult
rat is just over 2% per day [42–44] and this rate is even lower in humans [45]. However,
rates of β-cell apoptosis are also low in adulthood, around 0.5% in the rat, allowing for
gradual replacement of β-cells and maintenance of β-cell mass (BCM) in adulthood [46].
Thus, BCM is considered to be fairly stable after birth. Nevertheless, the pancreas
undergoes extensive remodeling postnatally, which in the rat is characterized by a wave
of β-cell apoptosis peaking around postnatal day 14 [41]. This is immediately followed
by an additional wave of neogenesis which allows for replacement of β-cells and
maintenance of BCM (Fig. 1.3).
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Figure 1.3. Schematic diagram of the dynamic changes in BCM with age
The various determinants of β-cell growth in mice are shown as they change with age.
Reproduced from Bonner-Weir et al. Ups. J. Med. Sci. 2016;121:155-158, with minor
revisions.
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1.3

Mechanisms and Dynamics of Insulin Secretion

The first step in the cascade that initiates insulin secretion from pancreatic β-cells
involves a glucose molecule entering the β-cell. This occurs via glucose-transporter-2,
Glut2, which is a transmembrane protein on the β-cell that permits for uptake of glucose
across the β-cell membrane, amongst other tissues, in response to high glucose
concentrations [47]. An important difference between glucose uptake mechanisms
between mice and humans is that human β-cells are able to use both Glut1 and Glut2 to
uptake glucose [48]. Nonetheless, Glut1 is considered to be the primary source of glucose
uptake in the β-cell in humans [49]. This is in contrast to mice where only Glut2 is used
[48]. Once glucose enters the cell, it is phosphorylated by glucokinase (Gck) and
converted into ATP via multiple steps in glucose metabolism (Fig. 1.4) [50]. The rising
ATP:adenosine diphosphate (ADP) ratio triggers the closure of ATP-sensitive K+
channels, resulting in β-cell membrane depolarization [51]. Depolarization of the β-cell
membrane triggers opening of voltage-dependent Ca2+ channels and a rapid influx of
Ca2+ into the cell, triggering exocytosis of insulin-containing granules [11]. To be more
effective at reducing blood glucose levels, insulin is secreted in pulses which is
postulated to be modulated by oscillations in [Ca2+] [52,53]. Insulin secretion occurs in a
biphasic pattern with first phase insulin secretion occurring rapidly within minutes of
stimulation and lasting only approximately 2 min [11]. This is followed by second phase
insulin secretion, which is considered to be a slow release, but sustained, phase. It is wellestablished that a loss of first phase insulin secretion and a blunted second phase is
characteristic of T2DM [54]. Once insulin is released into the circulation, it can interact
with the insulin receptor on peripheral tissues to stimulate glucose uptake via the insulin
receptor signaling pathway that results in trafficking of Glut4 transport vesicles to the
plasma membrane (Fig. 1.4) [55].
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Figure 1.4. Overview of insulin release and action
In mice, glucose enters the β-cell via Glut2 and is metabolized via glycolysis, generating
ATP. The accumulation of ATP in the cytoplasm leads to closure of ATP-sensitive K+
channels, and depolarization of the plasma membrane. Depolarization of the plasma
membrane results in opening of voltage-dependent Ca2+ channels. The influx of Ca2+ into
the cell leads to release of insulin granules, which are carried in the bloodstream to cells
throughout the body (i.e. liver, skeletal muscle, adipose) to bind the insulin receptor.
Upon binding, autophosphorylation of tyrosine residues occurs in addition to
phosphorylation of other cellular proteins, including recruitment of insulin receptor
substrates (INSR1/2). This results in recruitment of other proteins, activating various
signaling pathways (dashed lines). Ultimately, translocation of Glut4 vesicles to the
plasma membrane occurs permitting uptake of glucose into the cell, in addition to
activation of pathways that regulate metabolism, transcriptional changes and cell growth.
Reproduced from Abner Louis Notkins J. Biol. Chem. 2002;277:43545-43548, with minor
revisions.
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1.4

β-cell Plasticity

As mentioned in section 1.2, β-cell number is considered to remain stable after birth and
variations in BCM are minimal in adulthood [56]. Nonetheless, there are many studies
that have reported that β-cells display plasticity in injury models and certain
physiological situations (i.e. obesity and pregnancy). These findings have drawn interest
to understanding the mechanisms of β-cell plasticity and the stimuli for β-cell
regeneration in these models. Once elucidated, these mechanisms could be appealing
strategies for endogenous pancreatic β-cell replacement for diabetes reversal.

1.4.1 Models to Study β-cell Regeneration
Numerous animal models have been developed where an insult initiates β-cell
regeneration and have been pivotal for β-cell plasticity research. Some of these β-cell
stresses can be induced by surgical damage (partial pancreatectomy, pancreatic duct
ligation), and β-cell destruction (genetic or pharmacological) which will be briefly
described below.
Partial pancreatectomy
Partial pancreatectomy involves the removal of 90% of the pancreas resulting in diabetes
[57]. In this model, regeneration of both endocrine and exocrine pancreas, in addition to
generation of new lobes, was demonstrated in rats [57–59]. These studies were followed
by mechanistic lineage tracing experiments that showed that β-cell regeneration occurred
mainly through proliferation of pre-existing cells [60], although other studies report that
α- to β-cell transdifferentiation could also be occurring [61]. Similar mechanisms might
be operating in humans as there is evidence of pancreas regeneration in patients with
pancreatectomy [62].
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Pancreatic duct ligation
Pancreatic duct ligation (PDL) involves the surgical ligation of the pancreatic duct at the
pylorus, resulting in accumulation of exocrine secretions in the body and tail of the
pancreas. Studies of pancreas remodelling following PDL in rat have shown the
formation of new β-cells from progenitors in ductal epithelium [63] by activation of Ngn3
which gives rise to all islet cell types [64]. That being said, the origin of these progenitor
cells remains controversial (discussed below in section 1.4.3.2) as some experiments
suggest that pancreatic ductal cells are not pancreatic progenitors [65–67].
β-cell damage: genetic ablation
Islet cell plasticity has also been demonstrated in transgenic mouse models using in vivo
cell lineage tracing tools that allow for inducible (doxycycline (DOX) or tamoxifen
(TAM) administration) β-cell ablation and tracing of islet cells. In one model, upon DOX
administration to transgenic mice (Insulin-rtTA;TET-DTA), targeted ablation of
pancreatic β-cells occurred based on driving of insulin promoter and conditional ablation
of β-cells in specific transgenic strains. Upon DOX administration in this model, a
targeted β-cell loss of 70-80% was observed [68]. In this model, experiments concluded
that β-cell regeneration occurred due to replication of pre-existing β-cells. An additional
study using TAM administration to investigate β-cell regeneration showed that β-cell
proliferation was the driver of regeneration in this model [69].
β-cell damage: pharmacological
The two most commonly used pharmacological agents to induce β-cell ablation for study
of β-cell plasticity and regeneration are streptozotocin (STZ) and alloxan. Both drugs
enter the β-cell through Glut2 and trigger β-cell death [70]. STZ is a cytotoxic product
produced by Streptomycetes achromogenes that causes damage to β-cells by entering the
β-cell [71]. STZ causes deoxyribonucleic acid (DNA) alkylation and damage ultimately
resulting in β-cell death. Alloxan triggers β-cell death by inducing production of reactive
oxygen species (ROS). Both models have been widely used to study β-cell regeneration
in various animal models [72–77].

16

1.4.2 β-cell Plasticity with Age
Although there is clear evidence of β-cell regeneration in the many discussed studies
above, it is important to note that the capacity for β-cell regeneration varies with age. It
has been well-established that β-cell replication declines drastically after birth in both
humans and rodents implicating a long lifespan and low turnover rate for β-cells
[42,43,56,78–80]. The impairment of this replicative process correlates with the induction
of processes preventing the β-cell from re-entering the cell cycle [81,82]. Furthermore,
aged islets have been shown to exhibit inflammatory markers, including nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-kB), which has been shown to
upregulate socs2, a gene that inhibits β-cell proliferation [83]. In addition to reduced
replicative capacity, some studies in humans show that β-cell function is also impaired
with age [84]. The reduced capacity for β-cell regeneration in the adult could also be due
to the reduction of multipotent precursor cells, expressing insulin but low levels of
glucose-transporter 2, Glut2 (Ins+Glut2LO), which have been previously shown to
decrease with age in both humans and mice [85].
Regeneration of β-cells following β-cell loss has been shown to occur in young mice
[68,86] although studies with aged mice have shown a limited capacity for regeneration
[87,88]. Similarly, regeneration might be restricted in non-human primates as a study
using STZ-mediated β-cell ablation in middle-aged velvet monkeys did not find a
compensatory increase in β-cell replication [89]. Another example in humans showed that
young children (between 2 and 9 years old) had complete pancreas regeneration
following a pancreatectomy [62]. However, pancreatectomy in adults (39-72 years) did
not yield an increase in pancreatic volume [90]. Studies in mice treated with STZ
demonstrated that neonates treated with STZ were able to partially regenerate their
pancreas. In contrast, mice treated with STZ in adulthood showed reduced regeneration
[87]. Elegant studies by Herrera’s group investigated the influence of age on islet cell
plasticity in β-cell ablated mice and demonstrated β-cell regeneration via reprogramming
of -cells in juvenile mice. Interestingly, this process involved the dedifferentiation of cells, subsequent proliferation and redifferentiation into β-cells which differed from
mechanisms that occurred in adults [91]. Taken together, these studies suggest that β-cell
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regeneration declines with age in mammals. The reduced replicative capacity of β-cells
and reduced β-cell function in aged islets are important considerations to address for
regenerative therapies or islet replacement protocols.

1.4.3 Sources of New β-cells From Within the Pancreas
It is important to elucidate the sources of new β-cells in order to be able to better
manipulate these populations to increase BCM as a strategy for diabetes reversal. In this
section, 5 topics will be discussed including replication from pre-existing β-cells,
conversion from ductal progenitors, pancreatic progenitors within the endocrine pancreas,
α- to β-cell transdifferentiation, and acinar to β-cell transdifferentiation (Fig. 1.5).
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Figure 1.5. Schematic diagram of sources of new β-cells from within the pancreas
Overview of some of the sources of new β-cells from within the pancreas discussed in
this thesis. Sources include the differentiation of pancreatic progenitor cells (A),
reprogramming of cells from within the exocrine and endocrine pancreas (B), and selfreplication of pre-existing β-cells (C). Figure was created in Biorender.
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1.4.3.1 Replication from Pre-Existing β-cells
As previously mentioned β-cells have a slow cellular turnover. Nonetheless, in stressful
situations, such as the injury models described in section 1.4.1, evidence of increased
replication from pre-existing β-cells has been documented [60,68]. Additionally, in some
physiological situations, such as in pregnancy, increased β-cell replication has also been
demonstrated [92]. A milestone study that lineage traced β-cells in young adult mice
demonstrated that most β-cells arise by self-replication rather than from a progenitor
source [60]. In this study, a pulse-chase experiment was performed using transgenic mice
that tagged existing mature insulin-expressing β-cells with human placental alkaline
phosphatase following tamoxifen injection. After following the mice for up to a year the
authors concluded that the new β-cells were products of self-renewal. Important
limitations of this study however arise due to only 30% of β-cells undergoing tamoxifeninduced recombination [93]. Furthermore, tamoxifen-independent recombinase activity
poses a technical limitation for mice in these experiments [93,94]. However, additional
studies re-affirmed these findings by also detecting no evidence of β-cell neogenesis
arising from progenitors to contribute to β-cell regeneration using an innovative DNA
double-labelling experiment [95]. In this study the authors also concluded that replication
occurred from pre-existing β-cells. In humans, fewer studies have investigated the
contribution of β-cell replication, therefore less is known regarding the contribution of
this mechanism to β-cell renewal [80,96]. However, there is evidence from pancreas
samples that suggests mature human β-cells can proliferate in vivo [97]. Thus,
manipulation of existing β-cells presents as an attractive strategy to β-cell deficiency
reversal.
β-cells possess cell cycle regulators although they are sequestered in the cytoplasm of
mature β-cells [98,99]. Transfection of cell cycle regulators into β-cell lines in vitro have
successfully led to an increase in replicative rate [100]. However, overexpression of
oncogenes could increase the risk of carcinogenesis hindering the safety of such
therapeutics. Application of growth factors and mitogens, such as growth hormone and
placental lactogen, has been shown to increase β-cell replication in mice in vivo and in
vitro [101,102]. Nonetheless, some of these agents have failed to produce a replicative
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response in human β-cells. Furthermore, this was accomplished by inducing targeted
expression via transgene which could result in off-target consequences if administered
systemically. Recently, dual-specificity tyrosine-regulated kinase 1A (DYRK1A) was
identified and shown to stimulate proliferation of human β-cells in vitro and transplanted
human β-cells in vivo [103–105]. Combined pharmacologic inhibition of DYRK1A and
transforming growth factor β superfamily signaling resulted in a synergistic increase in
human β-cell proliferation [105]. This occurred due to activation of cyclins and
reductions of cell cycle inhibitors. In conclusion, the identification of molecules that
stimulate β-cell replication which have reversible effects and are β-cell-specific are
needed to optimize strategies of stimulating endogenous β-cell replication as a
therapeutic for diabetes reversal.

1.4.3.2 Exocrine Conversion: Differentiation from Ductal
Progenitors
An additional endogenous source of β-cell reversal for diabetes would be an existing
progenitor population in the pancreas. There are many studies that have implicated
pancreatic ductal cells as the source of progenitor cells in the pancreas, dating back to
1911 when it was observed that small endocrine cell clusters were budding from ducts
[106]. This was a convincing hypothesis considering endocrine cells and pancreatic
ductal cells stem from a common developmental ductal lineage, prior to endocrine
lineage delineation by Ngn3. An initial study by Xu et al. reported evidence of β-cell
neogenesis in a PDL model via formation of β-cells from Ngn3+ cells resulting in an
increased BCM [64]. Proliferation increased in ductal cells and importantly the Ngn3+
cells were shown to migrate away from the duct into islet structures. Further evidence of
this contribution stems from a study that tagged ductal cells with the Cre-Lox system
using carbonic anhydrase II promoter. In this study, new islets were traced back to
carbonic anhydrase II-expressing cells as progenitors after PDL [63,107]. These findings
were supported by additional pancreas-injury models where β-cell regeneration occurred
from pancreatic ducts [23,108,109]. A more recent study importantly showed via lineage
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tracing that under certain conditions (mild hyperglycemia, gastrin or epidermal growth
factor treatment) pancreatic ductal cells can be induced to differentiate into β-cells and
reverse diabetes [110]. On the contrary, there are studies that have failed to observe the
contribution of ductal cells to β-cell regeneration [65–67,111], which is postulated to be
due to potential differences in lineage tracing tools, markers for ductal cells or injury
models used. An additional argument is that embryonic-specific transcription factors
(Ngn3/Pax4) are not expressed during postnatal life, suggesting that postnatal β-cells
should arise from an additional source. Nonetheless, convincing data suggesting the
therapeutic potential of a ductal progenitor pool has been demonstrated in STZ-treated
mice where β-cell regeneration was successful using isolated ductal cells [112,113]. This
has also been extrapolated to non-rodents as a recent study showed that β-cell
differentiation can occur from ductal progenitor cells in zebrafish [114]. Importantly,
human pancreatic ductal cells have been grown in vitro and induced to differentiate into
glucose-responsive, insulin-producing cells [115]. The authors concluded that the
pancreatic ductal epithelium thus serves as a pool of pancreatic progenitor cells [116].

1.4.3.3 Pancreatic Progenitors Within the Endocrine
Pancreas
The existence of β-cell progenitors remains one of the most controversial concepts in βcell biology. Dor’s initial landmark study suggested that new β-cells are predominantly
generated by self-replication of pre-existing β-cells rather than from new islets arising
from a progenitor [60]. Nonetheless, this conclusion remains open-ended as the study
does not consider mechanisms of regeneration that can occur in injury models such as the
convincing evidence discussed in section 1.4.3.2 and below. In this section, evidence for
pancreatic progenitors will be discussed.
A study by Liu et al. opposed the work done by Dor, where the same transgenic mouse
model was used to track β-cells with age, in addition to STZ-mediated β-cell ablation
[77]. In this study, β-cell progenitors were identified that had an immature β-cell
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phenotype (lack of Nkx6.1 and Glut2). Importantly, these cells proliferated in STZablated pancreas and were concluded to be a group of progenitor cells with substantial
endocrine lineage plasticity. Additional studies have identified putative adult pancreatic
stem/progenitor cells in mouse pancreas [117,118]. Suzuki et al. isolated progenitor cells
with flow cytometry from neonatal pancreas, while Seaberg’s study also identified rare
single clonal cells from adult mouse pancreas [117,118]. Importantly, these cells were
shown to have the capacity to differentiate into functional β-cells and were thus
concluded to be a source of multipotent precursors cells in mouse pancreas [118].
Follow-up studies from this group validated Liu’s findings that these progenitor cells
represent “immature” β-cells, characterized by decreased levels of Nkx6.1 and Pdx1, and
lacked Glut2 [119]. These cells were also found to be capable of proliferation, renewal,
and differentiation into multiple endocrine lineages in both isolated mouse and human
islet tissues [119]. Importantly, after transplantation into mice with diabetes, both mouse
and human pancreatic progenitor cells decreased hyperglycemia in the rodents,
demonstrating the therapeutic potential of these progenitors. As discussed in section
1.4.3.2, additional proof for the existence of pancreatic progenitors was shown by lineage
tracing studies where one of the origins of the progenitors was suggested to be in ductal
cells, as shown by reactivated Ngn3 expression in endocrine cells [63,64].
Since these landmark studies, additional studies have supported the hypothesis of
multipotent pancreatic precursor cells including a progenitor pool expressing insulin but
low levels of glucose-transporter 2, Glut2 (Ins+Glut2LO). These progenitors have been
identified in mouse in addition to human pancreas and have been shown to have the
ability to differentiate into mature β-cells under metabolic stress [118,119]. Ins+Glut2LO
cells have been shown to decrease with advancing age in both human and mouse
pancreas, however they retain a progenitor-type plasticity as they have a higher
proliferation rate compared to mature Ins+Glut2HI cells [120]. Thus, these cells may
represent a progenitor pool capable of differentiating into new β-cells. An additional
recent publication used a marker to identify immature β-cells in a “neogenic niche” at the
islet periphery, that are importantly present throughout life [121]. These immature β-cells
express insulin, but represent an immature β-cell as they lack key markers (i.e. Glut2)
including the maturation marker, Urocortin3 [122]. The authors suggested that the
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Urocortin-Insulin+ cells represent an intermediate stage in transdifferentiation of α-cells
into β-cells (discussed below in section 1.4.3.4). Importantly, Urocortin-Insulin+cells
were also identified in human pancreas of varying ages, including donors with T1DM.
Although there are inherently going to be challenges in using these populations as a
therapeutic, such as the findings that many of these progenitor populations are extremely
small, the therapeutic potential of the research has been convincing thus far and could be
important for diabetes reversal should the methods be optimized.

1.4.3.4 Endocrine Conversion: α- to β-cell
Transdifferentiation
An alternative source for β-cell regeneration for diabetes reversal could be from reprogramming of the closely-related glucagon-producing α-cells. After β-cells, α-cells are
the most abundant cell type in islets. Importantly, α-cells remain viable in diabetes, and
both mice and humans are able to survive without α-cells should existing α-cells be used
as a therapeutic [123,124]. As was discussed in section 1.2, the pancreas arises from a
common Pdx1-expressing progenitor. Upon expression of Ngn3 in ductal cells, islet
lineages develop. Perhaps most interesting in the transcriptional changes in development
of specific endocrine cell lineages is the overlap of transcription factors common to both
mature α- and β-cells. It was once thought that the development of mature α- and β-cells
was static and a definitive lineage. However, studies have discovered that both α- and βcells are able to interconvert between one another. Remarkable pioneer studies
demonstrated that the misexpression of α-cell specific transcription factors, such as Arx,
in β-cells can result in conversion to α-cells [125]. Conversely, expression of β-cell
specific transcription factors, such as Pax4, can cause conversion of α-cells into β-cells
[126]. Moreover, these new β-cells displayed most characteristics of mature β-cells. On
the contrary, β-cells have also been shown to undergo de-differentiation into α-cells,
which contributed to loss of BCM in T2DM [127]. The epigenetic chromatin signature of
α-cells, resembling stem cells, likely attributes to this remarkable plasticity [128].
Nonetheless, this process has also been shown without genetic manipulation of
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transcription factors. One of the first studies demonstrating interconversion between αand β-cells was reported in 2007 in a β-cell ablated model of diabetes using zebrafish
[129]. In this study, the authors lineage traced the regenerated β-cells and found that they
arose from a non-β-cell origin located at the periphery of the islet. These studies were
followed by lineage tracing experiments to show that α- to β-cell conversion was the
main contributor of β-cell regeneration. Interestingly the location of these cells at the
periphery of the islet supports the more novel findings of the Urocortin3 study that
proposes a neogenic niche where α-cells can convert to β-cells in order to facilitate β-cell
regeneration [121]. Additional compelling evidence for this process exists in many
models of β-cell regeneration. Studies using a model of extreme β-cell ablation
demonstrated β-cell regeneration via conversion from α-cells, or -cells, depending on
the age of the mice [86,91]. The regeneration has been shown to occur even after multiple
insults of β-cell ablation and is postulated to arise from a pancreatic ductal cell origin
[108]. To compensate for the shortage of α-cells, α-cell neogenesis was stimulated via reactivation of Ngn3 in ductal cells, which enabled subsequent conversion into β-cells upon
Pax4 expression or Arx inhibition resulting in a continuous cycle of neogenesis and
conversion [108,126,130].
As exciting as these studies are they do have practical limitations as these processes are
only observed in extreme and acute models of β-cell ablation, which do not have clinical
equivalents. The amount of β-cell loss and injury model used will also determine whether
α- to β-cell transdifferentiation occurs and this will further influence the degree of reprogramming. Thorel and colleagues showed that β-cell loss must be near total for
triggering the re-programming process as in situations of milder β-cell ablation (less than
95%), less α-cell reprogramming occurred and the mechanism of β-cell regeneration was
self-replication of existing β-cells [86]. Importantly, an even milder form of β-cell
ablation showed no evidence of reprogramming at all. Furthermore, although some
studies suggest that this process can occur in humans [131,132], without lineage tracing
studies direct evidence is lacking.
Despite these limitations, an endogenous source of β-cell replacement for diabetes, such
as the closely related, and increasingly proven to be plastic, α-cell, is appealing if shown
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to be feasible. Some molecules have been suggested to promote α- to β-cell conversion
including γ-aminobutyric acid (GABA) [132], GLP-1 [133] and artemisinins [134].
Nonetheless, some of these findings remain controversial as a study rebutted the
suggestion that artemisinins cause α- to β-cell conversion [135]. Thus, the detailed
mechanisms and reasons for differences in these studies should be further addressed.
However, continued research efforts to identify stimulators for α- to β-cell conversion are
warranted.

1.4.3.5 Exocrine Conversion: Acinar to β-cell
Transdifferentiation
As was discussed in section 1.2, the pancreas has both an endocrine and an exocrine
portion. In addition to the findings of exocrine ductal cells as a source of progenitor cells
discussed in section 1.4.3.2, there is data to support the reprogramming of exocrine acinar
cells into insulin-producing β-cells as well [136–139]. Similar to the studies involved in
α- to β-cell conversion involving transcriptional manipulation, studies using mouse acinar
cells have shown that by expressing β-cell transcription factors (Pdx1, Ngn3 and MafA)
via adenoviral vectors injected into pancreatic parenchyma, new β-cells arose in vivo.
Furthermore, when these cells were transplanted into rodents with diabetes,
hyperglycemia was reduced and importantly recurred upon removal of the graft
[138,139]. The new β-cells also resembled a mature β-cell phenotype and have been
confirmed to persist for up to 1 year in vivo [140]. These results were confirmed in vitro
using primary human pancreatic exocrine cells cultured in specific conditions
(transforming growth factor-B1, Rho-associated kinase inhibitors) that generated cells
amongst which 18% were mature, glucose responsive β-cells in vitro and in vivo [141].
Upon transplantation, these cells were able to prevent diabetes in STZ-β-cell ablated
mice. More recently, the same group demonstrated that by suppressing the α-cell specific
transcription factor, Arx, while simultaneously overexpressing the β-cell specific
transcription factor, Pax4, there was an enhanced production of functional insulinproducing β-cells from exocrine tissue [142]. When transplanted into mice with diabetes,
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there was an immediate and prolonged effect of reduced blood glucose levels. As with
previous transdifferentiation studies, some of these studies are nonetheless limited in
terms of clinical applications due to the use of viral vectors. Furthermore, the results are
still controversial as one publication used in vivo lineage tracing after partial
pancreatectomy and demonstrated no evidence of acinar to β-cell conversion; rather the
authors concluded that new exocrine cells arose from replication of pre-existing acinar
cells [143].
In summary, although the topic remains controversial, many studies do provide evidence
for multiple alternate endogenous sources of β-cell replacement for diabetes reversal.
Most data suggest that β-cells replicate from pre-existing β-cells, although some more
severe injury models demonstrate convincing evidence for alternate sources of β-cell reprogramming from the other pancreatic cell types discussed above. Importantly, these
alternate mechanisms could still be contributing to β-cell replacement, even if the
contribution is minor. These mechanisms should be studied further in order to allow for
the implementation of targeted therapeutics which increase BCM during pathological
conditions characterized by β-cell insufficiency. Translational applications will be limited
by the need to produce stable, and functional β-cells. This will be complicated by the
need to evaluate the safety of molecules to induce in vivo programming of β-cells. Thus,
there are many remaining questions, nevertheless the results have tremendous potential to
have an influential impact on diabetes research and treatment.

1.5 Metabolic Situations of β-cell Adaptability
In contrast to the models of regeneration discussed in section 1.4.1 that are used to study
the sources of new β-cells, in this section, real physiological situations of β-cell
adaptability in response to metabolic stress will be discussed. As mentioned in section
1.2, β-cells are considered to be a slowly renewing cell type with low levels of apoptosis
and replication enabling for gradual replacement of β-cells to maintain BCM. In contrast,
there are compensatory mechanisms that occur in certain physiological situations to
rapidly increase BCM. Two such situations where β-cell compensation must occur in

27

order to maintain euglycemia are the insulin-resistant states of obesity and pregnancy
[144].

1.5.1 Obesity
Obesity is described as a pathological condition that involves excess deposition of
adipose tissue. It is diagnosed by body mass index (BMI) and fat distribution through the
waist-hip ratio. In the context of β-cell biology, obese patients show increased BCM
expansion compared to lean individuals [80,145,146] with the increase being from 5090% [147,148]. Interestingly, one study found a lack of β-cell replication in human
samples and the authors suggested that BCM increased via neogenesis through
differentiation of ductal cells [80]. Two subsequent studies supported this hypothesis,
demonstrating a lack of β-cell replication in obese human patients, rather the authors
found an increased number of cells coexpressing insulin and a ductal marker, cytokeratin
19, in patients with insulin resistance [80,149]. Interestingly, one study found an increase
in the number of bihormonal (Insulin+Glucagon+) cells in insulin resistant patients, which
could implicate α- to β-cell conversion as a compensatory mechanism for increased
insulin demand [149]. Although most reports implicate neogenesis rather than β-cell
proliferation to increased BCM expansion in obesity, most authors warrant that the
conclusion should be taken with caution. One cannot exclude the possibility that β-cell
proliferation was simply too small to be detected, or importantly could occur prior to the
insulin resistance manifestation in obesity. Other studies have indeed found evidence of
β-cell proliferation contributing to BCM expansion in obesity [150,151]. Thus, it is clear
that the exact mechanisms of β-cell expansion in obesity have yet to be delineated.
Several downstream effectors of the insulin signaling pathway have been implicated in
BCM expansion in animal models of insulin resistance. For example, FoxM1 activation
in islets was shown to increase compensatory β-cell proliferation in obese mice via
neuronal input [152]. Nevertheless, further elucidation of these mechanisms is warranted.
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1.5.2 Pregnancy
An additional metabolic situation requiring successful, and a remarkably reversible,
adaptation of pancreatic β-cells is during the insulin-resistant state of pregnancy. There
are numerous physiological changes that occur during pregnancy. In humans, one of
these changes is driven by the release of placental growth hormone from the placental
syncytiotrophoblast, which contributes to a state of peripheral maternal insulin resistance
[153]. These changes are also modulated by release of placental lactogen, estrogen,
progesterone and other pregnancy hormones [153]. The state of maternal insulin
resistance occurs in order to maintain trans-placental transport of glucose to the fetus to
ensure optimal fetal development. Nonetheless, in order to compensate for the state of
insulin resistance, the maternal pancreas must respond by increasing BCM to maintain
euglycemia. As previously mentioned, the steady state β-cell replication rate in adult
mammals is low. Remarkably, the rise in levels of the hormones placental lactogen and
prolactin during mouse pregnancy have been shown to initiate proliferation of insulin
producing β-cells in early pregnancy in order to prepare for adaptation of BCM
[101,154]. The insulin resistance is thus countered by an increase in BCM and enhanced
insulin secretion which maintains euglycemia in a healthy pregnancy [155,156]. Similar
changes in BCM are believed to occur in humans however fewer studies have been
performed.

1.5.2.1 Pancreatic Compensation in Mouse vs. Human
Pregnancy
Pancreatic adaptation in mouse pregnancy has been extensively studied. It is well
understood that there is a substantial increase in BCM during gestation in order to
compensate for the increased metabolic demand [155,157,158]. In mice, successful
adaptation of BCM during pregnancy occurs, in part, due to increased β-cell hypertrophy
and proliferation which peak at mid-gestation and are mediated by increased levels of
lactogenic hormones [92,155,159]. In mice, placental lactogen-1 is synthesized at early
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gestation and peaks on gestational day (GD) 10.5. Mouse placental lactogen-1 is then
replaced by mouse placental lactogen 2 which peaks at GD14.5 and remains high
throughout the remainder of pregnancy [160]. This is in contrast to humans which only
have one placental lactogen (human placental lactogen or human chorionic
somatomammotropin) which gradually increases throughout pregnancy. Furthermore,
estrogen levels increase during pregnancy which are associated with decreased β-cell
apoptosis, suggesting a protective role for β-cells [161]. Collectively, these changes
enable for expansion of BCM which peaks towards the latter portion of gestation
(GD18.5, in mouse comparable to late gestation in human) [159,162]. Increased GSIS, in
part due to a decrease in threshold for glucose stimulation, from β-cells further
contributes to the maintenance of euglycemia during the insulin resistant state of
pregnancy [155,163,164]. The adaptive increase in BCM is reversible and returns to prepregnancy levels after birth through progesterone-mediated increases in β-cell apoptosis
[165], concomitant with decreased levels of placental lactogen reducing β-cell
proliferation. The mechanisms and timing of these changes in mouse pregnancy are wellestablished. In contrast, due to a scarcity of pancreas samples from pregnant humans,
these adaptive mechanisms in human pregnancy remain unclear.
There have only been two studies exploring changes in endocrine pancreas in human
pregnancy. Importantly, both studies found an increase in endocrine pancreas mass in
pregnancy thus implicating endocrine adaptation to the metabolic changes of pregnancy
in both humans and mice. The first study conducted by Van Assche et al. [166] reported a
2.4-fold increase in β-cell fractional area in pregnant women compared to non-pregnant
controls. More recently, Butler et al. [96] found a 1.4-fold increase in β-cell fractional
area during pregnancy. Differences in the extent of endocrine pancreas adaptation have
been postulated to occur due to varying factors between the two studies (such as women
who died in car accidents, women with inflammatory diseases, varying pre-pregnancy
BMI, wide ranges of gestational ages). Nonetheless, the studies collectively confirm that
β-cell expansion occurs in human pregnancy.
The most controversial studied difference between human and mouse compensatory βcell mechanisms in pregnancy is in regard to β-cell proliferation and neogenesis. In
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addition to differences in distribution and composition of islets between mice and humans
[28], adult human β-cells are thought to be very stable and rarely divide [167]. The Butler
study found that the increased β-cell fractional area was not due to β-cell proliferation,
rather there was an increased number of small islets implicating islet neogenesis as the
driver of endocrine pancreas adaptation. In contrast, β-cell proliferation has been shown
to peak at mid-gestation in mice driving the compensatory adaptations in endocrine
pancreas. Nonetheless, prior to concluding islet neogenesis as the sole contributor to
BCM expansion in human pregnancy based on the findings of the Butler study it is
important to consider that samples were pooled across all gestational ages. Thus, it is
plausible that pooling the samples could have diluted an increase in β-cell proliferation if
proliferation occurs in a timing-specific manner such as in mice. Furthermore, it is
possible that a much lower rate of β-cell proliferation is sufficient to achieve BCM
expansion in humans over 9 months of pregnancy vs. 3 weeks in mice which requires a
higher rate of proliferation to achieve maximal BCM expansion in a shorter time [154].
Further contributing to the potential difference of β-cell replication as a driver of
endocrine pancreas adaptation between humans and mice is the role of lactogenic
hormones. In mice, placental lactogen has been shown to drive β-cell replication via
signaling through the prolactin receptor (PRLR) in pancreatic β-cells [168]. Signaling via
PRLR increases serotonin receptor expression, which upon ligand binding further
regulates β-cell proliferation and insulin secretion [169]. Studies of lactogen treatment in
human β-cells have reported conflicting results, with some studies suggesting that
treatment with lactogens increases GSIS and β-cell proliferation [170] in contrast to
others which showed a lack of a mitogenic response to lactogens [171]. Differences in
humans could be due to lower expression of PRLR on human β-cells than in mice [172].
Evidently there are differences between the behaviour of mouse and human β-cells during
pregnancy which require careful consideration when translating animal data to humans.
Nonetheless, the scarcity of human pancreas samples in pregnancy poses a challenge to
studies in this field.
Although there is evidence to suggest adaptive increases in BCM in pregnancy in both
humans and mice, based on current evidence it is likely that the mechanisms leading to
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this adaptation differ between mice and humans. Nonetheless, current studies provide
clear evidence that both mice and humans rely on compensatory adaptation of β-cells to
successfully counter insulin resistance in pregnancy.

1.5.2.2 Mechanisms of Endocrine Compensation During
Pregnancy
Since human pancreas samples during pregnancy are sparse, the cellular mechanisms for
maternal β-cell expansion during pregnancy have only been possible to decipher in mice.
Expansion of maternal BCM in mouse pregnancy is predominantly due to β-cell
replication. Adaptation to metabolic demands of pregnancy also involves lowering the
threshold for GSIS, β-cell hypertrophy and increased insulin biosynthesis [92,158].
Whether increased GSIS and β-cell proliferation contribute to expansion in humans
remains controversial. In this section, the contribution of β-cell progenitors to BCM
expansion in pregnancy will be discussed, in addition to unveiling a potential
contribution of other islet cell types (Fig. 1.6).
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Figure 1.6. Endocrine pancreas adaptations in pregnancy
Beta- and α-cell mass expansion occur in response to increased insulin demand during
the insulin resistant state of pregnancy. Endocrine mass expansion occurs due to
increased replication, increased hypertrophy of individual cells, and neogenesis from
resident progenitor cells. Transdifferentiation of α- to β-cells is also possible. These
adaptations maintain euglycemia together with enhanced glucose-stimulated insulin
secretion. Reproduced from Szlapinski et al. Curr. Vasc. Pharmacol. 2020;18.
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β-cell neogenesis
Expansion of maternal BCM in mouse pregnancy is predominantly due to β-cell
replication mediated through PRLR signaling, although the source of these cells remains
to be determined. Some studies suggest that the majority of BCM expansion occurs
through replication of pre-existing β-cells [173–176]. However, there is also evidence via
lineage tracing that up to 25% of β-cells could arise from non-β-cell progenitors
[173,175]. We and others have found an increase in the number of islets during mouse
pregnancy which further contributes evidence to this hypothesis [159,177]. Additional
studies from our laboratory have shown that the proportion of proliferating multipotent
precursor cells (Ins+Glut2LO) significantly increased at GD9, which preceded β-cell
proliferation at GD12 and facilitated BCM expansion at GD18. The increase in
proliferating progenitor cells at GD9 occurred at the same time as an increase in Pdx1
mRNA expression which is a transcriptional marker for endocrine progenitor and mature
β-cells. Thus, these cells may represent a progenitor pool capable of differentiating into
new β-cells and in the context of pregnancy are present to facilitate BCM expansion.
Islet cell transdifferentiation
An alternative source of β-cells during pregnancy could be from re-programming of
pancreatic glucagon-producing α-cells. The majority of the endocrine islet of Langerhans
is composed of α- and β-cells, with the balance being regulated by changes in expression
of the MafA and MafB transcription factors. MafA levels increase in mature β-cells while
MafB expression becomes restricted to α-cells [31]. As discussed in section 1.4.3.5,
studies have discovered that both α- and β-cells are able to convert between one another.
Thus, an appealing method for regenerating β-cells in situations of β-cell deficiency
would be through transdifferentiation of the closely related α-cells.
The lineage-tracing methods used in the studies that failed to detect neogenesis in
pregnant mouse models cannot exclude transdifferentiation from other islet types. Thus,
it is possible that this process could contribute to a portion of the 25% increase in β-cells
from non-β-cell progenitors during pregnancy. Although there was a lack of literature
about other islet cell types in gestation in mice, a study was published in 2019 that
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investigated the pancreatic α-cell in pregnancy. The study reported that, similar to BCM
expansion, ACM expansion occurred in a healthy pregnancy and was maximal at GD18.5
[178]. The authors further concluded that this was due to increased α-cell proliferation
which followed a similar mechanism to pancreatic β-cells which proliferate during
pregnancy to facilitate BCM expansion. Hypertrophy of α-cells was also observed at
GD18.5. Additionally, the study investigated the role of gestational hormones in α-cell
adaptations during pregnancy. It was found that in α-tc1.9 cells, placental lactogen and
prolactin stimulated α-cell proliferation in vitro. This study also claimed that there was a
negligible amount of α- to β-cell transdifferentiation occurring in mouse pregnancy, as
was postulated to occur in an additional study in 2010 investigating this phenomenon in a
healthy pregnancy [173]. However, one must acknowledge that the amount of β-cell loss
will determine whether α- to β-cell transdifferentiation occurs and this will further
influence the degree of re-programming. Thorel and colleagues showed that β-cell loss
must be near total for triggering the re-programming process as in situations of milder βcell ablation, less α-cell reprogramming occurred [86]. Importantly, an even milder form
of β-cell ablation showed no evidence of reprogramming at all. In the case of the healthy
animals, there is no loss of β-cells rather an adaptive increase in BCM expansion occurs
successfully in pregnancy. Therefore, it is likely that the metabolic stress of pregnancy is
insufficient to trigger reprogramming of α-cells and without the stressor of β-cell loss, αto β-cell transdifferentiation will not occur. In contrast, it is plausible that in a situation of
higher metabolic stress in pregnancy, such as in gestational diabetes mellitus (GDM) or
in obese pregnancies, α- to β-cell transdifferentiation could occur. In conclusion, this
study implicated the importance of other islet cell types in pregnancy that were
previously overlooked.
In summary, evidence suggests that the majority of BCM expansion during pregnancy
likely occurs due to replication of pre-existing β-cells which is mediated by PRLR
signaling of placental hormones. Nonetheless, there is evidence for alternate sources of βcells. These mechanisms should be studied further in order to allow for the
implementation of targeted therapeutics which increase BCM during pathological
pregnancies which are characterized by β-cell insufficiency (such as GDM, discussed
below in section 1.6).
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1.5.2.3 PRLR Signaling-Mediated JAK2/STAT5 Cascade
It is important to understand and identify the mediators influencing adaptive β-cell
expansion during pregnancy in order to permit for implementation of targeted
therapeutics to reverse this deficiency in pathological pregnancies such as GDM. In this
section, some intracellular mechanisms involved in adaptive BCM expansion in
pregnancy will be discussed, with many genes being primarily downstream of the
lactogens.
PRLR signaling
As previously mentioned, β-cell replication from pre-existing β-cells is the predominant
source of BCM expansion in mouse pregnancy. β-cell proliferation is mediated by
lactogenic (prolactin and placental lactogen) signaling through the PRLR receptor which
is expressed specifically in β-cells in mice [179]. Upon binding of ligand, JAK2
phosphorylates the receptor and allows recruitment and phosphorylation of STAT5 to the
nucleus where regulated expression of target genes occurs. The requirement of PRLR
signaling in gestational BCM expansion and maintenance of euglycemia was
demonstrated in pregnant female mice heterozygous for the PRLR null mutation. These
animals were glucose intolerant and had a reduced BCM during pregnancy due to
reduced β-cell proliferation [168]. Conversely, overexpression of placental lactogen
caused increased β-cell proliferation, and increased BCM leading to hypoglycemia [180].
Signals for adaptive maternal β-cell expansion
The influence of lactogens on adaptive maternal BCM expansion has been well studied
and additional studies are discovering various important intracellular signals that mediate
these effects. PRLR signaling has been shown to activate multiple signaling pathways in
addition to the canonical JAK2/STAT5 pathway, including: mitogen-activated protein
kinase (MAPK), phosphatidylinositol 3-kinase (PI3k) and insulin receptor substrate (IRS)
1/2 pathways in order to initiate adaptive BCM expansion [181–185]. Some of these
signaling pathways activate cell-cycle proteins and ultimately increase β-cell
proliferation. For example, one pathway involves increased expression of tryptophan
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hydroxylase (Tph1) which is involved in the rate limiting step of serotonin synthesis.
Initial studies on the effects of serotonin in islets postulated an inhibitory effect on GSIS.
However, recent studies show that serotonin was upregulated in pregnant rat islets and
upon inhibition of serotonin synthesis there was decreased gestational β-cell proliferation
and BCM expansion resulting in glucose intolerance [169]. Serotonin was also shown to
play a role in GSIS [186]. The authors of this study further concluded that serotonin acts
downstream of PRLR signaling to drive β-cell proliferation [169]. Another mechanistic
pathway involved in mediating an adaptive response in β-cells is via suppression of
menin by JAK2/STAT5 signaling. In a non-pregnant state menin, a tumor suppressor
protein, regulates expression of cyclin dependent kinase inhibitors p27 and p18 which
inhibit β-cell proliferation by blocking the cell-cycle protein cyclin-D2 (CCND2).
However, signaling through PRLR during pregnancy decreases levels of menin, which
subsequently decreases p27 and p18, enabling CCND2 to increase β-cell replication and
facilitate an adaptive increase in BCM [187,188]. The regulation of menin has been
shown to occur due to increased expression of Bcl6, a transcriptional repressor of the
Men1 gene [188]. Proof of principle studies showed that when expression of Men1 was
increased in pregnant mice, BCM expansion was impaired due to blocked β-cell
proliferation resulting in impaired glucose tolerance during pregnancy.
A second intracellular pathway that signals downstream of JAK2/STAT5 in the PRLR
pathway is the PI3k/Akt1 pathway. PRLR signaling acts through this pathway to increase
mTOR (mechanistic target of rapamycin) signaling which increases β-cell proliferation
[185]. The mTOR signaling pathway regulates β-cell proliferation and BCM [189]. Thus,
unsurprisingly when this pathway was inhibited by rapamycin in pregnant mice, there
were impairments in β-cell proliferation and BCM [190].

1.5.2.4 Transcriptional Regulation of Endocrine Adaptations
The mitogenic response of β-cells in response to pregnancy in mice has been shown to be
mediated by changes in expression of transcription factors in the islet. These transcription
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factors initiate the processes leading to adaptive β-cell proliferation and BCM expansion
in pregnancy. Some of these transcription factors include the orphan nuclear receptor
hepatocyte nuclear factor-4 (HNF-4) [191], Foxm1 [192] and MafB [179].
HNF-4
Mutations in the human ortholog of HNF-4 have been shown to cause maturity onset
diabetes of the young type 1 (MODY1) [193]. As could be expected, studies in nonpregnant mice lacking HNF-4 demonstrated β-cell impairments [194]. It was then
shown in pregnant mice that HNF-4 is required for expansion of BCM since upon
elimination of HNF-4 from β-cells, proliferation and BCM were reduced leading to
glucose intolerance [191].
Foxm1
Mice lacking Foxm1 have been shown to have a reduced BCM since the transcription
factor plays a role in cell proliferation [195]. Unsurprisingly, pregnant mice with
pancreatic deletion of FoxM1 had decreased β-cell replication and BCM contributing to
glucose intolerance at late gestation [192]. Inactivation of FoxM1 prevented lactogenmediated β-cell proliferation and thus was implicated to be a downstream regulator of
lactogens.
MafB
The transcription factor MafB is normally restricted to -cells. Interestingly, during
pregnancy in mice, MafB expression was induced in a subset of β-cells [196].
Subsequent studies showed that the loss of MafB in β-cells decreased gestational
proliferation, implicating the transcription factor in gestational β-cell proliferation [179].

Collectively, multiple components discussed in this section are part of the same signaling
pathways and are mediated by signaling via PRLR. The increase in β-cell proliferation
leading to increased BCM and GSIS permit successful endocrine adaptation to counter
hormone-mediated insulin resistance that progressively increases during pregnancy. The
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importance of mediating an adaptive increase in BCM can be seen in situations of
pathology where BCM expansion is suboptimal and can precipitate GDM.

1.6 Gestational Diabetes as a Consequence of Inadequate
β-cell Compensation
Although there have been advances in understanding the mechanisms leading to β-cell
adaptation during pregnancy there is still much that is unknown about β-cell dysfunction
in GDM. However, it appears that a suboptimal increase in BCM is equally as important
as a failure to adaptively increase GSIS.
GDM is described as diabetes that first appears during pregnancy with diagnosis
occurring around 24-28 weeks of gestation by oral-glucose tolerance test [197]. GDM
can develop as a result of severe insulin resistance, insufficient compensation of β-cells
and insufficient insulin secretion, leading to maternal hyperglycemia [198]. Thus, GDM
occurs due to insufficient β-cell adaptation to compensate for insulin resistance in
pregnancy. The incidence of GDM worldwide is around 17% of all pregnancies [197]
although a true estimate is difficult to conclude as the incidence will vary depending on
the population characteristics and diagnostic criteria. The incidence will only continue to
rise as more women enter pregnancy obese or at an older age, both of which are risk
factors for GDM [199]. Although obesity increases the risk of developing GDM, many of
the women who develop GDM are not obese implicating dysfunction at the level of the βcell to GDM pathophysiology [199–201]. While GDM reverts after pregnancy in most
situations, growing evidence unfortunately associates GDM with adverse maternal and
fetal outcomes. In terms of maternal health, GDM can result in pregnancy complications
during labour and delivery, and increase the risk of T2DM postpartum [202]. The rates of
these manifestations vary ranging between 3% and 90%, nonetheless there is up to a 7fold increase in risk compared to normoglycemic pregnancies [203]. In terms of the
health of the offspring, exposure to GDM in utero has been linked to an increased risk of
pre-term birth, respiratory distress syndrome, obesity and developing T2DM [204–206].
The increase in incidence of obesity and T2DM observed in children today may be partly
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due to the increased cases of GDM. These pathologies in the current generation of youth
may lead to further increases in GDM occurrences as they mature, continuing the cycle
and implicating the urgent need for a therapeutic to prevent GDM. Currently in Canada,
management strategies for GDM involve strict lifestyle management (dietary regulation
and exercise) to manage blood glucose levels [197]. If blood glucose targets are not met
within 2 weeks, the patient is given insulin or metformin as a treatment to accommodate
pancreatic β-cell insufficiency. Thus, dysfunction at the level of the pancreatic β-cell is
hypothesized to be the key determinant of GDM pathogenesis.
β-cell defects in GDM
GDM, like most human diseases, is multi-factorial which makes it difficult to determine a
specific mechanistic origin. Nonetheless, clinical studies have implicated β-cell failure as
a major driver to development of GDM [207] which has been confirmed in animal
models of GDM where diabetes occurred when β-cell expansion and β-cell dysfunction
failed to compensate for insulin resistance during pregnancy [92,157,168,188,192]. Some
factors that contribute to inadequate β-cell compensation and β-cell dysfunction include
signaling via PRLR, adipokines, inflammation, and oxidative stress. Studies found that
the targeted loss of signaling through the PRLR in β-cells of mice resulted in reduced βcell proliferation and BCM expansion, leading to GDM (Fig. 1.7) [179].
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Figure 1.7. Adverse pancreatic β-cell stress during pregnancy can impair adaptation
to pregnancy
Reproduced from Szlapinski et al. Curr. Vasc. Pharmacol. 2020;18.
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Role of inflammation and oxidative stress in β-cell dysfunction in GDM
Cytokines released from adipose tissue influence metabolism during pregnancy; leptin
and adiponectin representing two main adipokines that have been shown to be
dysregulated in GDM. Changes in adipose-derived adipokines and pro-inflammatory
cytokines associated with maternal obesity are likely to exacerbate the risk of β-cell
dysfunction during pregnancy, leading to GDM. Circulating leptin, which increases
insulin sensitivity, is 2-3 fold higher in pregnancy due to placental as well as adipose
expression [208]. Compared to healthy pregnant women, placental leptin expression was
increased in patients with GDM and women with high levels of leptin preconception had
a 20 times higher incidence of developing GDM [209]. In the context of pancreatic β-cell
biology, it has been well-documented that inflammation can contribute to β-cell
dysfunction [210]. Inflammation leads to endoplasmic reticulum stress which directly
influences β-cell dysfunction in addition to causing decreased insulin sensitivity, as has
been documented in GDM patients [211]. Women with GDM have been shown to have
increased circulating levels of the proinflammatory cytokines tumor necrosis factor
(TNF-α), Interleukin (IL) -1β, and IL-6 which are also associated with β-cell dysfunction
[199,212,213]. In one study, human and mouse islets treated in vitro with IL-1β showed a
reduction in GSIS in addition to β-cell de-differentiation, implicating inflammation to βcell dysfunction [214]. TNF-α has been shown to contribute to insulin resistance by
impairing insulin receptor signaling [104] and observations in women with GDM support
the role of TNF-α in the development of insulin resistance [211]. Since leptin increases
production of TNF-α, increased levels of leptin in GDM are additive to the pre-existing
inflammatory state in late pregnancy that normally contributes to insulin resistance. This
increases the metabolic pressure on β-cells to adapt during pregnancy and thus can
contribute to the pathophysiology of β-cell dysfunction in GDM. This has also been
shown in obesity where both hyper-leptinemia and leptin resistance can impair GSIS and
β-cell proliferation [215,216]. In contrast to leptin, adiponectin has been shown to
increase β-cell proliferation in mouse islets [217] and was thus, unsurprisingly, shown to
influence adaptive BCM expansion in pregnancy. Qiao et al. found that pregnant mice
with an adiponectin gene knockout had reduced BCM and developed glucose intolerance
in pregnancy [218]. Interestingly, the deficiencies were reversed with adiponectin
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reconstitution and may be mediated by protection of β-cells against lipotoxic damage
[219]. Importantly, hypoadiponectinemia was found and associated with β-cell
dysfunction in women with GDM [220]. Collectively these studies implicate
inflammation to play a role in dysfunctional β-cell properties in GDM.
Pancreatic β-cell dysfunction can also occur due to oxidative stress, which can be induced
in part by chronic hyperglycemia [221]. GDM is also characterized by hyperlipidemia
[222] and in the context of β-cell biology, pancreatic β-cells are susceptible to
lipotoxicity-induced β-cell dysfunction. Thus, both lipotoxicity and glucotoxicity are
contributors to β-cell dysfunction in GDM by causing a buildup of oxidative stress which
impairs insulin production and can result in β-cell apoptosis [223].
In conclusion, β-cell dysfunction is one of the key determinants of GDM pathogenesis.
Although two studies have looked at β-cells in pregnant humans [96,166], no studies
have examined pancreas histology in GDM pregnancies due to lack of human samples
and imaging modalities available for in vivo examination [224]. Thus, we highly rely on
animal models of diabetes in pregnancy to advance our understanding of mechanisms of
reduced β-cell adaptability.

1.7 Animal Models of Diabetes in Pregnancy
There are many risk factors for the development of GDM such as being 35 years of age
or older or from a high-risk group (Asian, Indigenous, African, Hispanic), in addition to
having obesity and GDM in a previous pregnancy [197]. These many factors make it
difficult to accurately reproduce the heterogenous pathogenesis of GDM. Nonetheless,
many attempts have been made using various approaches that have been reviewed
elsewhere [224,225] but will be briefly introduced here. These include: pharmacological,
surgical, genetic, and nutritional manipulations.
Pharmacological
One example of a pharmacologically-induced approach for modeling diabetes in
pregnancy is via STZ-mediated β-cell ablation which can be utilized to portray mild or
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severe hyperglycemia depending on the dosage/timing of administration [225]. An
advantage of this model is that β-cell destruction can occur rapidly. However, many of
these models show severe hyperglycemia which is rarely seen in humans as GDM usually
presents as a mild glucose intolerance [224]. Furthermore, the rapid insult does not
present true GDM pathogenesis which occurs gradually. An additional limitation is that
permanent β-cell destruction and diabetes often remain after pregnancy, which usually
does not occur in GDM as symptoms tend to reverse in most women after delivery.
Importantly, the β-cell destruction in this model better resembles insulin deficiency and
can be described as being more similar to T1DM rather than the progressive insulin
resistance and β-cell deficiency that develops during GDM.
Surgical
As discussed in section 1.4.1, one type of surgical manipulation that results in removal of
β-cells and has been used to model GDM is partial pancreatectomy. Nonetheless, results
in these studies have produced inconsistent findings [224]. Furthermore, this complex
technique can result in diabetes onset that can take long to manifest. Importantly, GDM
does not occur due to a sudden insult and similarly to the pharmacological manipulation,
the GDM phenotype described here better resembles T1DM.
Genetic
The db/db mouse is characterized by a mutation in the leptin receptor gene and is used for
studying obesity [226]. Although homozygous females (db/db) are sterile, heterozygotes
are fertile and importantly non-pregnant females do not show glucose intolerance
[227,228]. During pregnancy, females display increased adiposity contributing to insulin
resistance and mild glucose intolerance [228,229]. Thus, this model accurately mimics
many features of human GDM. Although obesity is a major driver of GDM, some
features of this model better resemble the increased adiposity that is observed in some
cases with T2DM. It is important to consider that non-obese individuals develop GDM as
well, thus implicating dysfunction at the level of the β-cell rather than due to obesity
alone. Furthermore, the use of genetic models is limited for translational use in larger
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animal models and simplifies the human condition as GDM is influenced by many genes
and environmental factors [224].
Nutritional
Animal models using high-fat diet (HFD) feeding have been used to mimic GDM
symptoms where HFD feeding before and during pregnancy results in a GDM phenotype
by late gestation in rats [230]. Experiments in mice have reproduced these findings
showing that HFD feeding prior to and throughout gestation results in elevated blood
glucose and insulin levels during pregnancy [231]. However, the phenotype was present
prior to pregnancy in these experiments and thus does not accurately represent the human
phenotype. This method has several advantages to modeling the disease, since obesity is
a major driver of GDM in humans, and permits for study in larger animals where genetic
manipulation is unfeasible [224]. Nonetheless, similarly to the db/db mice, this phenotype
better resembles the T2DM condition as the animals show increased adiposity and insulin
resistance. Therefore, existing pre-gestational diabetes/obesity is more likely driving the
disease in this model which does not take into consideration that lean women also
develop GDM.

Although each model presents both advantages and limitations, an important concept of
GDM pathogenesis that each model lacks is the progressive development of transient
hyperglycemia during pregnancy that is restricted to late gestation and reverts after
pregnancy. Thus, continued efforts to produce an accurate model of GDM characterized
by defects in β-cell adaptability with restricted hyperglycemia to late pregnancy are
needed in order to be able to implement novel methods of intervention. One animal
model that has been well-characterized and shown to impact β-cell plasticity is the low
protein model of fetal programming.
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1.8 Low Protein Model
The hypothesis of fetal programming of adult diseases first formulated by Professor Sir
David Barker proposes that the intrauterine environment during development can
influence the risk of metabolic diseases later in life in the offspring [232]. More
specifically, nutrient availability during fetal and early postnatal life plays an important
role in determining adult health. Metabolic disturbances during these critical
developmental timepoints, such as dietary restriction, contribute to the development of
adult chronic diseases such as T2DM, obesity, and cardiovascular disease [233]. After the
hypothesis was formulated, Snoeck and colleagues demonstrated that a low protein (LP)
diet during gestation in rats (in comparison to a control, C, diet) resulted in reduced birth
weight (intra-uterine growth restricted, IUGR) offspring [234]. The LP diet was made
isocaloric to the C diet via increased carbohydrate. IUGR is described as the failure of a
fetus to achieve its genetic potential for size which in clinical terms would be below the
10th percentile for gestational age [235]. When the dams were maintained on a LP diet
during lactation, body weight of offspring was reduced until weaning [236]. IUGR affects
the development of multiple organs, including the pancreas [236,237]. Using the
established model of dietary protein restriction during pregnancy and lactation, it has
been extensively published that dietary insufficiency in early life alters normal pancreatic
development in the offspring, which ultimately contributes to impaired glucose
homeostasis in adulthood. We found that maternal protein restriction altered cell-cycle
kinetics in offspring by increasing the incidence of β-cell apoptosis and decreasing the
proliferative rate of β-cells, ultimately resulting in a reduced BCM [236,238,239].
Although offspring of LP-fed dams displayed impaired GSIS, glucose intolerance did not
manifest until 130 days of age in female rats [240,241]. In females, glucose intolerance
was attributed to decreased BCM. Interestingly, the males in this study displayed insulin
resistance in adipose and skeletal muscle in contrast to the reduced BCM observed in
females. These findings have also been supported in additional larger animal IUGR
models, as in sheep decreased β-cell replication was also shown to result in reduced
BCM, in addition to β-cell dysfunction, leading to decreased GSIS [242–244].
Furthermore, IUGR human fetuses have also been shown to have decreased BCM [245].
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More recently, β-cell plasticity was examined in mice treated with LP and STZ [246].
The results showed that control fed offspring had largely regenerated their β-cells and
replaced BCM after STZ, since young mice normally show a regenerative capability
following β-cell loss. Nonetheless, LP exposure limited the capacity for recovery of BCM
in both males and females after STZ treatment. In the same study, there was a delayed
ability to increase α-cell mass (ACM) implying that mechanisms involved might be
common to multiple endocrine cell types. In addition to histological and functional
differences in endocrine cells, pancreatic vascularity and signaling between β-cells and
endothelial cells has been shown to play a role in β-cell dysfunction of IUGR fetuses.
Lower pancreatic islet vascularity has been observed in IUGR humans [245] and animal
models of IUGR [247,248]. Importantly, islet size and GSIS was limited by vascular
supply [248,249]. Furthermore, expression of angiogenic factor vascular endothelial
growth factor A (VEGFA) was decreased in LP rats [234,236]. VEGFA is important in
islet development and β-cell function. Proof of concept studies showed that gestational
taurine supplementation in the LP rat prevented the decrease in fetal islet vascularity and
VEGFA expression [237]. β-cell apoptosis was also attenuated in taurine-supplemented
LP rats compared to non-supplemented, resulting in higher BCM [250].

Collectively these studies demonstrate strong evidence for impaired β-cell development
and plasticity after exposure to the LP diet during development, which is potentially
reversible.

1.8.1. Relevance to Humans
One model that represents the effects of famine on fetal development is the calorie
restriction model. However, the effects of famine on fetal development are of lesser
concern in North America. In contrast, the LP model shares common features to human
placental insufficiency. Placental insufficiency is a major cause of IUGR in North
America and complicates 4-8% of pregnancies [251]. Similar to the LP diet model,
placental insufficiency in humans can produce a protein deficiency in the fetus [252].
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Since placental insufficiency results in both decreased oxygen and nutrient delivery, the
LP model permits for differentiation of the specific effects of amino acid deficiency
[252]. Importantly, the LP diet has no major effects on maternal physiology (including
maternal food intake and weight gain) and no effect on offspring food intake [253]. These
findings are important as altered food intake in the mother could add confounding
variables to the model and is in contrast to the caloric restriction model which adversely
affects both maternal and fetal physiology.

1.9 Rationale, Objectives, Hypothesis
Rationale
GDM seriously impacts the short and long-term health of both the mother and her child.
Unfortunately, there is a lack of effective methods for prevention/treatment to reverse βcell insufficiency in GDM. Given that rates of GDM are increasing, and the in utero
environment is an important determinant of adult health, it is important to investigate the
underlying mechanisms of GDM. The mechanisms leading to GDM are poorly
understood and β-cells of pregnant humans with GDM have yet to be analysed.
Furthermore, changes in endocrine pancreas of humans with GDM cannot be viewed in
vivo due to lack of imaging modalities available at present for pregnant humans.
However, the reliance on animal models is hindered as models that accurately represent
symptoms of GDM are currently lacking. These models present multiple limitations such
as demonstrating pre-gestational glucose intolerance and obesity which is not a true
diagnosis of clinical GDM, while others better resemble T1DM or T2DM pathogenesis as
opposed to the characteristics of insulin resistance seen in conditions such as GDM.
Furthermore, these models importantly lack the transient hyperglycemia that is diagnosed
at late gestation. Given that β-cell dysfunction is a key determinant to GDM
pathogenesis, a better model characterized by impairments of reduced β-cell adaptability
is needed so that targeted methods of intervention can be implemented. The LP model
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has been well-characterized, and much evidence supports altered pancreatic β-cell
development. However, no studies have investigated the plasticity of β-cells during a
subsequent time of increased metabolic stress, such as pregnancy. Thus, we sought to use
this model in an attempt to produce an animal model of reduced β-cell adaptability in
pregnancy that can be used to better understand β-cell insufficiency in GDM.
Hypothesis
It is hypothesized that exposure to LP diet during fetal and neonatal development will
impair β-cell adaptability in pregnant F1 females. This will result in glucose intolerance
during pregnancy, which can be reversed with treatment.
Objectives

1. Establish a mouse model of impaired glucose tolerance during pregnancy

2. Determine the long-term effects of GDM on glucose tolerance and pancreas
histology after pregnancy

3. Investigate the contribution of α- to β-cell transdifferentiation to gestational BCM
expansion

4. Test strategies to improve glucose tolerance in pregnancy through the
manipulation of BCM

49

1.10 References
[1]

WHO | The top 10 causes of death, WHO. (2017).

[2]

The Emerging Risk Factors Collaboration, N. Sarwar, P. Gao, S.R.K. Seshasai, R.
Gobin, S. Kaptoge, E. Di Angelantonio, E. Ingelsson, D.A. Lawlor, E. Selvin, M.
Stampfer, C.D.A. Stehouwer, S. Lewington, L. Pennells, A. Thompson, N. Sattar,
I.R. White, K.K. Ray, J. Danesh, Diabetes mellitus, fasting blood glucose
concentration, and risk of vascular disease: a collaborative meta-analysis of 102
prospective studies, Lancet. 375 (2010) 2215–2222.
https://doi.org/10.1016/S0140-6736(10)60484-9.

[3]

R. Saran, Y. Li, B. Robinson, J. Ayanian, R. Balkrishnan, J. Bragg-Gresham,
J.T.L. Chen, E. Cope, D. Gipson, K. He, W. Herman, M. Heung, R.A. Hirth, S.S.
Jacobsen, K. Kalantar-Zadeh, C.P. Kovesdy, A.B. Leichtman, Y. Lu, M.Z. Molnar,
H. Morgenstern, B. Nallamothu, A.M. O’Hare, R. Pisoni, B. Plattner, F.K. Port, P.
Rao, C.M. Rhee, D.E. Schaubel, D.T. Selewski, V. Shahinian, J.J. Sim, P. Song, E.
Streja, M. Kurella Tamura, F. Tentori, P.W. Eggers, L.Y.C. Agodoa, K.C. Abbott,
US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney
Disease in the United States, Am. J. Kidney Dis. 66 (2015) A7.
https://doi.org/10.1053/j.ajkd.2015.05.001.

[4]

R.R.A. Bourne, G.A. Stevens, R.A. White, J.L. Smith, S.R. Flaxman, H. Price, J.B.
Jonas, J. Keeffe, J. Leasher, K. Naidoo, K. Pesudovs, S. Resnikoff, H.R. Taylor,
Vision Loss Expert Group, Causes of vision loss worldwide, 1990–2010: a
systematic analysis, Lancet Glob. Heal. 1 (2013) e339–e349.
https://doi.org/10.1016/S2214-109X(13)70113-X.

[5]

P. Rorsman, M. Braun, Regulation of Insulin Secretion in Human Pancreatic Islets,
Annu. Rev. Physiol. 75 (2013) 155–179. https://doi.org/10.1146/annurev-physiol030212-183754.

[6]

F.G. Banting, C.H. Best, J.B. Collip, W.R. Campbell, A.A. Fletcher, Pancreatic
Extracts in the Treatment of Diabetes Mellitus., Can. Med. Assoc. J. 12 (1922)
141–146.

[7]

L. Szablewski, Role of immune system in type 1 diabetes mellitus pathogenesis,

50

Int. Immunopharmacol. 22 (2014) 182–191.
https://doi.org/10.1016/j.intimp.2014.06.033.
[8]

A.M.J. Shapiro, C. Ricordi, B.J. Hering, H. Auchincloss, R. Lindblad, R.P.
Robertson, A. Secchi, M.D. Brendel, T. Berney, D.C. Brennan, E. Cagliero, R.
Alejandro, E.A. Ryan, B. DiMercurio, P. Morel, K.S. Polonsky, J.-A. Reems, R.G.
Bretzel, F. Bertuzzi, T. Froud, R. Kandaswamy, D.E.R. Sutherland, G. Eisenbarth,
M. Segal, J. Preiksaitis, G.S. Korbutt, F.B. Barton, L. Viviano, V. SeyfertMargolis, J. Bluestone, J.R.T. Lakey, International Trial of the Edmonton Protocol
for Islet Transplantation, N. Engl. J. Med. 355 (2006) 1318–1330.
https://doi.org/10.1056/NEJMoa061267.

[9]

M.A. Atkinson, G.S. Eisenbarth, A.W. Michels, Type 1 diabetes., Lancet (London,
England). 383 (2014) 69–82. https://doi.org/10.1016/S0140-6736(13)60591-7.

[10] C.J. Nolan, P. Damm, M. Prentki, Type 2 diabetes across generations: from
pathophysiology to prevention and management, Lancet. 378 (2011) 169–181.
https://doi.org/10.1016/S0140-6736(11)60614-4.
[11] S. Seino, T. Shibasaki, K. Minami, Dynamics of insulin secretion and the clinical
implications for obesity and diabetes., J. Clin. Invest. 121 (2011) 2118–2125.
https://doi.org/10.1172/JCI45680.
[12] E.T. Kato, S.R. Das, D.K. McGuire, Antihyperglycemic therapies and
cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art
and future directions, Trends Cardiovasc. Med. (2020).
https://doi.org/10.1016/j.tcm.2019.12.010.
[13] K. Ogurtsova, J.D. da Rocha Fernandes, Y. Huang, U. Linnenkamp, L. Guariguata,
N.H. Cho, D. Cavan, J.E. Shaw, L.E. Makaroff, IDF Diabetes Atlas: Global
estimates for the prevalence of diabetes for 2015 and 2040, Diabetes Res. Clin.
Pract. 128 (2017) 40–50. https://doi.org/10.1016/j.diabres.2017.03.024.
[14] Betts GJ, Desaix P, Johnson E, Korol O, Kruse D, Poe B et al. Human Anatomy
and Physiology. OpenStax College: Houston, TX, USA, 2013.
[15] H. Ohlsson, K. Karlsson, T. Edlund, IPF1, a homeodomain-containing
transactivator of the insulin gene., EMBO J. 12 (1993) 4251–4259.
[16] H. Kaneto, T. Miyatsuka, D. Kawamori, K. Yamamoto, K. Kato, T. Shiraiwa, N.

51

Katakami, Y. Yamasaki, M. Matsuhisa, T.-A. Matsuoka, PDX-1 and MafA play a
crucial role in pancreatic beta-cell differentiation and maintenance of mature betacell function., Endocr. J. 55 (2008) 235–252.
[17] D.A. Stoffers, R.S. Heller, C.P. Miller, J.F. Habener, Developmental expression of
the homeodomain protein IDX-1 in mice transgenic for an IDX-1 promoter/lacZ
transcriptional reporter., Endocrinology. 140 (1999) 5374–5381.
https://doi.org/10.1210/endo.140.11.7122.
[18] A. Krapp, M. Knofler, B. Ledermann, K. Burki, C. Berney, N. Zoerkler, O.
Hagenbuchle, P.K. Wellauer, The bHLH protein PTF1-p48 is essential for the
formation of the exocrine and the correct spatial organization of the endocrine
pancreas, Genes Dev. 12 (1998) 3752–3763.
https://doi.org/10.1101/gad.12.23.3752.
[19] A. Bastidas-Ponce, K. Scheibner, H. Lickert, M. Bakhti, Cellular and molecular
mechanisms coordinating pancreas development, Development. 144 (2017) 2873–
2888. https://doi.org/10.1242/dev.140756.
[20] M.F. Offield, T.L. Jetton, P.A. Labosky, M. Ray, R.W. Stein, M.A. Magnuson,
B.L. Hogan, C. V Wright, PDX-1 is required for pancreatic outgrowth and
differentiation of the rostral duodenum., Development. 122 (1996) 983–995.
[21] J.F. Habener, D.M. Kemp, M.K. Thomas, Minireview: Transcriptional Regulation
in Pancreatic Development, Endocrinology. 146 (2005) 1025–1034.
https://doi.org/10.1210/en.2004-1576.
[22] M. Sander, M.S. German, The β cell transcription factors and development of the
pancreas, J. Mol. Med. 75 (1997) 327–340.
https://doi.org/10.1007/s001090050118.
[23] F.C. Pan, E.D. Bankaitis, D. Boyer, X. Xu, M. Van de Casteele, M.A. Magnuson,
H. Heimberg, C.V.E. Wright, Spatiotemporal patterns of multipotentiality in Ptf1aexpressing cells during pancreas organogenesis and injury-induced facultative
restoration, Development. 140 (2013) 751–764.
https://doi.org/10.1242/dev.090159.
[24] A.E. Schaffer, K.K. Freude, S.B. Nelson, M. Sander, Nkx6 transcription factors
and Ptf1a function as antagonistic lineage determinants in multipotent pancreatic

52

progenitors., Dev. Cell. 18 (2010) 1022–1029.
https://doi.org/10.1016/j.devcel.2010.05.015.
[25]

A. Grapin-Botton, A.R. Majithia, D.A. Melton, Key events of pancreas formation
are triggered in gut endoderm by ectopic expression of pancreatic regulatory
genes., Genes Dev. 15 (2001) 444–454. https://doi.org/10.1101/gad.846001.

[26] G. Gradwohl, A. Dierich, M. LeMeur, F. Guillemot, neurogenin3 is required for
the development of the four endocrine cell lineages of the pancreas, Proc. Natl.
Acad. Sci. 97 (2000) 1607–1611. https://doi.org/10.1073/pnas.97.4.1607.
[27] T.G. Sanders, W.J. Rutter, The developmental regulation of amylolytic and
proteolytic enzymes in the embryonic rat pancreas., J. Biol. Chem. 249 (1974)
3500–3509.
[28] J. Dolenšek, M.S. Rupnik, A. Stožer, Structural similarities and differences
between the human and the mouse pancreas, Islets. 7 (2015) e1024405.
https://doi.org/10.1080/19382014.2015.1024405.
[29] B. Svendsen, O. Larsen, M.B.N. Gabe, C.B. Christiansen, M.M. Rosenkilde, D.J.
Drucker, J.J. Holst, Insulin Secretion Depends on Intra-islet Glucagon Signaling,
Cell Rep. 25 (2018) 1127-1134.e2. https://doi.org/10.1016/j.celrep.2018.10.018.
[30] R. Rodriguez-Diaz, R.D. Molano, J.R. Weitz, M.H. Abdulreda, D.M. Berman, B.
Leibiger, I.B. Leibiger, N.S. Kenyon, C. Ricordi, A. Pileggi, A. Caicedo, P.-O.
Berggren, Paracrine Interactions within the Pancreatic Islet Determine the
Glycemic Set Point, Cell Metab. 27 (2018) 549-558.e4.
https://doi.org/10.1016/J.CMET.2018.01.015.
[31] I. Artner, Y. Hang, M. Mazur, T. Yamamoto, M. Guo, J. Lindner, M.A.
Magnuson, R. Stein, MafA and MafB regulate genes critical to beta-cells in a
unique temporal manner., Diabetes. 59 (2010) 2530–2539.
https://doi.org/10.2337/db10-0190.
[32] L.C. Murtaugh, Pancreas and beta-cell development: from the actual to the
possible, Development. 134 (2006) 427–438. https://doi.org/10.1242/dev.02770.
[33] M.D. Gahete, J. Cordoba-Chacón, M. Duran-Prado, M.M. Malagón, A.J.
Martinez-Fuentes, F. Gracia-Navarro, R.M. Luque, J.P. Castaño, Somatostatin and
its receptors from fish to mammals, Ann. N. Y. Acad. Sci. 1200 (2010) 43–52.

53

https://doi.org/10.1111/j.1749-6632.2010.05511.x.
[34] M.R. DiGruccio, A.M. Mawla, C.J. Donaldson, G.M. Noguchi, J. Vaughan, C.
Cowing-Zitron, T. van der Meulen, M.O. Huising, Comprehensive alpha, beta and
delta cell transcriptomes reveal that ghrelin selectively activates delta cells and
promotes somatostatin release from pancreatic islets., Mol. Metab. 5 (2016) 449–
458. https://doi.org/10.1016/j.molmet.2016.04.007.
[35] P. Rorsman, M.O. Huising, The somatostatin-secreting pancreatic δ-cell in health
and disease., Nat. Rev. Endocrinol. 14 (2018) 404–414.
https://doi.org/10.1038/s41574-018-0020-6.
[36] R. Arrojo e Drigo, S. Jacob, C.F. García-Prieto, X. Zheng, M. Fukuda, H.T.T.
Nhu, O. Stelmashenko, F.L.M. Peçanha, R. Rodriguez-Diaz, E. Bushong, T.
Deerinck, S. Phan, Y. Ali, I. Leibiger, M. Chua, T. Boudier, S.-H. Song, M. Graf,
G.J. Augustine, M.H. Ellisman, P.-O. Berggren, Structural basis for delta cell
paracrine regulation in pancreatic islets, Nat. Commun. 10 (2019) 3700.
https://doi.org/10.1038/s41467-019-11517-x.
[37] R.A. Liddle, Regulation of Pancreatic Secretion, Physiol. Gastrointest. Tract.
(2018) 895–929. https://doi.org/10.1016/B978-0-12-809954-4.00040-2.
[38] A. Kastin, Handbook of Biologically Active Peptides, 2013.
https://doi.org/10.1016/C2010-0-66490-X.
[39] L. Scaglia, C.J. Cahill, D.T. Finegood, S. Bonner-Weir, Apoptosis participates in
the remodeling of the endocrine pancreas in the neonatal rat., Endocrinology. 138
(1997) 1736–1741. https://doi.org/10.1210/endo.138.4.5069.
[40] J. Petrik, E. Arany, T.J. McDonald, D.J. Hill, Apoptosis in the pancreatic islet cells
of the neonatal rat is associated with a reduced expression of insulin-like growth
factor II that may act as a survival factor., Endocrinology. 139 (1998) 2994–3004.
https://doi.org/10.1210/endo.139.6.6042.
[41] S. Bonner-Weir, C. Aguayo-Mazzucato, G.C. Weir, Dynamic development of the
pancreas from birth to adulthood., Ups. J. Med. Sci. 121 (2016) 155–158.
https://doi.org/10.3109/03009734.2016.1154906.
[42] D.T. Finegood, L. Scaglia, S. Bonner-Weir, Dynamics of beta-cell mass in the
growing rat pancreas. Estimation with a simple mathematical model., Diabetes. 44

54

(1995) 249–256.
[43] S. Perl, J.A. Kushner, B.A. Buchholz, A.K. Meeker, G.M. Stein, M. Hsieh, M.
Kirby, S. Pechhold, E.H. Liu, D.M. Harlan, J.F. Tisdale, Significant human betacell turnover is limited to the first three decades of life as determined by in vivo
thymidine analog incorporation and radiocarbon dating., J. Clin. Endocrinol.
Metab. 95 (2010) E234-9. https://doi.org/10.1210/jc.2010-0932.
[44] J.J. Meier, A.E. Butler, Y. Saisho, T. Monchamp, R. Galasso, A. Bhushan, R.A.
Rizza, P.C. Butler, Beta-cell replication is the primary mechanism subserving the
postnatal expansion of beta-cell mass in humans., Diabetes. 57 (2008) 1584–1594.
https://doi.org/10.2337/db07-1369.
[45] L. Bouwens, D.G. Pipeleers, Extra-insular beta cells associated with ductules are
frequent in adult human pancreas., Diabetologia. 41 (1998) 629–633.
https://doi.org/10.1007/s001250050960.
[46]

S. Bonner-Weir, beta-cell turnover: its assessment and implications., Diabetes. 50
Suppl 1 (2001) S20-24.

[47] B. Thorens, GLUT2, glucose sensing and glucose homeostasis, Diabetologia. 58
(2015) 221–232. https://doi.org/10.1007/s00125-014-3451-1.
[48] A. De Vos, H. Heimberg, E. Quartier, P. Huypens, L. Bouwens, D. Pipeleers, F.
Schuit, Human and rat beta cells differ in glucose transporter but not in
glucokinase gene expression., J. Clin. Invest. 96 (1995) 2489–2495.
https://doi.org/10.1172/JCI118308.
[49] L.J. McCulloch, M. van de Bunt, M. Braun, K.N. Frayn, A. Clark, A.L. Gloyn,
GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic
beta cells: Implications for understanding genetic association signals at this locus,
Mol. Genet. Metab. 104 (2011) 648–653.
https://doi.org/10.1016/j.ymgme.2011.08.026.
[50] F.W. Pagliuca, D.A. Melton, S. Kato, J.P. Thiery, P. Czernichow, S. Bellusci, R.
Scharfmann, How to make a functional β-cell., Development. 140 (2013) 2472–
2483. https://doi.org/10.1242/dev.093187.
[51] F.M. Ashcroft, ATP-sensitive potassium channelopathies: focus on insulin
secretion, J. Clin. Invest. 115 (2005) 2047–2058.

55

https://doi.org/10.1172/JCI25495.
[52] D.R. Matthews, B.A. Naylor, R.G. Jones, G.M. Ward, R.C. Turner, Pulsatile
Insulin Has Greater Hypoglycemic Effect Than Continuous Delivery, Diabetes. 32
(1983) 617–621. https://doi.org/10.2337/diab.32.7.617.
[53] P. Gilon, M.A. Ravier, J.-C. Jonas, J.-C. Henquin, Control Mechanisms of the
Oscillations of Insulin Secretion In Vitro and In Vivo, Diabetes. 51 (2002) S144–
S151. https://doi.org/10.2337/diabetes.51.2007.S144.
[54] S.N. Davis, P.M. Piatti, L. Monti, M.D. Brown, W. Branch, C.N. Hales, K.G.M.M.
Alberti, Proinsulin and insulin concentrations following intravenous glucose
challenges in normal, obese, and non-insulin-dependent diabetic subjects,
Metabolism. 42 (1993) 30–35. https://doi.org/10.1016/0026-0495(93)90168-N.
[55] R.A. Haeusler, T.E. McGraw, D. Accili, Biochemical and cellular properties of
insulin receptor signalling, Nat. Rev. Mol. Cell Biol. 19 (2018) 31–44.
https://doi.org/10.1038/nrm.2017.89.
[56] M. Teta, S.Y. Long, L.M. Wartschow, M.M. Rankin, J.A. Kushner, Very Slow
Turnover of Beta-Cells in Aged Adult Mice, Diabetes. 54 (2005) 2557–2567.
https://doi.org/10.2337/diabetes.54.9.2557.
[57] J.S. Brockenbrough, G.C. Weir, S. Bonner-Weir, Discordance of Exocrine and
Endocrine Growth After 90% Pancreatectomy in Rats, Diabetes. 37 (1988) 232–
236. https://doi.org/10.2337/diab.37.2.232.
[58] H.C. Lee, S. Bonner-Weir, G.C. Weir, J.L. Leahy, Compensatory Adaption to
Partial Pancreatectomy in the Rat, Endocrinology. 124 (1989) 1571–1575.
https://doi.org/10.1210/endo-124-3-1571.
[59] S. Bonner-Weir, D.F. Trent, G.C. Weir, Partial pancreatectomy in the rat and
subsequent defect in glucose-induced insulin release., J. Clin. Invest. 71 (1983)
1544–1553. https://doi.org/10.1172/JCI110910.
[60] Y. Dor, J. Brown, O.I. Martinez, D.A. Melton, Adult pancreatic beta-cells are
formed by self-duplication rather than stem-cell differentiation., Nature. 429
(2004) 41–46. https://doi.org/10.1038/nature02520.
[61] K.Y. Hayashi, H. Tamaki, K. Handa, T. Takahashi, A. Kakita, S. Yamashina,
Differentiation and proliferation of endocrine cells in the regenerating rat pancreas

56

after 90% pancreatectomy, Arch. Histol. Cytol. 66 (2003) 163–174.
https://doi.org/10.1679/aohc.66.163.
[62] T. Berrocal, A.Á. Luque, I. Pinilla, L. Lassaletta, Pancreatic regeneration after
near-total pancreatectomy in children with nesidioblastosis, Pediatr. Radiol. 35
(2005) 1066–1070. https://doi.org/10.1007/s00247-005-1537-0.
[63] A. Inada, C. Nienaber, H. Katsuta, Y. Fujitani, J. Levine, R. Morita, A. Sharma, S.
Bonner-Weir, Carbonic anhydrase II-positive pancreatic cells are progenitors for
both endocrine and exocrine pancreas after birth., Proc. Natl. Acad. Sci. U. S. A.
105 (2008) 19915–19919. https://doi.org/10.1073/pnas.0805803105.
[64] X. Xu, J. D’Hoker, G. Stangé, S. Bonné, N. De Leu, X. Xiao, M. Van De Casteele,
G. Mellitzer, Z. Ling, D. Pipeleers, L. Bouwens, R. Scharfmann, G. Gradwohl, H.
Heimberg, β Cells Can Be Generated from Endogenous Progenitors in Injured
Adult Mouse Pancreas, Cell. 132 (2008) 197–207.
https://doi.org/10.1016/j.cell.2007.12.015.
[65] K. Furuyama, Y. Kawaguchi, H. Akiyama, M. Horiguchi, S. Kodama, T. Kuhara,
S. Hosokawa, A. Elbahrawy, T. Soeda, M. Koizumi, T. Masui, M. Kawaguchi, K.
Takaori, R. Doi, E. Nishi, R. Kakinoki, J.M. Deng, R.R. Behringer, T. Nakamura,
S. Uemoto, Continuous cell supply from a Sox9-expressing progenitor zone in
adult liver, exocrine pancreas and intestine, Nat. Genet. 43 (2011) 34–41.
https://doi.org/10.1038/ng.722.
[66] M. Solar, C. Cardalda, I. Houbracken, M. Martín, M.A. Maestro, N. De Medts, X.
Xu, V. Grau, H. Heimberg, L. Bouwens, J. Ferrer, Pancreatic Exocrine Duct Cells
Give Rise to Insulin-Producing β Cells during Embryogenesis but Not after Birth,
Dev. Cell. 17 (2009) 849–860. https://doi.org/10.1016/j.devcel.2009.11.003.
[67] J.L. Kopp, C.L. Dubois, A.E. Schaffer, E. Hao, H.P. Shih, P.A. Seymour, J. Ma,
M. Sander, Sox9+ ductal cells are multipotent progenitors throughout development
but do not produce new endocrine cells in the normal or injured adult pancreas,
Development. 138 (2011) 653–665. https://doi.org/10.1242/dev.056499.
[68] T. Nir, D.A. Melton, Y. Dor, Recovery from diabetes in mice by β cell
regeneration, J. Clin. Invest. 117 (2007) 2553–2561.
https://doi.org/10.1172/JCI32959.

57

[69] F. Shamsi, R. Parlato, P. Collombat, A. Mansouri, A genetic mouse model for
progressive ablation and regeneration of insulin producing beta-cells, Cell Cycle.
13 (2014) 3948–3957. https://doi.org/10.4161/15384101.2014.952176.
[70] V. Cigliola, F. Thorel, S. Chera, P.L. Herrera, Stress-induced adaptive islet cell
identity changes, Diabetes, Obes. Metab. 18 (2016) 87–96.
https://doi.org/10.1111/dom.12726.
[71] F. Zhong, Y. Jiang, Endogenous Pancreatic β Cell Regeneration: A Potential
Strategy for the Recovery of β Cell Deficiency in Diabetes., Front. Endocrinol.
(Lausanne). 10 (2019) 101. https://doi.org/10.3389/fendo.2019.00101.
[72] M. Kataoka, Y. Kawamuro, N. Shiraki, R. Miki, D. Sakano, T. Yoshida, T.
Yasukawa, K. Kume, S. Kume, Recovery from diabetes in neonatal mice after a
low-dose streptozotocin treatment, Biochem. Biophys. Res. Commun. 430 (2013)
1103–1108. https://doi.org/10.1016/j.bbrc.2012.12.030.
[73] R.N. Wang, L. Bouwens, G. Klöppel, Beta-cell proliferation in normal and
streptozotocin-treated newborn rats: site, dynamics and capacity., Diabetologia. 37
(1994) 1088–1096. https://doi.org/10.1007/bf00418372.
[74] R. De Haro-Hernández, L. Cabrera-Muñoz, J.D. Méndez, Regeneration of betacells and neogenesis from small ducts or acinar cells promote recovery of
endocrine pancreatic function in alloxan-treated rats., Arch. Med. Res. 35 (2004)
114–120. https://doi.org/10.1016/j.arcmed.2003.10.001.
[75] S. Thyssen, E. Arany, D.J. Hill, Ontogeny of Regeneration of β-Cells in the
Neonatal Rat after Treatment with Streptozotocin, Endocrinology. 147 (2006)
2346–2356. https://doi.org/10.1210/en.2005-0396.
[76] R. V Intine, A.S. Olsen, M.P. Sarras, Jr., A zebrafish model of diabetes mellitus
and metabolic memory., J. Vis. Exp. (2013) e50232.
https://doi.org/10.3791/50232.
[77] H. Liu, Y. Guz, M.H. Kedees, J. Winkler, G. Teitelman, Precursor cells in mouse
islets generate new beta-cells in vivo during aging and after islet injury.,
Endocrinology. 151 (2010) 520–528. https://doi.org/10.1210/en.2009-0992.
[78] M. Cnop, M. Igoillo-Esteve, S.J. Hughes, J.N. Walker, I. Cnop, A. Clark,
Longevity of human islet α- and β-cells, Diabetes, Obes. Metab. 13 (2011) 39–46.

58

https://doi.org/10.1111/j.1463-1326.2011.01443.x.
[79] M. Cnop, S.J. Hughes, M. Igoillo-Esteve, M.B. Hoppa, F. Sayyed, L. van de Laar,
J.H. Gunter, E.J.P. de Koning, G. V. Walls, D.W.G. Gray, P.R. V. Johnson, B.C.
Hansen, J.F. Morris, M. Pipeleers-Marichal, I. Cnop, A. Clark, The long lifespan
and low turnover of human islet beta cells estimated by mathematical modelling of
lipofuscin accumulation, Diabetologia. 53 (2010) 321–330.
https://doi.org/10.1007/s00125-009-1562-x.
[80] Y. Saisho, A.E. Butler, E. Manesso, D. Elashoff, R.A. Rizza, P.C. Butler, β-cell
mass and turnover in humans: effects of obesity and aging., Diabetes Care. 36
(2013) 111–117. https://doi.org/10.2337/dc12-0421.
[81] J. Krishnamurthy, M.R. Ramsey, K.L. Ligon, C. Torrice, A. Koh, S. Bonner-Weir,
N.E. Sharpless, p16INK4a induces an age-dependent decline in islet regenerative
potential, Nature. 443 (2006) 453–457. https://doi.org/10.1038/nature05092.
[82] H. Chen, X. Gu, I. Su, R. Bottino, J.L. Contreras, A. Tarakhovsky, S.K. Kim,
Polycomb protein Ezh2 regulates pancreatic Beta-cell Ink4a/Arf expression and
regeneration in diabetes mellitus, Genes Dev. 23 (2009) 975–985.
https://doi.org/10.1101/gad.1742509.
[83] S. Janjuha, S.P. Singh, A. Tsakmaki, S.N. Mousavy Gharavy, P. Murawala, J.
Konantz, S. Birke, D.J. Hodson, G.A. Rutter, G.A. Bewick, N. Ninov, Age-related
islet inflammation marks the proliferative decline of pancreatic beta-cells in
zebrafish, Elife. 7 (2018). https://doi.org/10.7554/eLife.32965.
[84] A.M. Chang, J.B. Halter, Aging and insulin secretion, Am. J. Physiol. Metab. 284
(2003) E7–E12. https://doi.org/10.1152/ajpendo.00366.2002.
[85] C.A. Beamish, S. Mehta, B.J. Strutt, S. Chakrabarti, M. Hara, D.J. Hill, Decrease
in Ins+Glut2LO β-cells with advancing age in mouse and human pancreas., J.
Endocrinol. 233 (2017) 229–241. https://doi.org/10.1530/JOE-16-0475.
[86] F. Thorel, V. Népote, I. Avril, K. Kohno, R. Desgraz, S. Chera, P.L. Herrera,
Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell
loss., Nature. 464 (2010) 1149–1154. https://doi.org/10.1038/nature08894.
[87] S.-I. Tschen, S. Dhawan, T. Gurlo, A. Bhushan, Age-Dependent Decline in BetaCell Proliferation Restricts the Capacity of Beta-Cell Regeneration in Mice,

59

Diabetes. 58 (2009) 1312–1320. https://doi.org/10.2337/db08-1651.
[88] M.M. Rankin, J.A. Kushner, Adaptive β-cell proliferation is severely restricted
with advanced age, Diabetes. 58 (2009) 1365–1372. https://doi.org/10.2337/db081198.
[89] Y. Saisho, E. Manesso, A.E. Butler, R. Galasso, K. Kavanagh, M. Flynn, L.
Zhang, P. Clark, T. Gurlo, G.M. Toffolo, C. Cobelli, J.D. Wagner, P.C. Butler,
Ongoing β-Cell Turnover in Adult Nonhuman Primates Is Not Adaptively
Increased in Streptozotocin-Induced Diabetes, Diabetes. 60 (2011) 848–856.
https://doi.org/10.2337/db09-1368.
[90] B.A. Menge, A. Tannapfel, O. Belyaev, R. Drescher, C. Muller, W. Uhl, W.E.
Schmidt, J.J. Meier, Partial Pancreatectomy in Adult Humans Does Not Provoke
Beta-Cell Regeneration, Diabetes. 57 (2008) 142–149.
https://doi.org/10.2337/db07-1294.
[91] S. Chera, D. Baronnier, L. Ghila, V. Cigliola, J.N. Jensen, G. Gu, K. Furuyama, F.
Thorel, F.M. Gribble, F. Reimann, P.L. Herrera, Diabetes recovery by agedependent conversion of pancreatic δ-cells into insulin producers., Nature. 514
(2014) 503–507. https://doi.org/10.1038/nature13633.
[92] S. Rieck, K.H. Kaestner, Expansion of β-cell mass in response to pregnancy,
Trends Endocrinol. Metab. 21 (2010) 151–158.
https://doi.org/10.1016/j.tem.2009.11.001.
[93] R.J. Nichols, C. New, J.P. Annes, Adult tissue sources for new β cells., Transl.
Res. 163 (2014) 418–431. https://doi.org/10.1016/j.trsl.2013.11.012.
[94] Y. Liu, J. Suckale, J. Masjkur, M.G. Magro, A. Steffen, K. Anastassiadis, M.
Solimena, Tamoxifen-Independent Recombination in the RIP-CreER Mouse,
PLoS One. 5 (2010) e13533. https://doi.org/10.1371/journal.pone.0013533.
[95] M. Teta, M.M. Rankin, S.Y. Long, G.M. Stein, J.A. Kushner, Growth and
Regeneration of Adult β Cells Does Not Involve Specialized Progenitors, Dev.
Cell. 12 (2007) 817–826. https://doi.org/10.1016/j.devcel.2007.04.011.
[96] A.E. Butler, L. Cao-Minh, R. Galasso, R.A. Rizza, A. Corradin, C. Cobelli, P.C.
Butler, Adaptive changes in pancreatic beta cell fractional area and beta cell
turnover in human pregnancy., Diabetologia. 53 (2010) 2167–2176.

60

https://doi.org/10.1007/s00125-010-1809-6.
[97] J.J. Meier, A. Bhushan, A.E. Butler, R.A. Rizza, P.C. Butler, Sustained beta cell
apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet
regeneration?, Diabetologia. 48 (2005) 2221–2228.
https://doi.org/10.1007/s00125-005-1949-2.
[98] N.M. Fiaschi-Taesch, J.W. Kleinberger, F.G. Salim, R. Troxell, R. Wills, M.
Tanwir, G. Casinelli, A.E. Cox, K.K. Takane, H. Srinivas, D.K. Scott, A.F.
Stewart, Cytoplasmic-Nuclear Trafficking of G1/S Cell Cycle Molecules and
Adult Human Beta-Cell Replication: A Revised Model of Human Beta-Cell G1/S
Control, Diabetes. 62 (2013) 2460–2470. https://doi.org/10.2337/db12-0778.
[99] N.M. Fiaschi-Taesch, J.W. Kleinberger, F.G. Salim, R. Troxell, R. Wills, M.
Tanwir, G. Casinelli, A.E. Cox, K.K. Takane, D.K. Scott, A.F. Stewart, Human
Pancreatic Beta-Cell G1/S Molecule Cell Cycle Atlas, Diabetes. 62 (2013) 2450–
2459. https://doi.org/10.2337/db12-0777.
[100] I. Cozar-Castellano, K.K. Takane, R. Bottino, A.N. Balamurugan, A.F. Stewart,
Induction of beta-cell proliferation and retinoblastoma protein phosphorylation in
rat and human islets using adenovirus-mediated transfer of cyclin-dependent
kinase-4 and cyclin D1., Diabetes. 53 (2004) 149–159.
https://doi.org/10.2337/diabetes.53.1.149.
[101] R.C. Vasavada, A. Garcia-Ocaña, W.S. Zawalich, R.L. Sorenson, P. Dann, M.
Syed, L. Ogren, F. Talamantes, A.F. Stewart, Targeted Expression of Placental
Lactogen in the Beta Cells of Transgenic Mice Results in Beta Cell Proliferation,
Islet Mass Augmentation, and Hypoglycemia, J. Biol. Chem. 275 (2000) 15399–
15406. https://doi.org/10.1074/jbc.275.20.15399.
[102] A. Garcia-Ocaña, K.K. Takane, M.A. Syed, W.M. Philbrick, R.C. Vasavada, A.F.
Stewart, Hepatocyte growth factor overexpression in the islet of transgenic mice
increases beta cell proliferation, enhances islet mass, and induces mild
hypoglycemia., J. Biol. Chem. 275 (2000) 1226–1232.
https://doi.org/10.1074/jbc.275.2.1226.
[103] K.I. Aamodt, R. Aramandla, J.J. Brown, N. Fiaschi-Taesch, P. Wang, A.F.
Stewart, M. Brissova, A.C. Powers, Development of a reliable automated

61

screening system to identify small molecules and biologics that promote human βcell regeneration, Am. J. Physiol. Metab. 311 (2016) E859–E868.
https://doi.org/10.1152/ajpendo.00515.2015.
[104] P. Wang, J.-C. Alvarez-Perez, D.P. Felsenfeld, H. Liu, S. Sivendran, A. Bender, A.
Kumar, R. Sanchez, D.K. Scott, A. Garcia-Ocaña, A.F. Stewart, A highthroughput chemical screen reveals that harmine-mediated inhibition of DYRK1A
increases human pancreatic beta cell replication., Nat. Med. 21 (2015) 383–388.
https://doi.org/10.1038/nm.3820.
[105] W. Shen, B. Taylor, Q. Jin, V. Nguyen-Tran, S. Meeusen, Y.-Q. Zhang, A.
Kamireddy, A. Swafford, A.F. Powers, J. Walker, J. Lamb, B. Bursalaya, M.
DiDonato, G. Harb, M. Qiu, C.M. Filippi, L. Deaton, C.N. Turk, W.L. SuarezPinzon, Y. Liu, X. Hao, T. Mo, S. Yan, J. Li, A.E. Herman, B.J. Hering, T. Wu, H.
Martin Seidel, P. McNamara, R. Glynne, B. Laffitte, Inhibition of DYRK1A and
GSK3B induces human β-cell proliferation, Nat. Commun. 6 (2015) 8372.
https://doi.org/10.1038/ncomms9372.
[106] R.R. Bensley, Studies on the pancreas of the guinea pig, Am. J. Anat. 12 (1911)
297–388. https://doi.org/10.1002/aja.1000120304.
[107] S. Bonner-Weir, A. Inada, S. Yatoh, W.-C. Li, T. Aye, E. Toschi, A. Sharma,
Transdifferentiation of pancreatic ductal cells to endocrine β-cells, Biochem. Soc.
Trans. 36 (2008) 353–356. https://doi.org/10.1042/BST0360353.
[108] K. Al-Hasani, A. Pfeifer, M. Courtney, N. Ben-Othman, E. Gjernes, A. Vieira, N.
Druelle, F. Avolio, P. Ravassard, G. Leuckx, S. Lacas-Gervais, D. Ambrosetti, E.
Benizri, J. Hecksher-Sorensen, P. Gounon, J. Ferrer, G. Gradwohl, H. Heimberg,
A. Mansouri, P. Collombat, Adult Duct-Lining Cells Can Reprogram into β-like
Cells Able to Counter Repeated Cycles of Toxin-Induced Diabetes, Dev. Cell. 26
(2013) 86–100. https://doi.org/10.1016/j.devcel.2013.05.018.
[109] A. Criscimanna, J.A. Speicher, G. Houshmand, C. Shiota, K. Prasadan, B. Ji, C.D.
Logsdon, G.K. Gittes, F. Esni, Duct Cells Contribute to Regeneration of Endocrine
and Acinar Cells Following Pancreatic Damage in Adult Mice, Gastroenterology.
141 (2011) 1451-1462.e6. https://doi.org/10.1053/J.GASTRO.2011.07.003.
[110] M. Zhang, Q. Lin, T. Qi, T. Wang, C.-C. Chen, A.D. Riggs, D. Zeng, Growth

62

factors and medium hyperglycemia induce Sox9+ ductal cell differentiation into β
cells in mice with reversal of diabetes, Proc. Natl. Acad. Sci. 113 (2016) 650–655.
https://doi.org/10.1073/PNAS.1524200113.
[111] D. Kopinke, M. Brailsford, J.E. Shea, R. Leavitt, C.L. Scaife, L.C. Murtaugh,
Lineage tracing reveals the dynamic contribution of Hes1+ cells to the developing
and adult pancreas., Development. 138 (2011) 431–441.
https://doi.org/10.1242/dev.053843.
[112] M.R. Katdare, R.R. Bhonde, P.B. Parab, Analysis of morphological and functional
maturation of neoislets generated in vitro from pancreatic ductal cells and their
suitability for islet banking and transplantation., J. Endocrinol. 182 (2004) 105–
112. https://doi.org/10.1677/joe.0.1820105.
[113] R.N. Wang, L. Bouwens, G. Kloppel, Beta-cell growth in adolescent and adult rats
treated with streptozotocin during the neonatal period, Diabetologia. 39 (1996)
548–557. https://doi.org/10.1007/BF00403301.
[114] K.-C. Liu, G. Leuckx, D. Sakano, P.A. Seymour, C.L. Mattsson, L. Rautio, W.
Staels, Y. Verdonck, P. Serup, S. Kume, H. Heimberg, O. Andersson, Inhibition of
Cdk5 Promotes β-Cell Differentiation From Ductal Progenitors, Diabetes. 67
(2018) 58–70. https://doi.org/10.2337/db16-1587.
[115] S. Bonner-Weir, M. Taneja, G.C. Weir, K. Tatarkiewicz, K.-H. Song, A. Sharma,
J.J. O’Neil, In vitro cultivation of human islets from expanded ductal tissue, Proc.
Natl. Acad. Sci. 97 (2000) 7999–8004. https://doi.org/10.1073/pnas.97.14.7999.
[116] S. Bonner-Weir, E. Toschi, A. Inada, P. Reitz, S.Y. Fonseca, T. Aye, A. Sharma,
The pancreatic ductal epithelium serves as a potential pool of progenitor cells.,
Pediatr. Diabetes. 5 Suppl 2 (2004) 16–22. https://doi.org/10.1111/j.1399543X.2004.00075.x.
[117] A. Suzuki, H. Nakauchi, H. Taniguchi, Prospective isolation of multipotent
pancreatic progenitors using flow-cytometric cell sorting., Diabetes. 53 (2004)
2143–2152. https://doi.org/10.2337/diabetes.53.8.2143.
[118] R.M. Seaberg, S.R. Smukler, T.J. Kieffer, G. Enikolopov, Z. Asghar, M.B.
Wheeler, G. Korbutt, D. van der Kooy, Clonal identification of multipotent
precursors from adult mouse pancreas that generate neural and pancreatic

63

lineages., Nat. Biotechnol. 22 (2004) 1115–1124. https://doi.org/10.1038/nbt1004.
[119] S.R. Smukler, M.E. Arntfield, R. Razavi, G. Bikopoulos, P. Karpowicz, R.
Seaberg, F. Dai, S. Lee, R. Ahrens, P.E. Fraser, M.B. Wheeler, D. van der Kooy,
The adult mouse and human pancreas contain rare multipotent stem cells that
express insulin., Cell Stem Cell. 8 (2011) 281–293.
https://doi.org/10.1016/j.stem.2011.01.015.
[120] C.A. Beamish, B.J. Strutt, E.J. Arany, D.J. Hill, Insulin-positive, Glut2-low cells
present within mouse pancreas exhibit lineage plasticity and are enriched within
extra-islet endocrine cell clusters., Islets. 8 (2016) 65–82.
https://doi.org/10.1080/19382014.2016.1162367.
[121] T. van der Meulen, A.M. Mawla, M.R. DiGruccio, M.W. Adams, V. Nies, S.
Dólleman, S. Liu, A.M. Ackermann, E. Cáceres, A.E. Hunter, K.H. Kaestner, C.J.
Donaldson, M.O. Huising, Virgin Beta Cells Persist throughout Life at a Neogenic
Niche within Pancreatic Islets, Cell Metab. 25 (2017) 911-926.e6.
https://doi.org/10.1016/j.cmet.2017.03.017.
[122] T. van der Meulen, R. Xie, O.G. Kelly, W.W. Vale, M. Sander, M.O. Huising,
Urocortin 3 marks mature human primary and embryonic stem cell-derived
pancreatic alpha and beta cells., PLoS One. 7 (2012) e52181.
https://doi.org/10.1371/journal.pone.0052181.
[123] R. Abs, L. Verbist, M. Moeremans, P. Blockx, I. De Leeuw, J. Bekaert,
Hypoglycemia owing to inappropriate glucagon secretion treated with a
continuous subcutaneous glucagon infusion system, Acta Endocrinol. (Copenh).
122 (1990) 319–322. https://doi.org/10.1530/acta.0.1220319.
[124] A.S. Hancock, A. Du, J. Liu, M. Miller, C.L. May, Glucagon Deficiency Reduces
Hepatic Glucose Production and Improves Glucose Tolerance In Adult Mice, Mol.
Endocrinol. 24 (2010) 1605–1614. https://doi.org/10.1210/me.2010-0120.
[125] P. Collombat, J. Hecksher-Sørensen, J. Krull, J. Berger, D. Riedel, P.L. Herrera, P.
Serup, A. Mansouri, Embryonic endocrine pancreas and mature beta cells acquire
alpha and PP cell phenotypes upon Arx misexpression., J. Clin. Invest. 117 (2007)
961–970. https://doi.org/10.1172/JCI29115.
[126] P. Collombat, X. Xu, P. Ravassard, B. Sosa-Pineda, S. Dussaud, N. Billestrup,

64

O.D. Madsen, P. Serup, H. Heimberg, A. Mansouri, The Ectopic Expression of
Pax4 in the Mouse Pancreas Converts Progenitor Cells into α and Subsequently β
Cells, Cell. 138 (2009) 449–462. https://doi.org/10.1016/J.CELL.2009.05.035.
[127] M.G. White, H.L. Marshall, R. Rigby, G.C. Huang, A. Amer, T. Booth, S. White,
J.A.M. Shaw, Expression of mesenchymal and α-cell phenotypic markers in islet
β-cells in recently diagnosed diabetes., Diabetes Care. 36 (2013) 3818–3820.
https://doi.org/10.2337/dc13-0705.
[128] N.C. Bramswig, L.J. Everett, J. Schug, C. Dorrell, C. Liu, Y. Luo, P.R. Streeter, A.
Naji, M. Grompe, K.H. Kaestner, Epigenomic plasticity enables human pancreatic
α to β cell reprogramming, J. Clin. Invest. 123 (2013) 1275–1284.
https://doi.org/10.1172/JCI66514.
[129] H. Pisharath, J.M. Rhee, M.A. Swanson, S.D. Leach, M.J. Parsons, Targeted
ablation of beta cells in the embryonic zebrafish pancreas using E. coli
nitroreductase, Mech. Dev. 124 (2007) 218–229.
https://doi.org/10.1016/j.mod.2006.11.005.
[130] M. Courtney, E. Gjernes, N. Druelle, C. Ravaud, A. Vieira, N. Ben-Othman, A.
Pfeifer, F. Avolio, G. Leuckx, S. Lacas-Gervais, F. Burel-Vandenbos, D.
Ambrosetti, J. Hecksher-Sorensen, P. Ravassard, H. Heimberg, A. Mansouri, P.
Collombat, The Inactivation of Arx in Pancreatic α-Cells Triggers Their
Neogenesis and Conversion into Functional β-Like Cells, PLoS Genet. 9 (2013)
e1003934. https://doi.org/10.1371/journal.pgen.1003934.
[131] X. Xiao, P. Guo, C. Shiota, T. Zhang, G.M. Coudriet, S. Fischbach, K. Prasadan, J.
Fusco, S. Ramachandran, P. Witkowski, J.D. Piganelli, G.K. Gittes, Endogenous
Reprogramming of Alpha Cells into Beta Cells, Induced by Viral Gene Therapy,
Reverses Autoimmune Diabetes, Cell Stem Cell. 22 (2018) 78-90.e4.
https://doi.org/10.1016/j.stem.2017.11.020.
[132] N. Ben-Othman, A. Vieira, M. Courtney, F. Record, E. Gjernes, F. Avolio, B.
Hadzic, N. Druelle, T. Napolitano, S. Navarro-Sanz, S. Silvano, K. Al-Hasani, A.
Pfeifer, S. Lacas-Gervais, G. Leuckx, L. Marroquí, J. Thévenet, O.D. Madsen,
D.L. Eizirik, H. Heimberg, J. Kerr-Conte, F. Pattou, A. Mansouri, P. Collombat,
Long-Term GABA Administration Induces Alpha Cell-Mediated Beta-like Cell

65

Neogenesis, Cell. 168 (2017) 73-85.e11.https://doi.org/10.1016/j.cell.2016.11.002.
[133] Z. Zhang, Y. Hu, N. Xu, W. Zhou, L. Yang, R. Chen, R. Yang, J. Sun, H. Chen, A
New Way for Beta Cell Neogenesis: Transdifferentiation from Alpha Cells
Induced by Glucagon-Like Peptide 1., J. Diabetes Res. 2019 (2019) 2583047.
https://doi.org/10.1155/2019/2583047.
[134] J. Li, T. Casteels, T. Frogne, C. Ingvorsen, C. Honoré, M. Courtney, K.V.M.
Huber, N. Schmitner, R.A. Kimmel, R.A. Romanov, C. Sturtzel, C.-H. Lardeau, J.
Klughammer, M. Farlik, S. Sdelci, A. Vieira, F. Avolio, F. Briand, I. Baburin, P.
Májek, F.M. Pauler, T. Penz, A. Stukalov, M. Gridling, K. Parapatics, C. Barbieux,
E. Berishvili, A. Spittler, J. Colinge, K.L. Bennett, S. Hering, T. Sulpice, C. Bock,
M. Distel, T. Harkany, D. Meyer, G. Superti-Furga, P. Collombat, J. HecksherSørensen, S. Kubicek, Artemisinins Target GABAA Receptor Signaling and
Impair α Cell Identity, Cell. 168 (2017) 86-100.e15.
https://doi.org/10.1016/j.cell.2016.11.010.
[135] T. van der Meulen, S. Lee, E. Noordeloos, C.J. Donaldson, M.W. Adams, G.M.
Noguchi, A.M. Mawla, M.O. Huising, Artemether Does Not Turn α Cells into β
Cells., Cell Metab. 27 (2018) 218-225.e4.
https://doi.org/10.1016/j.cmet.2017.10.002.
[136] K. Minami, M. Okuno, K. Miyawaki, A. Okumachi, K. Ishizaki, K. Oyama, M.
Kawaguchi, N. Ishizuka, T. Iwanaga, S. Seino, Lineage tracing and
characterization of insulin-secreting cells generated from adult pancreatic acinar
cells, Proc. Natl. Acad. Sci. 102 (2005) 15116–15121.
https://doi.org/10.1073/pnas.0507567102.
[137] L. Baeyens, S. De Breuck, J. Lardon, J.K. Mfopou, I. Rooman, L. Bouwens, In
vitro generation of insulin-producing beta cells from adult exocrine pancreatic
cells, Diabetologia. 48 (2005) 49–57. https://doi.org/10.1007/s00125-004-1606-1.
[138] E. Akinci, A. Banga, L.V. Greder, J.R. Dutton, J.M.W. Slack, Reprogramming of
pancreatic exocrine cells towards a beta (β) cell character using Pdx1, Ngn3 and
MafA, Biochem. J. 442 (2012) 539–550. https://doi.org/10.1042/BJ20111678.
[139] Q. Zhou, J. Brown, A. Kanarek, J. Rajagopal, D.A. Melton, In vivo
reprogramming of adult pancreatic exocrine cells to β-cells, Nature. 455 (2008)

66

627–632. https://doi.org/10.1038/nature07314.
[140] W. Li, C. Cavelti-Weder, Y. Zhang, K. Clement, S. Donovan, G. Gonzalez, J. Zhu,
M. Stemann, K. Xu, T. Hashimoto, T. Yamada, M. Nakanishi, Y. Zhang, S. Zeng,
D. Gifford, A. Meissner, G. Weir, Q. Zhou, Q. Zhou, Long-term persistence and
development of induced pancreatic beta cells generated by lineage conversion of
acinar cells, Nat. Biotechnol. 32 (2014) 1223–1230.
https://doi.org/10.1038/nbt.3082.
[141] M.J. Lima, K.R. Muir, H.M. Docherty, R. Drummond, N.W.A. McGowan, S.
Forbes, Y. Heremans, I. Houbracken, J.A. Ross, S.J. Forbes, P. Ravassard, H.
Heimberg, J. Casey, K. Docherty, Suppression of epithelial-to-mesenchymal
transitioning enhances ex vivo reprogramming of human exocrine pancreatic tissue
toward functional insulin-producing β-like cells., Diabetes. 62 (2013) 2821–2833.
https://doi.org/10.2337/db12-1256.
[142] M.J. Lima, K.R. Muir, H.M. Docherty, N.W.A. McGowan, S. Forbes, Y.
Heremans, H. Heimberg, J. Casey, K. Docherty, Generation of Functional BetaLike Cells from Human Exocrine Pancreas, PLoS One. 11 (2016) e0156204.
https://doi.org/10.1371/journal.pone.0156204.
[143] B.M. Desai, J. Oliver-Krasinski, D.D. De Leon, C. Farzad, N. Hong, S.D. Leach,
D.A. Stoffers, Preexisting pancreatic acinar cells contribute to acinar cell, but not
islet β cell, regeneration, J. Clin. Invest. 117 (2007) 971–977.
https://doi.org/10.1172/JCI29988.
[144] M.M. Sachdeva, D.A. Stoffers, Minireview: Meeting the demand for insulin:
molecular mechanisms of adaptive postnatal beta-cell mass expansion., Mol.
Endocrinol. 23 (2009) 747–758. https://doi.org/10.1210/me.2008-0400.
[145] A.E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R.A. Rizza, P.C. Butler, BetaCell Deficit and Increased Beta-Cell Apoptosis in Humans With Type 2 Diabetes,
Diabetes. 52 (2003) 102–110. https://doi.org/10.2337/diabetes.52.1.102.
[146] R.F. Ogilvie, The islands of langerhans in 19 cases of obesity, J. Pathol. Bacteriol.
37 (1933) 473–481. https://doi.org/10.1002/path.1700370314.
[147] K.H. Yoon, S.H. Ko, J.H. Cho, J.M. Lee, Y.B. Ahn, K.H. Song, S.J. Yoo, M. Il
Kang, B.Y. Cha, K.W. Lee, H.Y. Son, S.K. Kang, H.S. Kim, I.K. Lee, S. Bonner-

67

Weir, Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes
Mellitus in Korea, J. Clin. Endocrinol. Metab. 88 (2003) 2300–2308.
https://doi.org/10.1210/jc.2002-020735.
[148] S.C. Hanley, E. Austin, B. Assouline-Thomas, J. Kapeluto, J. Blaichman, M.
Moosavi, M. Petropavlovskaia, L. Rosenberg, β-Cell Mass Dynamics and Islet
Cell Plasticity in Human Type 2 Diabetes, Endocrinology. 151 (2010) 1462–1472.
https://doi.org/10.1210/en.2009-1277.
[149] T. Mezza, G. Muscogiuri, G.P. Sorice, G. Clemente, J. Hu, A. Pontecorvi, J.J.
Holst, A. Giaccari, R.N. Kulkarni, Insulin Resistance Alters Islet Morphology in
Nondiabetic Humans, Diabetes. 63 (2014) 994–1007.
https://doi.org/10.2337/db13-1013.
[150] R.E. Stamateris, R.B. Sharma, D.A. Hollern, L.C. Alonso, Adaptive β-cell
proliferation increases early in high-fat feeding in mice, concurrent with metabolic
changes, with induction of islet cyclin D2 expression, Am. J. Physiol. Metab. 305
(2013) E149–E159. https://doi.org/10.1152/ajpendo.00040.2013.
[151] A.R. Cox, C.J. Lam, M.M. Rankin, K.A. King, P. Chen, R. Martinez, C. Li, J.A.
Kushner, Extreme obesity induces massive beta cell expansion in mice through
self-renewal and does not alter the beta cell lineage, Diabetologia. 59 (2016) 1231–
1241. https://doi.org/10.1007/s00125-016-3922-7.
[152] J. Yamamoto, J. Imai, T. Izumi, H. Takahashi, Y. Kawana, K. Takahashi, S.
Kodama, K. Kaneko, J. Gao, K. Uno, S. Sawada, T. Asano, V. V. Kalinichenko,
E.A. Susaki, M. Kanzaki, H.R. Ueda, Y. Ishigaki, T. Yamada, H. Katagiri,
Neuronal signals regulate obesity induced β-cell proliferation by FoxM1
dependent mechanism, Nat. Commun. 8 (2017) 1930.
https://doi.org/10.1038/s41467-017-01869-7.
[153] D. Newbern, M. Freemark, Placental hormones and the control of maternal
metabolism and fetal growth, Curr. Opin. Endocrinol. Diabetes Obes. 18 (2011)
409–416. https://doi.org/10.1097/MED.0b013e32834c800d.
[154] L. Baeyens, S. Hindi, R.L. Sorenson, M.S. German, β-Cell adaptation in
pregnancy., Diabetes. Obes. Metab. 18 Suppl 1 (2016) 63–70.
https://doi.org/10.1111/dom.12716.

68

[155] J.A. Parsons, T.C. Brelje, R.L. Sorenson, Adaptation of islets of Langerhans to
pregnancy: increased islet cell proliferation and insulin secretion correlates with
the onset of placental lactogen secretion., Endocrinology. 130 (1992) 1459–1466.
https://doi.org/10.1210/endo.130.3.1537300.
[156] K.Y. Lain, P.M. Catalano, Metabolic Changes in Pregnancy, Clin. Obstet.
Gynecol. 50 (2007) 938–948. https://doi.org/10.1097/GRF.0b013e31815a5494.
[157] F.A. Van Assche, L. Aerts, W. Gepts, Morphological changes in the endocrine
pancreas in pregnant rats with experimental diabetes., J. Endocrinol. 80 (1979)
175–179.
[158] R.L. Sorenson, T.C. Brelje, Adaptation of islets of Langerhans to pregnancy: betacell growth, enhanced insulin secretion and the role of lactogenic hormones.,
Horm. Metab. Res. 29 (1997) 301–307. https://doi.org/10.1055/s-2007-979040.
[159] C.A. Beamish, L. Zhang, S.K. Szlapinski, B.J. Strutt, D.J. Hill, An increase in
immature β-cells lacking Glut2 precedes the expansion of β-cell mass in the
pregnant mouse, PLoS One. 12 (2017) e0182256.
https://doi.org/10.1371/journal.pone.0182256.
[160] A. Malassine, J.-L. Frendo, D. Evain-Brion, A comparison of placental
development and endocrine functions between the human and mouse model, Hum.
Reprod. Update. 9 (2003) 531–539. https://doi.org/10.1093/humupd/dmg043.
[161] F. Mauvais-Jarvis, Role of Sex Steroids in β Cell Function, Growth, and Survival.,
Trends Endocrinol. Metab. 27 (2016) 844–855.
https://doi.org/10.1016/j.tem.2016.08.008.
[162] S.K. Szlapinski, R.T. King, G. Retta, E. Yeo, B.J. Strutt, D.J. Hill, A mouse model
of gestational glucose intolerance through exposure to a low protein diet during
fetal and neonatal development, J. Physiol. 597 (2019) 4237–4250.
https://doi.org/10.1113/JP277884.
[163] A.J. Bone, K.W. Taylor, Metabolic adaptation to pregnancy shown by increased
biosynthesis of insulin in islets of Langerhans isolated from pregnant rats, Nature.
262 (1976) 501–502. https://doi.org/10.1038/262501a0.
[164] I.C. Green, S.L. Howell, W. Montague, K.W. Taylor, Regulation of insulin release
from isolated islets of Langerhans of the rat in pregnancy. The role of adenosine

69

3’:5’-cyclic monophosphate., Biochem. J. 134 (1973) 481–487.
https://doi.org/10.1042/bj1340481.
[165] L. Scaglia, F.E. Smith, S. Bonner-Weir, Apoptosis contributes to the involution of
beta cell mass in the post partum rat pancreas., Endocrinology. 136 (1995) 5461–
5468. https://doi.org/10.1210/endo.136.12.7588296.
[166] F.A. Van Assche, L. Aerts, F. De Prins, A morphological study of the endocrine
pancreas in human pregnancy., Br. J. Obstet. Gynaecol. 85 (1978) 818–820.
[167] P. Wang, N.M. Fiaschi-Taesch, R.C. Vasavada, D.K. Scott, A. García-Ocaña, A.F.
Stewart, Diabetes mellitus—advances and challenges in human β-cell
proliferation, Nat. Rev. Endocrinol. 11 (2015) 201–212.
https://doi.org/10.1038/nrendo.2015.9.
[168] C. Huang, F. Snider, J.C. Cross, Prolactin receptor is required for normal glucose
homeostasis and modulation of beta-cell mass during pregnancy., Endocrinology.
150 (2009) 1618–1626. https://doi.org/10.1210/en.2008-1003.
[169] H. Kim, Y. Toyofuku, F.C. Lynn, E. Chak, T. Uchida, H. Mizukami, Y. Fujitani,
R. Kawamori, T. Miyatsuka, Y. Kosaka, K. Yang, G. Honig, M. van der Hart, N.
Kishimoto, J. Wang, S. Yagihashi, L.H. Tecott, H. Watada, M.S. German,
Serotonin regulates pancreatic beta cell mass during pregnancy., Nat. Med. 16
(2010) 804–808. https://doi.org/10.1038/nm.2173.
[170] T.C. Brelje, D.W. Scharp, P.E. Lacy, L. Ogren, F. Talamantes, M. Robertson, H.G.
Friesen, R.L. Sorenson, Effect of homologous placental lactogens, prolactins, and
growth hormones on islet B-cell division and insulin secretion in rat, mouse, and
human islets: implication for placental lactogen regulation of islet function during
pregnancy., Endocrinology. 132 (1993) 879–887.
https://doi.org/10.1210/endo.132.2.8425500.
[171] H. Chen, J.W. Kleinberger, K.K. Takane, F. Salim, N. Fiaschi-Taesch, K. Pappas,
R. Parsons, J. Jiang, Y. Zhang, H. Liu, P. Wang, A.S. Bender, S.J. Frank, A.F.
Stewart, Augmented Stat5 Signaling Bypasses Multiple Impediments to LactogenMediated Proliferation in Human β-Cells., Diabetes. 64 (2015) 3784–3797.
https://doi.org/10.2337/db15-0083.
[172] C. Benner, T. van der Meulen, E. Cacéres, K. Tigyi, C.J. Donaldson, M.O.

70

Huising, The transcriptional landscape of mouse beta cells compared to human
beta cells reveals notable species differences in long non-coding RNA and proteincoding gene expression., BMC Genomics. 15 (2014) 620.
https://doi.org/10.1186/1471-2164-15-620.
[173] S. Abouna, R.W. Old, S. Pelengaris, D. Epstein, V. Ifandi, I. Sweeney, M. Khan,
Non-β-cell progenitors of β-cells in pregnant mice., Organogenesis. 6 (2010) 125–
133. https://doi.org/10.4161/org.6.2.10374.
[174] X. Xiao, Z. Chen, C. Shiota, K. Prasadan, P. Guo, Y. El-Gohary, J. Paredes, C.
Welsh, J. Wiersch, G.K. Gittes, No evidence for β cell neogenesis in murine adult
pancreas, J. Clin. Invest. 123 (2013) 2207–2217. https://doi.org/10.1172/JCI66323.
[175] C. Toselli, C.M. Hyslop, M. Hughes, D.R. Natale, P. Santamaria, C.T.L. Huang,
Contribution of a non-β-cell source to β-cell mass during pregnancy., PLoS One. 9
(2014) e100398. https://doi.org/10.1371/journal.pone.0100398.
[176] X. Zhao, Increase of beta cell mass by beta cell replication, but not neogenesis, in
the maternal pancreas in mice., Endocr. J. 61 (2014) 623–628.
https://doi.org/10.1507/endocrj.ej14-0040.
[177] E. Hakonen, J. Ustinov, J. Palgi, P.J. Miettinen, T. Otonkoski, EGFR Signaling
Promotes β-Cell Proliferation and Survivin Expression during Pregnancy, PLoS
One. 9 (2014) e93651. https://doi.org/10.1371/journal.pone.0093651.
[178] C. Quesada-Candela, E. Tudurí, L. Marroquí, P. Alonso-Magdalena, I. Quesada,
Á. Nadal, Morphological and functional adaptations of pancreatic alpha-cells
during late pregnancy in the mouse., Metabolism. 102 (2019) 153963.
https://doi.org/10.1016/j.metabol.2019.153963.
[179] R.R. Banerjee, H.A. Cyphert, E.M. Walker, H. Chakravarthy, H. Peiris, X. Gu, Y.
Liu, E. Conrad, L. Goodrich, R.W. Stein, S.K. Kim, Gestational Diabetes Mellitus
From Inactivation of Prolactin Receptor and MafB in Islet β-Cells, Diabetes. 65
(2016) 2331–2341. https://doi.org/10.2337/db15-1527.
[180] R.C. Vasavada, A. Garcia-Ocaña, W.S. Zawalich, R.L. Sorenson, P. Dann, M.
Syed, L. Ogren, F. Talamantes, A.F. Stewart, Targeted expression of placental
lactogen in the beta cells of transgenic mice results in beta cell proliferation, islet
mass augmentation, and hypoglycemia., J. Biol. Chem. 275 (2000) 15399–15406.

71

[181] A. Radhakrishnan, R. Raju, N. Tuladhar, T. Subbannayya, J.K. Thomas, R. Goel,
D. Telikicherla, S.M. Palapetta, B.A. Rahiman, D.D. Venkatesh, K.-K. Urmila,
H.C. Harsha, P.P. Mathur, T.S.K. Prasad, A. Pandey, C. Shemanko, A. Chatterjee,
A pathway map of prolactin signaling., J. Cell Commun. Signal. 6 (2012) 169–
173. https://doi.org/10.1007/s12079-012-0168-0.
[182] T.C. Brelje, L.E. Stout, N. V. Bhagroo, R.L. Sorenson, Distinctive Roles for
Prolactin and Growth Hormone in the Activation of Signal Transducer and
Activator of Transcription 5 in Pancreatic Islets of Langerhans, Endocrinology.
145 (2004) 4162–4175. https://doi.org/10.1210/en.2004-0201.
[183] M.E.C. Amaral, D.A. Cunha, G.F. Anhê, M. Ueno, E.M. Carneiro, L.A. Velloso,
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2.1

Introduction

Gestational diabetes mellitus (GDM) is a form of diabetes that develops during
pregnancy and regresses postpartum. Between 3%-20% of women develop GDM,
depending on their risk factors [1]. GDM increases the risk of the mother developing
subsequent type 2 diabetes mellitus (T2DM) by up to 7-fold compared to euglycaemic
pregnancies [2]. For the offspring, exposure to GDM in utero has been linked to an
increased risk of childhood obesity and development of T2DM [3].
GDM develops due to insufficient insulin secretion during the relatively insulin-resistant
state in pregnancy [4]. The state of peripheral maternal insulin resistance is most
prominent during the third trimester when placental growth hormone and placental
lactogen levels are highest [5,6]. This ensures normal fetal development by maintaining
trans-placental flux of glucose to the fetus. Consequently, maternal euglycaemia is
normally maintained through adaptations of β-cell mass (BCM) in maternal pancreas.
Both mouse and human β-cells replicate at a low rate in adulthood (~2% per day) [7,8].
However, the rise in circulating placental lactogen and prolactin during mouse pregnancy
has been shown to trigger proliferation of β-cells around gestational day (GD) 12, which
increases BCM and enhances insulin secretion [9,10]. In mice, BCM increases via β-cell
replication and hypertrophy, reaching maximal levels towards late gestation [10,11].
Elevated maternal estrogen levels during pregnancy protect β-cells against apoptosis [12].
As estrogen levels drop after parturition, β-cell apoptosis increases [13] while β-cell
proliferation decreases [11,14] returning BCM to pre-pregnancy levels. The
compensatory changes in human BCM remain controversial as the dynamics of BCM
expansion are hypothesized to be slightly different than in mouse [15]. Nonetheless, the
only two human studies conducted to date have both reported an increase in β-cell area in
pancreata of pregnant women at post-mortem [16,17]. These data suggest that the
pancreas of humans, like mice, should be able to increase BCM and enhance insulin
secretion during pregnancy. Consequently, in situations where BCM expansion is
suboptimal, GDM can arise [18]. Thus, murine GDM models characterized by alterations
to BCM may relate to the pathology in humans as both animal models and genome-wide
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association studies in humans implicate β-cell dysfunction as the largest determinant to
GDM pathogenesis [19].
There is currently no reproducibly effective prevention or reversal intervention for GDM.
As rates of GDM are on the rise, this poses a threat to both the long- and short-term
health of the mother and her offspring. Non-invasive imaging to analyse expansion of
BCM in human pregnancy has ethical and technical issues making animal models a
desirable alternative for studying the mechanisms leading to GDM. Although there are
inevitable differences between mouse and human gestation, these differences are well
characterized; consequently, mice are considered to be valid models for studies of
pregnancy pathophysiology. One important similarity between mouse and human
gestation is the fact that both the extent of β-cell dysfunction and insulin resistance play
an important role in determining metabolic dysfunction in human and animal models
[19]. A useful animal model of GDM would not demonstrate pre-gestational diabetes but
show abnormal glucose tolerance as pregnancy progressed. As there are currently few
clinically applicable animal models of GDM [20] that meet these criteria, we sought to
develop a mouse model relevant to the clinical characteristics of GDM through dietary
insult.
It has been established that maternal (F0) dietary protein restriction (low protein (LP)
diet) during early life has long-term effects on the endocrine pancreas of the offspring
(F1), which contributes to glucose intolerance in adulthood [21]. Offspring born to dams
fed a LP diet have reduced BCM as neonates resulting from decreased rates of β-cell
proliferation and increased apoptosis [22]. LP-exposed offspring also have impaired βcell insulin release which further contributes to glucose intolerance in adulthood [23].
Using this well-characterized model, we examined whether female offspring (F1) of LP
diet-fed dams (F0) would develop glucose intolerance during pregnancy, and whether this
was associated with an altered adaptation of BCM in maternal endocrine pancreas and/or
insulin secretion in isolated islets of Langerhans. We hypothesized that female offspring
(F1) of LP diet-fed dams would be glucose intolerant during pregnancy as a result of
impaired β-cell plasticity and reduced insulin secretion.
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2.2

Methods

2.2.1. Ethical Approval
All animal procedures were approved by the Animal Care Committee of Western
University in accordance with the guidelines of the Canadian Council for Animal Care
(Approval #2018-027).

2.2.2. Animals
Adult (6-week-old) C57BL/6 male and female mice were obtained from Charles River
Laboratories (Wilmington, MA, USA) and housed in a temperature-controlled room with
12-h light/dark cycle at Lawson Health Research Institute, London, ON, Canada. Water
and food were given ad libitum. Timed pregnancies were accomplished by establishing
mouse estrous cycling [24]. Individual female and male mice were housed together for
mating and separated the following morning. Day zero of pregnancy was determined by
identification of a vaginal plug. Females were housed individually for the remainder of
pregnancy. F0-females were randomly allocated to either a control (C, 20% protein, BioServ, Frenchtown, NJ, USA) or low protein diet (LP, 8%) group (Fig. 2.1A), where an
increase in carbohydrate in LP diet (Table 2.1) yields an isocaloric diet compared to
control chow [25]. F0-dams were fed either the LP or C diet throughout gestation and
lactation. A total of 24 control and 21 LP litters were used for the study. Since the
primary objective of our study was to produce a novel mouse model of GDM we worked
only with female offspring. On postnatal day (PND) 21, all female offspring (F1) were
weaned onto C diet for the remainder of the study while males were euthanized (Fig.
2.1B). At maturity (PND42), female offspring (F1) born to dams fed either a C or LP diet
were randomly allocated into 2 subsequent study groups: pregnant (CP, LPP) or nonpregnant (CNP, LPNP, Fig. 2.1A). All pregnant grouped females were time-mated with C
diet-fed males, separated the following morning and housed individually for the
remainder of the experiment. Dams were euthanized by CO2 asphyxia following an intraperitoneal glucose tolerance test (IPGTT) on a randomly assigned day of gestation (GD9,
12, or 18) for comparison to non-pregnant age-matched F1 females. Maternal (F1) blood

84

was collected via cardiac puncture following the IPGTT and serum insulin and glucagon
quantified using an Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem, Downers
Grove, IL, USA) or Mouse Glucagon ELISA kit (Crystal Chem, Downers Grove, IL,
USA). Pancreata were removed for fixation in 4% paraformaldehyde and sectioned for
histology as previously described [26]. At least three 7 μm-thick cryosections (replicates)
were cut from each pancreas with an interval between each section >100 μm.
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Table 2.1. Composition (g/100g of diet) of control vs. low protein rodent chow (BioServ, Frenchtown, NJ, USA)

Component

Control

Low Protein

Cornstarch

40.0

40.0

Casein (88% protein)

22.3

8.6

Maltodextrin

13.2

13.2

Sucrose

10.0

23.6

Soybean oil

4.5

4.5

Cellulose

5.0

5.0

Mineral mix

3.5

3.5

Vitamin mix

1.0

1.0

L-Cystine

0.3

0.3

Choline Bitartrate

0.25

0.25

Tert-butyl

0.0014

0.0014

hydroquinone
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Figure 2.1. Murine model of gestational glucose intolerance
A) Schematic flow chart of experimental groups. F0 females were allocated to LP and C
diet groups. F1 female offspring were separated into pregnant, CP and LPP (gestational
day 9, 12, 18) and non-pregnant groups (CNP and LPNP). B) Timeline for treatment and
sample collection. The F1 offspring were exposed to the low protein (LP) or control (C)
diet during gestation and lactation and weaned onto control diet. At maturity, F1 females
were time-mated with control-fed males. Stars demonstrate timepoints where an intraperitoneal glucose tolerance test was performed prior to euthanasia and removal of the
pancreas for histology (n = 4−7 animals for each group). At each timepoint, serum was
also collected.
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2.2.3. Glucose Tolerance Test
An intra-peritoneal glucose tolerance test (IPGTT) was performed on all animals in their
home cage prior to euthanasia as previously described [27]. For the F0 mice, this was one
month after parturition while the IPGTT’s for the F1 mice were performed at the assigned
gestational day or age for the age-matched group. Mice were fasted for 4-h with free
access to water, injected intraperitoneally with 5μl·g-1 body weight of 40% glucose
solution (2g·kg-1 body weight glucose, Sigma Aldrich, St. Louis, Missouri, USA), and
blood glucose measured from the tail at 0, 5, 15, 30, 60, 90, and 120 min using a One
Touch Ultra2 glucometer. Area under the glucose tolerance curve was analysed using
GraphPad Prism software (Version 5.0, La Jolla, CA, USA).

2.2.4. Immunohistochemistry
Immunofluorescence immunohistochemistry was performed to co-localize insulin and
Ki-67 as a marker for insulin-immunopositive cells undergoing proliferation as
previously described [10]. Slides were viewed by a blinded technician using a Zeiss
fluorescence Axioskop microscope and cell counting analysis was performed using
Image J [28]. Every insulin-expressing cell was imaged at 20X and counted manually. In
this study, an “islet” was considered to contain >5 β-cells, and an extra-islet “cluster” as
containing 1-5 β-cells.
Immunofluorescence immunohistochemistry was also performed to localize insulin (βcells) and glucagon (α-cells) for morphometric analysis. Antibodies against insulin
(1:2000, anti-mouse, Sigma-Aldrich, St. Louis, MO, USA, Cat. No:I2018,
RRID:AB_260137) and glucagon (1:200, anti-rabbit, Santa Cruz, Santa Cruz, TX, USA,
Cat. No:NB110-41547, RRID:AB_805593) were applied to cryosections and incubated
overnight at 4°C. The following day, secondary antibodies (1:500 ThermoFisher,
Waltham, MA, USA) were applied against the primary antibody using 555 (Cat. No:A31570, RRID:AB_2536180) and 488 fluorophores (Cat. No:A-21206,
RRID:AB_141708), respectively, along with DAPI (4, 6-diamidino-2 phenylindole,
dihydrochloride, 1:500, ThermoFisher, Waltham, MA, USA, Cat. No:D3571,
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RRID:AB_2307445) to counterstain nuclei. Alpha-cell mass (ACM) and BCM were
calculated from at least 2 sections (replicates) per pancreas (n = 4−7 C and LP animals
per timepoint) as previously described [10]. β-cell size was calculated by taking the sum
of the traced insulin-expressing area and dividing by the total number of β-cells counted
for that section. Islets were counted per tissue section and further separated by size into
small (less than 5000 μm2), medium (between 5000 and 10,000μm2) and large islets
(more than 10,000 μm2). Tissue represented both the head and tail of the pancreas [29].

2.2.5. Islet Isolation and Static Insulin Secretion
Pancreatic islets were isolated from CP (n = 7−9 animals) and LPP (n = 6−8 animals)
pancreata on GD18 by collagenase V (Sigma-Aldrich, St. Louis, MO, USA) digestion
using a modified sequential Dextran gradient protocol [30,31]. Islets were incubated
(37°C) overnight in RPMI media containing 6.5 mmol·L-1 D-glucose, 10% fetal calf
serum, and 1% Penicillin Streptomycin. The following day, islets were pre-incubated in
Krebs buffer solution (KRB’s, 119 mmol·L-1 NaCl, 4.7 mmol·L-1 KCl, 25 mmol·L-1
NaHCO3, 2.5 mmol·L-1 CaCl22H2O, 1.2 mmol·L-1 MgSO47H2O, 1.2 mmol·L-1
KH2PO4, 1% bovine serum albumin, 10 mmol·L-1 Hepes) containing 2.8 mmol·L-1
glucose for 1-h at 37°C. Groups of 10 islets of similar size were collected into 1 mL of
KRB’s containing either 2.8 mmol·L-1 or 16.7 mmol·L-1 glucose (1−3 replicate tubes per
animal). Insulin release was determined in the supernatant after 90 min at 37°C using an
Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem, Downers Grove, IL, USA).

2.2.6. Statistical Analysis
The sample size of 4−7 animals per variable in either the LP or control groups was
calculated based on achieving a statistically significant difference with an expected
standard deviation around mean values for BCM and glucose tolerance of 15% or less
based on our previous studies [10]. Each animal presented as a single unit of analysis (n)
for the experiments with the F0 dams and F1 offspring. For comparisons of litters, each n
represented an average value for each litter. Data are presented as mean±SEM, with
statistics analysed using GraphPad Prism software (Version 5.0, La Jolla, CA, USA). An
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unpaired two-tailed Student’s t-test was used to compare treatment groups (LP versus C).
A two-way ANOVA followed by Bonferroni’s post-hoc test was used for comparison
between treatment groups (LP versus C) at each timepoint during gestation. A repeated
measures two-way ANOVA followed by Bonferroni’s post-hoc test was used for
comparison of IPGTT curves between treatment groups (LP versus C) at each timepoint
during gestation. Animals with fewer than 2 fetuses or more than 8 were excluded from
statistical analyses. Statistical significance was determined as P < 0.05.

2.3

Results

2.3.1. F0 Animals
No differences were found between consumption of control or LP diet throughout
gestation. Maternal weight gain increased steadily in both control and LP diet-fed dams
throughout gestation (Fig. 2.2A). Furthermore, LP diet consumption had no effect on
litter size (Fig. 2.2B). There were no differences in the number (Fig. 2.2C) or ratio (Fig.
2.2D) of males to females born to LP versus C diet-fed dams. To test for a possible
impact of diet on glucose homeostasis, an IPGTT was performed at 1-month postpartum.
No differences were found between the IPGTT curves (Fig. 2.2E) or area under the
glucose tolerance curves (AUC, Fig. 2.2F) of LP diet-fed females compared to control
diet-fed females.
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Figure 2.2. Low protein diet during pregnancy does not alter pregnancy
characteristics of F0 dams
A–C, low protein (LP) and control (C) diet-fed F0 dams did not statistically differ in
mean values for maternal weight gain (A) (n = 13−14 animals for each group), litter size
(B) (n = 24 C litters, 21 LP litters), the number of male and female offspring (C) (n = 19
C litters, 20 LP litters), or the ratio of male to female offspring (D) (n = 19 C litters, 20
LP litters). E and F, similarly, glucose tolerance (E) and area under the glucose tolerance
curve (F) did not differ (n = 8 C and 7 LP animals for each group).
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2.3.2. F1 Animals
Offspring born to dams fed a LP diet weighed less at birth (1.25±0.02g vs. 1.34±0.03g,
p<0.05, unpaired two-tailed Student’s t-test, Fig. 3A) and at PND7 (3.56±0.11g vs.
4.03±0.15g, p<0.05, unpaired two-tailed Student’s t-test, Fig. 2.3A). Offspring born to
dams fed a LP diet continued to weigh less with age, demonstrating significantly reduced
body weights compared to controls at weaning, PND21, (8.20±0.34g vs. 9.59±0.36g,
p<0.001, two-way ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.3A), which
persisted until maturity, PND42, (14.81±0.27g vs. 16.25±0.19g, p<0.001, two-way
ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.3A). The LPP females continued
to weigh less than CP females (p<0.001) throughout their own pregnancy (Fig. 2.3B).
This was especially apparent during late gestation where the LPP females gained
significantly less weight compared to CP females (12.78±1.22g vs. 15.24±1.44g,
p<0.001, two-way ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.3C). No
differences in fetal resorptions were found in LPP females compared to CP females (Fig.
2.3D).
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Figure 2.3. Offspring of LP-fed dams show altered pregnancy characteristics
A, offspring of LP-fed mothers weighed less than controls by weaning (postnatal day
(PND) 21, n = 13−22 litters for each group). B and C, LPP females weighed less than CP
females throughout gestation (B) and put on less weight at late gestation (C) compared to
CP females (n = 25 CP and 24 LPP animals). D, the number of fetuses did not differ
throughout gestation between CP and LPP females (n = 7−22 animals for each group).
***P < 0.001, **P < 0.01, *P < 0.05, LP vs. C.
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2.3.2.1. Offspring of low protein-fed mothers are glucoseintolerant during their own gestation
There were no significant differences in fasting blood glucose levels between LPP and
CP females at any timepoint during gestation or between non-pregnant females (CNP,
LPNP). Furthermore, no differences in blood glucose levels or AUC were found for nonpregnant (Fig. 2.4A), GD9 (Fig. 2.4B) or GD12 (Fig. 2.4C) offspring born to dams fed a
LP or control diet when subjected to an IPGTT. By GD18, LPP females had significantly
higher blood glucose levels compared to CP at 5 min (18.88±2.22mmol·L-1 vs.
10.73±0.97 mmol·L-1, p<0.001, repeated measures two-way ANOVA followed by
Bonferroni’s post-hoc test) but no significant difference was found in AUC (Fig. 2.4D).

94

B)
800

25

600
400
200

20

0

15

on
C

l
tro

LP

Treatment

10
5

1000
800

25
20

600
400
200
0

l
tro
on
C

15

LP

Treatment

10
5
0

0

5

15

30

60

90

0
12

0

Time (minutes)

C)

600

AUC

25
20

400
200
0

15

o
C

l
ro
nt

LP

Treatment

10
5
0

Blood glucose (mmol·L-1)

800

15

30

60

90

0
12

Time (minutes)

D)

GD12

30

5

GD18

30

1000
800

***

25

AUC

0

Blood glucose (mmol·L-1)

GD9

30

AUC

30

1000

Blood glucose (mmol·L-1)

Non-pregnant
AUC

Blood glucose (mmol·L-1)

A)

20

600
400
200
0

15

l
tro
on
C

LP

Treatment

10
5
0

0

5

15

30

60

Time (minutes)

90

0
12

0

5

15

30

60

90

0
12

Time (minutes)

Figure 2.4. Offspring of low protein-fed mothers are glucose intolerant during their
own gestation
Blood glucose (mmol/L) and area under the glucose tolerance curve (AUC) data from
intraperitoneal glucose tolerance tests performed on offspring from low protein (LP,
continuous lines, closed squares) and control-fed (C, dashed lines, open squares) mothers.
A–C, there were no differences between blood glucose and AUC levels of non-pregnant
(A) (n = 6 CNP and 5 LPNP animals), gestational day (GD) 9 (B) (n = 4 animals for each
group), or GD12 (C) (n = 6 animals for each group) LPP and CP females. D, LPP
females displayed higher blood glucose levels on GD18 when compared to CP females.
However, no differences were found in AUC values (n = 7 CP and 4 LPP females). ***P
< 0.001, LP vs. C.

95

2.3.2.2. Offspring of low protein-fed mothers have altered
pancreatic morphology during pregnancy compared to
controls
We next evaluated whether impairments in endocrine pancreas could be contributing to
the glucose intolerance that was seen in late gestation of LPP females. Expansion of
BCM was maximal on GD18 in CP females (Fig. 2.5A). However, BCM was
significantly lower in LPP females compared to CP females on GD18 (0.93±0.16g vs.
1.96±0.41g, p<0.01, two-way ANOVA followed by Bonferroni’s post-hoc test). CP
females also showed a maximal peak of ACM on GD18 (Fig. 2.5B). However, LPP
females had significantly lower ACM expansion on GD18 compared to CP females
(0.17±0.05g vs. 0.55±0.17g, p<0.01, two-way ANOVA followed by Bonferroni’s posthoc test, Fig. 2.5B).
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Figure 2.5. Offspring of LP-fed mothers have altered pancreatic morphology during
pregnancy compared to controls
β-cell mass expansion (A) and α-cell mass expansion (B) were impaired in LPP females
compared to CP females on GD18 (n = 4−6 animals for each group, 2−3 replicates for
each animal). C, total β-cell proliferation was reduced during gestation in LPP females on
GD12 (n = 4−7 animals for each group, at least 2 replicates for
each animal). D, β-cell proliferation was reduced in clusters during gestation in LPP
females on GD12 (n = 4−7 animals for each group, at least 2 replicates for each animal).
**P < 0.01, *P < 0.05, LP vs. C.
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2.3.2.3. Mechanisms of reduced BCM expansion
To determine whether the reduced BCM was due to decreased β-cell proliferation we
used immunohistochemistry to identify insulin-containing cells co-localized with the
DNA synthesis marker, Ki-67. Proliferating, insulin-expressing cells were identified in
both clusters and islets of C and LP animals. Beta-cell proliferation increased during
pregnancy in CP females but was significantly reduced in LPP females on GD12
(2.11±0.31%Ki67+Ins+/Ins+(total) vs. 3.48±0.66%Ki67+Ins+/Ins+(total), p<0.05, two-way
ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.5C). The reduced β-cell
proliferation at GD12 was specific to small β-cell clusters
(3.03±1.14%Ki67+Ins+/Ins+(clusters) vs. 6.47±1.22%Ki67+Ins+/Ins+(clusters), p<0.05,
two-way ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.5D). Representative
images of proliferating β-cells (%Ki67+Ins+) in non-pregnant, GD12 and GD18 animals
are shown in Figure 2.6. We found no evidence of co-localized insulin/TUNEL cells
during gestation (GD12 and 18) in either the control or LP diet-exposed groups.
Although there was no effect of treatment on the ratio of α- to β-cells there was a change
with day of pregnancy (p<0.001, two-way ANOVA, Fig. 2.7A). Mean islet size was
reduced at GD18 in LPP females (4323±463μm2 vs. 7967±1542μm2, p<0.05, two-way
ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.7B), however there were no
differences in β-cell size (Fig. 2.7C). No differences in distribution of islet sizes were
observed in non-pregnant animals (Fig. 2.7D). Nonetheless, there was a reduction in the
number of small islets in LPP compared to CP mice at GD9 (3.80±0.93 vs. 12.50±1.43,
p<0.001, two-way ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.7E), GD12
(5.92±1.27 vs. 11.33±2.32, p<0.05, two-way ANOVA followed by Bonferroni’s post-hoc
test, Fig. 2.7F), and GD18 (7.90±1.39) vs. 17.88±2.98, p<0.001, two-way ANOVA
followed by Bonferroni’s post-hoc test, Fig. 2.7G).
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Figure 2.6. LPP females show reduced β-cell replication at GD12 compared to CP
females
Representative immunofluorescence images demonstrating insulin (red), Ki-67 (yellow)
and nuclei (DAPI, blue) staining of CNP, LPNP, CP and LPP females (at GD12 and
GD18). White arrows demonstrate co-localized insulin and Ki-67 cells as an example of
proliferating β-cells within an islet. Scale bar represents 50 μm.
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Figure 2.7. LPP females have an altered distribution of islet sizes, contributing to a
reduced mean islet size and BCM expansion at late gestation
A, α- to β-cell ratio varies with day of pregnancy but not between dietary groups. B,
mean islet size was reduced in LPP females compared to CP females on GD18. C,
however, this was not due to a change in β-cell size. D, the number of small islets did not
differ in LPNP females. However, the number of small islets was reduced in LPP females
on GD9 (E), GD12 (F) and GD18 (G) (n = 4−6 animals for each group, 2−3 replicates for
each animal). ***P < 0.001, *P < 0.05, LP vs. C.
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2.3.2.4. Offspring of low protein-fed mothers show
gestational β-cell dysfunction in vitro and in vivo
To assess β-cell function, we measured insulin secretion of isolated pancreatic islets from
GD18 CP and LPP females. Levels of insulin were similar between LPP and CP females
after 90 min in medium containing 2.8 mmol·L-1 glucose (Fig. 2.8A). However, islets
from LPP females secreted less insulin in the presence of 16.7 mmol·L-1 glucose than CP
females (0.22±0.04ng·mL-1·islet-1 vs. 0.49±0.07ng·mL-1·islet-1, p<0.01, two-way
ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.8A). To confirm these findings in
vivo, serum insulin was quantified from blood drawn by cardiac puncture following the
IPGTT. Confirming the in vitro findings, LPP females had lower serum insulin levels
compared to CP females on GD18 (0.57±0.10ng·mL-1 vs. 1.34±0.25ng·mL-1, p<0.05,
unpaired two-tailed Student’s t-test, Fig. 2.8B). Although serum glucagon levels appeared
to be lower in LPP females on GD18, there were no significant differences found when
compared to CP females (Fig. 2.8C).
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Figure 2.8. Offspring of low protein-fed mothers show gestational β-cell dysfunction
in vitro and in vivo
A, glucose-stimulated insulin secretion was reduced on GD18 from isolated pancreatic
islets from LPP females (n = 6−9 animals for each group, 1−3 replicates for each animal).
B, serum insulin levels of LPP females were reduced on GD18 (n = 7 animals for each
group). C, serum glucagon levels did not differ between CP and LPP females on GD18 (n
= 5 animals for each group). **P < 0.01, *P < 0.05, LP vs. C.
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2.4

Discussion

This study proposes a novel mouse model of gestational glucose intolerance in which
metabolic impairments are restricted to late gestation, as is seen clinically in human
GDM. Epidemiological studies in humans have demonstrated strong associations
between poor fetal growth, for instance as encountered in times of famine, and
susceptibility to metabolic syndrome in adult life [32,33]. These observations have been
replicated in maternal malnutrition studies in animals, resulting in permanent changes in
tissue composition and cell size in the offspring during adulthood, ultimately contributing
to the metabolic syndrome phenotype [34]. In agreement with the concept of
developmental origins of health and disease [35], we show in this study that the
intrauterine environment influences the risk of metabolic disease in offspring later in life.
We previously showed that offspring of LP-fed mothers had reduced BCM and
developed glucose intolerance in adulthood [31]. In this study we investigated whether
offspring of LP-fed mothers would have a predisposition to glycaemic dysfunction during
pregnancy, and the underlying pancreatic physiology that might contribute towards this
phenotype. Overall, LP diet did not impact the pregnancy characteristics of F0 dams as
no differences in maternal weight gain, litter size/sex of offspring or glucose homeostasis
were found. Furthermore, it has previously been shown that isolated islets from pregnant
LP-fed rats had a similar response to physiological glucose concentrations compared to
controls [36], while another study concluded that a short period of LP-diet consumption
did not alter total area under the glucose and insulin curves during a GTT, or basal serum
glucose measurements, indicating preservation of pancreatic function [37]. Although this
is being extrapolated from rats, we would not anticipate that LP-fed dams in our study
would demonstrate gestational glucose intolerance and provide a model for GDM.
However, the phenotype was altered in offspring of LP-fed mothers showing a reduced
body weight at birth and PND7, which persisted with age and throughout their own
pregnancy. Although we do not have data on visceral adipose tissue in our study, a
previous study in our laboratory found no differences in visceral adipose tissue between
offspring of LP and C-fed rats at 130 days of age [27]. Furthermore, because we are using
young, pre-estropausal mice in our study, we anticipate that there would be no
differences in visceral adipose tissue present in our model at this age. In humans,
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postmenopausal women begin to have increased visceral fat accrual [38]. Therefore,
potential differences in visceral adipose tissue in our model might only be seen at
estropause which in mice is at 9-12 months of age [39].
In addition to the physical differences found between offspring of LP and C-fed mothers,
we found maternal glucose intolerance when LPP females were subjected to an IPGTT at
GD18. In comparison to our findings, a similar study using the LP diet model in rats
stated that their model did not promote the onset of GDM [40]. However, this claim is
made based on AUC data, for which our data are comparable on GD18. Nevertheless, the
authors did not include their IPGTT curves, which is where we noted abnormally
elevated maternal blood glucose levels in the LPP females. Previous studies found no
differences in fasting blood glucose levels in young offspring (PND1, 7, 14 and 30) of LP
and C-fed mothers [41]. Furthermore, LPNP female rodents did not demonstrate glucose
intolerance until later in adulthood [27,41,42] and the onset in young adults in this study
is likely to have been precipitated by the metabolic stress of pregnancy since there were
no differences in glucose tolerance between CNP and LPNP. Clinically, since prior GDM
increases the risk of the mother developing subsequent T2DM [43], it is plausible that the
LPP females could prematurely develop glucose intolerance following pregnancy
compared to non-pregnant animals. Future studies investigating metabolic differences
and pancreas histology postpartum using our animal model of GDM could prove
insightful.
Consistent with previous findings [10,44], we observed that CP females were able to
expand BCM to compensate for insulin resistance in pregnancy. However, BCM
expansion was impaired in LPP females compared to CP females, as has been postulated
to occur in human GDM [11,45,46]. In agreement with our previous work, the expansion
of BCM during pregnancy was associated with increased β-cell proliferation [10], which
was significantly reduced in LPP females. This was particularly apparent within the small
extra-islet endocrine clusters which we have previously shown to be a source of β-cell
progenitors [26]. This suggests that the proliferation of progenitors or their differentiation
into functional β-cells might be impaired in LPP females. Reduced β-cell proliferation in
LPP females contributed to a reduced mean islet size at GD18, consequently contributing
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to reduced BCM expansion. Although there were no differences in β-cell size in LPP
versus CP females, there were fewer small islets in LPP females at GD9, 12 and 18
compared to CP females. Since there was a relative increase in large-sized islets of CP
females at GD18 compared to GD9, we postulate that β-cell replication within small
islets facilitates islet growth into medium and large sized islets as gestation progresses
(GD18). This further contributed to increased BCM expansion in CP females at GD18.
However, since LPP females had fewer small islets, there were fewer available to
facilitate an adaptive expansion of BCM at GD18. Since there were no differences in islet
size distribution in the LPNP versus CNP animals, these differences were attributed to the
metabolic state of pregnancy. Although increased β-cell apoptosis is seen in offspring of
LP-fed mothers [22], here we found no evidence of apoptosis within β-cells of LPP or CP
females during a subsequent gestation; thus, excluding the possibility of β-cell apoptosis
contributing to the reduced capacity for BCM expansion in LPP females. These results
are in agreement with the findings of another animal model of maternal glucose
intolerance during gestation in which the authors also reported that β-cell apoptosis did
not contribute to the impairment of BCM expansion [47]. These results could be
attributed to the contribution of the protein survivin, which normally becomes
upregulated during gestation and acts as an inhibitor of apoptosis via epidermal growth
factor-receptor signalling [48]. In addition to the dynamics of BCM investigated in this
study, we are the first to report on α-cell dynamics in the pancreas during mouse
pregnancy. Although there was no effect of treatment on the ratio of α- to β-cells there
was a change with day of pregnancy. Further to reduced BCM, we found a relative
decrease in ACM in CP females throughout gestation when compared to CNP. While CP
females replenished ACM by GD18, this was not found in LPP females. There is
evidence through lineage tracing of α-cells that they can replenish β-cells following β-cell
loss or during β-cell stress via transdifferentiation [49,50]. These findings could implicate
α- to β-cell transdifferentiation as a contributor to expanded BCM during pregnancy,
which might be impaired in LPP females.
We also examined β-cell functional capacity in our model, since β-cell dysfunction is a
key feature of the pathophysiology of GDM [51]. Although insulin release from isolated
islets harvested in late pregnancy in response to basal glucose concentration did not differ
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between dietary groups, glucose-stimulated insulin secretion (GSIS) was significantly
decreased in LPP females. These results are in agreement with other reports in which
impaired GSIS was found in islets of offspring of LP-fed mothers as a result of
mitochondrial dysfunction in β-cells [52]. Future studies investigating mitochondrial βcell dysfunction in our model would be insightful as women with GDM demonstrate
increased oxidative stress, which has been suggested to contribute to β-cell dysfunction in
GDM [53]. We confirmed our in vitro findings in vivo, showing that LPP females had
reduced serum insulin levels at GD18 compared to CP females. These data supported our
hypothesis and implicate β-cell dysfunction both in vivo and in vitro at late gestation in
our model of gestational glucose intolerance. Therefore, in our model a combination of
reduced BCM and impaired GSIS most likely contributed to the glucose intolerance seen
in LPP females. Since our study was limited to changes in pancreas histology we cannot
eliminate the possibility that insulin resistance at the level of target tissues contributed to
glucose intolerance during pregnancy in offspring of LP-fed mothers. However, this has
previously been shown to occur only in late adulthood (130 days) and not within the
young adult mice used in these studies [27]. Indeed, pilot studies from our laboratory
provide further support for this claim, suggesting no differences in HOMA-IR (a measure
of insulin resistance) between CP and LPP females at GD18 (Supplemental Fig. 2.1).
Nevertheless, a major strength of our study was the ability to reproduce gestational
glucose intolerance during pregnancy complications such as GDM in which glucose
intolerance is not diagnosed until late gestation. In our study, glucose intolerance was
restricted to GD18 and was not seen in the non-pregnant state as has been shown in other
models of gestational glucose intolerance [40]. Furthermore, additional animal models of
diabetes in pregnancy that demonstrate pre-gestational obesity and diabetes [54,55]
display glucose intolerance prior to conception, which is not a true diagnosis of clinical
GDM [56]. Animal models utilizing chemical destruction of β-cells are widely used for
modelling pre-gestational and gestational diabetes; however, these models more
accurately resemble pre-gestational type-1 diabetes as opposed to the characteristics of
insulin resistance seen in conditions such as GDM [57]. Therefore, in comparison to
other models, our model of fetal programming of gestational glucose intolerance via
dietary insult more accurately demonstrates the hyperglycaemic state of GDM, which
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occurs only at late gestation. Although our dietary insult involves protein restriction
during development, the LP diet is made isocaloric to the control diet through increased
carbohydrate, which prompts the question of whether our findings are due to the effects
of reduced protein or increased carbohydrate intake. However, the increase in
carbohydrate content represents only a 20% increase compared to the more prominent
40% reduction of protein (20% casein versus 8%) [58], which suggests that the glycaemic
dysfunction and impairments in pancreas histology and function in our model are more
likely the result of reduced protein.
Susceptibility to developing GDM arises from a complex combination of both
polygenetic and environmental factors. Taking this into account, the developmental
programming of adult metabolism utilized in this mouse model of glycaemic imbalance
during pregnancy does not reproduce the predominant predisposing causes of human
GDM, which include pre-gestational obesity and excessive gestational weight gain
[2,59]. Nonetheless, there are a number of anatomic and metabolic similarities including
a failure to adequately increase BCM during pregnancy and impaired GSIS in late
gestation. Post-mortem studies of human pancreata obtained from pregnant individuals
confirmed an increase in endocrine mass during healthy pregnancies compared to the
non-pregnant state [16,17], and it has been suggested that failure to adaptively increase
BCM might contribute to the risk of GDM in humans [18]. Thus, further research efforts
should focus on molecular mechanisms (i.e. signalling via prolactin and/or estrogen
receptors) leading to reduced BCM expansion during gestation so that targeted
interventions could be implemented. Measurements of serum placental lactogen,
prolactin and estrogen in our animal model could also prove insightful. In conclusion, the
model of hyperglycaemia in pregnancy described in this study could prove useful in
evaluating pharmacological interventions aimed at safely increasing BCM or GSIS
during pregnancy.
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Supplemental Figure 2.1. HOMA-IR measurements in control compared to LP mice
at GD18
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) values between
treatment groups at GD18. n = 3 control and 2 LP animals.
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3.1

Introduction

Pregnancy presents as a unique situation of endocrine pancreas β-cell adaptation that
reverses after parturition. Late pregnancy is characterized by a state of peripheral
maternal insulin resistance mediated by placental hormones [1] which is essential for
maintaining trans-placental transport of glucose to the fetus for optimal development. To
compensate for insulin resistance, the maternal pancreas responds by increasing
endocrine pancreatic β-cell mass (BCM) to help maintain euglycemia. An adaptive
expansion of BCM has been documented in both mice and humans and is maximal at late
gestation (around gestational day (GD) 18 in mice) [2–7]. The adaptive mechanisms of
BCM expansion during mouse pregnancy have been studied extensively and occur, in
part, due to increased β-cell hypertrophy and proliferation, and the expansion of a β-cell
precursor pool, all of which peak at mid-gestation [3,6–8]. These changes are mediated
by increased levels of hormones including placental lactogen, prolactin, and estrogen
[1,8]. After parturition, progesterone-mediated β-cell apoptosis increases while
proliferation decreases concomitant with an absence of placental lactogen, returning
BCM to pre-pregnancy levels [8,9]. If BCM expansion is suboptimal, gestational diabetes
mellitus (GDM) can arise.
GDM is described as diabetes that first appears during pregnancy and occurs due to
insufficient β-cell adaptation to compensate for insulin resistance in pregnancy. The
incidence of GDM worldwide is around 7-10% of all pregnancies [10,11] although the
incidence will vary depending on the population characteristics and diagnostic criteria.
As more women enter pregnancy obese, or at an older age, the incidence of GDM is
projected to continue to rise [12]. An increased incidence of GDM is associated with
morbidity due to adverse fetal outcomes [13–15] and adverse long-term maternal
outcomes including an increased risk of type-2 diabetes mellitus (T2DM) [16] between
3% to 90% [17]. Clinical studies have shown that glucose intolerance after parturition
involves β-cell dysfunction [18–21] which can occur, in part, due to inflammation and
glucotoxicity-induced oxidative stress in β-cells [22].
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Pregnancy can be characterized as a low-grade inflammatory state where the placenta is a
major source of cytokines that can alter β-cell function [23]. For example, studies have
postulated that 94% of the increased serum levels of tumor necrosis factor (TNF-α) in
women during pregnancy results from placental production [24]. The first and early
second trimester is a pro-inflammatory environment characterized by helper T-cell-1
(Th1) cytokines, such as TNF-α, interleukin-1β, (IL-1β,), and interferon (IFN)-γ,
resulting from implantation and placentation processes [23]. The second trimester is
characterized as an anti-inflammatory environment with Th2 cytokines that permit for
fetal growth and development [25]. Lastly, the third trimester is characterized by the
recurrence of a pro-inflammatory environment in preparation for parturition, as
inflammation promotes uterine contractions [26]. Thus, increased cytokine production
occurs in healthy pregnancies. However, increased activity of the immune-checkpoint
molecule programmed death-ligand 1 (PD-L1), and its receptor, PD-1, play a role in the
maintenance of immunological balance between mother and fetus [27] and likely protect
maternal β-cells from cytotoxic damage. In healthy pregnancies, PD-L1 is expressed by
syncytiotrophoblast cells of the placenta in response to pro-inflammatory stimuli and is
increasingly released into the maternal bloodstream as gestation progresses [28]. The
interaction between PD-L1 and PD-1 reduces clonal expansion of pathogenic
lymphocytes and their associated cytokine release [29]. Therefore, with decreased
lymphocyte expansion, cytokine production is decreased, and β-cells are protected
against cytokine-induced damage. In the context of GDM and persistent glucose
intolerance at postpartum, it is plausible that insufficient levels of PD-L1 cause maternal
β-cells to have greater susceptibility to cytotoxic damage, which can contribute to β-cell
dysfunction. In GDM pregnancies, the low-grade inflammation that normally takes place
in uncomplicated pregnancies is exacerbated [30]. The overexpression of proinflammatory cytokines contributes to excessive peripheral insulin resistance in the
mother, necessitating enhanced insulin secretion to maintain euglycemia, which is often
not met in GDM pregnancies [31]. Thus, it is plausible that a prolonged low-grade
inflammatory environment persisting after parturition in the absence of the placenta could
result from cytokines released by other organs, such as adipose tissue, which could
contribute to β-cell dysfunction postpartum and lead to dysglycemia. Inflammation can

118

contribute to β-cell dysfunction [32] via endoplasmic reticular stress resulting in
decreased insulin sensitivity, as has been documented in GDM patients [33].
We investigated the changes that occur in mouse pancreas during pregnancy and found a
three-fold increase in BCM on GD18, resulting largely from increased β-cell replication
which peaked at GD12 [6,7]. In our previous experiments, female offspring of mice fed a
low protein (LP) diet during gestation and lactation were glucose intolerant at GD18
during their own pregnancy when compared to offspring from control diet-fed mothers
[6]. Glucose intolerance was associated with reduced β-cell proliferation leading to a
lower BCM, in addition to reduced glucose-stimulated insulin secretion (GSIS). Since
GDM increases the risk of the mother developing subsequent T2DM, we have used the
above mouse model of gestational glucose intolerance to follow animals after parturition
and determine whether glucose tolerance normalizes postpartum, and what the long-term
effects of glucose intolerance during pregnancy are on maternal pancreas morphometry.
The mechanisms contributing to adaptive BCM expansion during pregnancy in mice have
been extensively studied. However, few studies exist investigating changes that occur
past 7-10 days postpartum and to our knowledge no data exists comparing pancreas
morphometry after hyperglycemic and control pregnancy. We aimed to determine: 1)
what happens to glucose tolerance and islet morphology postpartum after a normal vs. a
hyperglycemic pregnancy; and 2) the possible involvement of cytokines and PD-L1 in
long-term changes in islet morphology and glucose tolerance postpartum.

3.2

Methods

3.2.1. Animals and Sample Collection
Adult (6-week-old) C57BL/6 male and female mice were obtained from Charles River
Laboratories (Wilmington, MA, USA) and housed in a temperature-controlled room with
12-h light/dark cycle at Lawson Health Research Institute, London, ON, Canada. Water
and food were given ad libitum. Mice showing gestational glucose intolerance were
generated using a previously described protocol involving a dietary insult during early
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life [6, Chapter 2 of this thesis]. Briefly, timed pregnant F0-females were randomly
allocated to either a control (C, 20% protein, Bio-Serv, Frenchtown, NJ, USA) or low
protein diet (LP, 8%) group, where an increase in carbohydrate in LP diet yields an
isocalorific diet compared to control chow. F0-dams were fed either the LP or C diet
throughout gestation and lactation. A total of 12 LP and 12 C litters were used. On
postnatal day (PND) 21, female offspring (F1) were weaned onto C diet for the remainder
of the study (Fig. 3.1). At maturity (PND42), female offspring (F1) of LP and C diet-fed
mothers were randomly allocated into 2 subsequent study groups: pregnant (LPP, CP) or
non-pregnant (LPNP, CNP). All pregnant grouped females were mated with C diet-fed
males, separated upon confirmation of pregnancy by vaginal plug and housed
individually for the remainder of the experiment. Upon birth of pups, CP and LPP
females were randomly allocated to one of three timepoints after parturition (postpartum
day (PPD), PPD7, PPD30, or PPD90). For consistency, pups from all litters were
euthanized at postnatal day 7. Mothers (F1) were euthanized by CO2 asphyxia following
an intra-peritoneal glucose tolerance test (IPGTT) on PPD7, PPD30, or PPD90 for
comparison to non-pregnant age-matched F1 females. Data (histology and IPGTT) for
non-pregnant and GD18 animals, except for in vivo serum quantification, presented here
have previously been published and are being used as a comparison to novel postpartum
data in this study [6]. Following the IPGTT, maternal (F1) blood was collected via
cardiac puncture in order to quantify serum insulin, glucagon and PD-L1 quantified using
an Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem, Downers Grove, IL, USA),
Mouse Glucagon ELISA kit (Crystal Chem, Downers Grove, IL, USA) and PD-L1
ELISA assay (LifeSpan Biosciences, Seattle, WA, USA), respectively. Data were
collected using a BioRad iMark plate reader and analyzed using Microplate Manager
Software.
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Figure 3.1. Experimental timeline for the generation of mice with gestational glucose
intolerance and timepoints for sample collection
Female offspring (F1) were exposed to the low protein (LP) or control (C) diet during
gestation and lactation and weaned onto C diet. At maturity, F1 females were mated with
C-fed males. Pups (F2) from all litters were euthanized at postnatal day 7. Stars
demonstrate timepoints where an intraperitoneal glucose tolerance test was performed,
the pancreas was removed for histology (n = 4–7 animals for each group), and serum was
collected via cardiac puncture.
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Pancreata were removed immediately following euthanasia and fixed in 4%
paraformaldehyde for histology (PFA, Electron Microscopy Sciences, Hatfield, PA,
USA). Fixed pancreas tissue was prepared and sectioned as previously described [34]. At
least two 7 μm-thick cryosections (replicates) were cut from each pancreas with an
interval between each section >100 μm representing at least 2 longitudinal slices through
the pancreas. Sections included both the head and tail of the pancreas. All animal
procedures were approved by the Animal Care Committee of Western University in
accordance with the guidelines of the Canadian Council for Animal Care.

3.2.2. Glucose Tolerance Test
An IPGTT was performed on all animals prior to euthanasia as previously described [35]
at the assigned day postpartum or age for the age-matched group (n = 4−7 C and LP
animals per timepoint). Mice were fasted for 4-h with free access to water, injected
intraperitoneally with 5 μl/g body weight of 40% glucose solution (2g/kg body weight
glucose, Sigma Aldrich, St. Louis, Missouri, USA), and blood glucose measured from the
tail at 0, 5, 15, 30, 60, 90, and 120 min using a One Touch Ultra2 glucometer.

3.2.3. Immunohistochemistry and Morphometric Analysis
Fluorescence immunohistochemistry was performed to localize insulin (β-cells) and
glucagon (α-cells) for morphometric analysis as previously described [6]. Every insulin
and glucagon-expressing cell was imaged at 20X with the observer being blind to tissue
identity using a Nikon Eclipse TS2R inverted microscope (Nikon, Tokyo, Japan) with the
program NIS elements. The microscope was equipped with an LED light source with
emission bandwidths set to 460/50 nm for blue emission, 535/50 nm for green emission
and 590/40 nm for red emission. For morphometric analyses, manual tracing of all islets
for the tissue section was completed using ImageJ to quantitate fractional α- and β-cell
area (sum of all glucagon or insulin-expressing areas divided by the whole pancreas
surface area). Fractional areas were calculated from at least 2 sections (replicates) per
pancreas (n = 4−6 C and LP animals per timepoint). Islets were counted per tissue section
and further separated by size into small ( 5000 μm2), medium (5000–10,000 μm2) or
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large (10,000 μm2) islets as previously described [36]. ApopTag Plus In Situ Apoptosis
Fluorescein Detection Kit (S7111, EMD Millipore, Billerica, MA, USA) was used to
identify apoptotic β-cells using the terminal deoxynucleotidyl transferase dUTP nick end
labelling (TUNEL) assay.

3.2.4. Protein Extraction and Cytokine Analysis
Posterior subcutaneous white adipose tissue (27-50 mg) was lysed for 30 min in an icecold buffer as previously described [37]. Cytokine levels in adipose tissue protein
extracts (n = 3−4 C and LP animals per timepoint, PPD90 C n = 2) were determined by
multiplexing in a Bioplex system using customized kits from R&D systems (Magnetic
Luminex assay) for cytokines of interest (TNF-α, IL-6, IL-1, and IFN). Values were
normalized to weight of sample.

3.2.5. Statistical Analysis
Data are presented as mean ± SEM, with statistics analyzed using GraphPad Prism
software (Version 5.0, La Jolla, CA, USA). To determine effects of pregnancy on
pancreas morphometry postpartum (CP), a one-way ANOVA was used followed by
Bonferroni’s post-hoc test. For comparisons of LPP and CP groups over time, a two-way
ANOVA followed by Bonferroni’s post-hoc test was used. A repeated measures two-way
ANOVA followed by Bonferroni’s post-hoc test was used for comparison of the IPGTT
curves between treatment groups (LP vs. C) at each timepoint after parturition. An
unpaired two-tailed Student’s t-test was used for comparison of IL-6 levels at PPD7
between dietary groups. Each animal presented as a single unit of analysis (n). Only the
postpartum timepoints were included in statistical analyses to present novel data. To
account for differences in litter sizes, the mean litter size for LPP and CP groups was
determined. Litter sizes that were more than 2 standard deviations greater than the mean
were considered outliers. This did not result in any outliers in the data set. Statistical
significance was determined as P < 0.05.
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3.3

Results

3.3.1. Mice with gestational glucose intolerance display
altered pregnancy characteristics
Offspring born to dams fed a LP diet during gestation and lactation (F1, LPP) weighed
less than controls (F1, CP) throughout gestation (Fig. 3.2A) and gained significantly less
weight than CP females at GD17 and 19 (Fig. 3.2B). There were no significant
differences in body weight between dietary groups after parturition (Fig. 3.2C). Body
weight differed with time after parturition in both dietary groups (P<0.01, Fig. 3.2C).
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Figure 3.2. Mice with gestational glucose intolerance display altered pregnancy
characteristics
(A) Pregnant female mice born to dams fed a low protein diet (LPP) weighed less and (B)
gained less weight than pregnant female mice born to dams fed a control diet (CP)
throughout pregnancy (n = 7 CP females, n = 10 LPP females). (C) No differences in
body weight were found after parturition between dietary groups (n = 4–6 CP and LPP
females). ***P < 0.001, **P < 0.01, LPP vs. CP.
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3.3.2. Mice with gestational glucose intolerance demonstrate
prolonged glucose intolerance after parturition
We compared glucose tolerance in LPP vs. CP mice after parturition. LPP females that
were relatively glucose intolerant at GD18 continued to display glucose intolerance at
PPD7 with higher blood glucose levels at 15 and 30 min into an IPGTT (Fig. 3.3A). The
relative glucose intolerance persisted at 1 month postpartum (PPD30, Fig. 3.3B).
However, by 3 months postpartum (PPD90, Fig. 3.3C) LPP females had a similar
glycemic profile as that seen in controls. Furthermore, the glycemic profile at PPD90 was
restored to that of a non-pregnant animal (Fig. 3.3D). There were no significant
differences in fasting blood glucose levels between dietary groups or with time
(Supplemental Fig. 3.1A). Additionally, area under the glucose tolerance curve was
higher in the LPP group at PPD7 compared to controls (Supplemental Fig. 3.1B).

126

B)

7 days postpartum

30

CP
LPP

*

25

***

20

Blood glucose (mmol/L)

Blood glucose (mmol/L)

A)
15
10
5
0

1 month postpartum

30

**

25
20
15
10
5
0

C)

Blood glucose (mmol/L)

Blood glucose (mmol/L)

D)
3 months postpartum

30
25
20
15
10
5

Non-pregnant

30
25
20
15
10
5
0

0
0

5

15

30

60

90

0
12

Time (minutes)

0

5

15

30

60

90

0
12

Time (minutes)

Figure 3.3. LPP females show prolonged glucose intolerance after parturition
Pregnant female mice born to dams fed a low protein diet (LPP) show glucose intolerance
relative to pregnant female mice born to dams fed a control diet (CP) at (A) postpartum
day 7 (PPD7, n = 6 CP females, 7 LPP females) and continue to be glucose intolerant at
(B) 1 month postpartum (PPD30, n = 6 CP females, 5 LPP females). (C) However, by 3
months postpartum (n = 4 CP females, 4 LPP females) LPP females display a glycemic
profile similar to that of a control and demonstrate a similar glycemic profile to that of a
(D) non-pregnant animal (n = 6 C non-pregnant females, 5 LP non-pregnant females).
***P < 0.001, **P < 0.01, *P < 0.05, LPP vs. CP.
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3.3.3. Pregnancy alters pancreas morphology postpartum
after both control and hyperglycemic pregnancies
We investigated how endocrine pancreas morphology changed after parturition, both in
CP and LPP groups. Pancreatic sections were immunostained for insulin (β-cells) and
glucagon (α-cells) for morphometric analyses (Fig. 3.4). Since pancreas weight was
relatively higher in the LPP group at PPD30 and PPD90 (Fig. 3.5A), β/α-cell fractional
areas were used for histological analyses rather than BCM. Beta-cell fractional area was
lower in LPP animals compared to CP animals at PPD7 (Fig. 3.5B). Notably, relative to
PPD7, CP females had a ~30% reduction in BCM at PPD30 and a ~40% reduction by
PPD90 (Fig. 3.5B), the latter resulting in a β-cell fractional area comparable to a nonpregnant animal. In contrast to CP females, β-cell fractional area did not further decrease
postpartum in the LPP group; rather the values remained at a similar level from GD18 up
until PPD90 (Fig. 3.5B). Alpha-cell fractional area was lower in LPP animals compared
to CP at PPD7 (Fig. 3.5C). Furthermore, α-cell area was lower at PPD30 vs. PPD7 in CP
females. There were no significant differences in the α- to β-cell ratio (Fig. 3.5D)
between dietary groups or with time after parturition. No evidence of dual-stained
insulin/TUNEL cells was found when investigating the contribution of β-cell apoptosis at
PPD7.
Islet quantification demonstrated that the number of small, medium and large-sized islets
varied with time after parturition (Table 3.1). At PPD90, there were significantly more
small-sized islets in the LPP females compared to controls (Table 3.1). There were no
significant differences in mean islet size after parturition between dietary groups (Table
3.1). However, the mean islet size was 1.8-fold higher at PPD90 (6373 ± 2065 m2)
compared to PPD7 (3599 ± 452 m2) in the LPP group (P = 0.147, Table 3.1).
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Figure 3.4. Representative immunofluorescent images of islets after parturition
Representative immunofluorescent images demonstrating β- (insulin, red) and α-cells
(glucagon, green) in pregnant female mice born to dams fed a control diet (CP) and
pregnant female mice born to dams fed a low protein diet (LPP) at postpartum days
(PPD) 7 and PPD90. Nuclei were counterstained with DAPI (blue). Scale bar represents
25 microns.

129

A)

D

18

D7
PP

0
D3
PP

0
D9
PD

Timepoint

N

*
***

0.004
0.003
0.002
0.001
0.000

G

D

18

D7
PP

30
D
PP

90
D
PP

Timepoint

N

t
an
gn
e
r
-p
on

0.010

0.005

G

D)

0.005

*

0.015

0.000

t
an
gn
e
r
-p
on

D

18

7
D
PP

30
D
PP

90
D
PP

Timepoint

N

t
an
gn
e
r
-p
on

1.0

Alpha cell:Beta cell

Pancreas weight (g)

0.1

G

Alpha cell fractional area

CP
LPP

0.2

0.0

C)

*

*

Beta cell fractional area

B)
0.3

0.8
0.6
0.4
0.2
0.0

G

D

18

D7
PP

0
D3
PP

Timepoint

0
D9
PP

on
N

eg
pr

n
na

t

Figure 3.5. Pregnancy alters pancreas morphology postpartum after control and
hyperglycemic pregnancies
(A) Pancreas weight was higher in pregnant female mice born to dams fed a low protein
diet (LPP) at postpartum day (PPD) 30 and PPD90 relative to pregnant female mice born
to dams fed a control diet (CP). Both the fractional (B) β-cell area and (C) α-cell area
were lower in LPP animals vs controls at PPD7. Furthermore, α-cell area was lower at
PPD30 vs PPD7 in CP females. (D) Alpha to β-cell ratio did not differ between dietary
groups or timepoints after parturition (n = 4–6 CP and LPP females). ***P < 0.001, *P <
0.05, LPP vs. CP.
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Table 3.1 Islet size distributions are altered postpartum after control and
hyperglycemic pregnancies in mouse
The number of small, medium and large-sized islets varied with time after parturition in
both dietary groups (P<0.05). There were more small islets at postpartum day (PPD) 90
in pregnant female mice born to dams fed a low protein diet (LPP) compared to pregnant
female mice born to dams fed a control diet (CP). There were no significant differences
in mean islet size after parturition between dietary groups. * P<0.05 LPP vs. CP.

Timepoint

Treatment

Small (
5000 μm2)

Non-pregnant

Control
LP
CP
LPP
CP
LPP
CP
LPP
CP
LPP

9.64
7.50
17.88
7.90
13.92
11.80
17.20
13.73
5.29
12.29 *

GD18
PPD7
PPD30
PPD90

Medium
(5000–
10,000 μm2)
1.79
1.42
3.00
1.30
2.50
1.30
4.50
2.63
1.50
2.00

Large
(10,000
μm2)
2.00
1.33
5.00
1.60
3.83
1.80
6.70
4.00
2.13
2.00

Mean islet
size (um2)
4974
4076
7967
4324
6394
3599
6141
5390
6403
6373
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3.3.4. Cytokines may contribute to glucose intolerance after
parturition in mice experiencing hyperglycemic pregnancies
To investigate a potential contribution to prolonged glucose intolerance after parturition
in the LPP group, we measured levels of representative cytokines in adipose tissue
extracts by determining levels of TNF-α, IL-6, IL-1, and IFN. TNF-α levels varied
with time after parturition in both dietary groups and were 1.4-fold higher in the LPP
group at PPD7 compared to controls (3.56 ± 1.10 pg/mL/mg tissue vs. 2.55 ± 0.98
pg/mL/mg tissue, P=0.534, Fig. 3.6A). Levels of IL-6 were higher in the LPP group at
PPD7 compared to controls (Fig. 3.6B). There were no significant differences in levels of
IL-1 with time after parturition or between dietary groups (Fig. 3.6C). However, IL-1
was 1.4-fold higher at PPD7 in LPP compared to controls (698.5 ± 254.7 pg/mL/mg
tissue vs. 517.8 ± 274.2 pg/mL/mg tissue, P=0.654, Fig. 3.6C). Levels of IFN were 3.1fold higher at PPD7 in LPP compared to controls (68.63 ± 24.94 pg/mL/mg tissue vs.
21.88 ± 4.51 pg/mL/mg tissue, P=0.139, (Fig. 3.6D).
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Figure 3.6. Altered cytokines may contribute to glucose intolerance in
hyperglycemic mice after parturition
Adipose tissue content of: (A) TNF-α, (B) IL-6, (C) IL-1β, and (D) IFNγ for pregnant
female mice born to dams fed a control diet (CP) and pregnant female mice born to dams
fed a low protein diet (LPP) at postpartum days (PPD) 7, 30, and 90. (A) TNF-α content
significantly increased with time postpartum but not between dietary groups. (B) IL-6
content decreased with time but was significantly higher in LPP animals. (C) IL-1β and
(D) IFNγ content did not differ with time or between diets. n = 3–4, **P < 0.01, *P <
0.05, LPP vs. CP.
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Next, circulating levels of PD-L1, insulin and glucagon in serum were quantified. There
were no significant differences in levels of PD-L1 between dietary groups. However,
values differed with time after parturition as levels of PD-L1 were higher at PPD90
compared to PPD7 in controls, but not in LPP mice (Fig. 3.7A). Of note, there was also a
2.7-fold higher amount of PD-L1 present in LPP animals at PPD7 compared to controls
(145 ± 49.54 pg/mL vs. 54.76 ± 28.9 pg/mL, P=0.214, Fig. 3.7A). The ratio of serum
insulin to glucagon varied with time after parturition in both CP and LPP mice (Fig.
3.7B) with a trend towards a higher ratio in the LPP group (P=0.071 LP vs. C, Fig. 3.7B).
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Figure 3.7. Pregnancy results in long-term alterations in serum levels of PD-L1,
insulin, and glucagon after parturition
Serum levels of (A) PD-L1 and (B) insulin:glucagon ratio. (A) PD-L1 levels increased
with time in pregnant female mice born to dams fed a control diet (CP) but not in
pregnant female mice born to dams fed a low protein diet (LPP). (B) The serum
insulin:glucagon ratio trended to be higher in LPP animals compared to controls (P =
0.0705) and varied with time in both groups. n = 3–5, ***P < 0.001, *P < 0.05, LPP vs.
CP.
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3.4

Discussion

GDM increases the subsequent risk of maternal dysglycemia or T2DM by up to 7-fold
[17], although the relationship of this risk to longstanding changes in β-cell histology
postpartum is unknown. Using a mouse model of gestational glucose intolerance, we
addressed this knowledge gap by showing that dams continue to show glucose
intolerance for at least a month after parturition (PPD30), and glycemic control did not
normalize until 3 months postpartum (PPD90). This persistent glucose intolerance was
associated with lower β- and α-cell fractional areas at PPD7 compared with control
pregnancies representing an extension of the relative differences seen in late pregnancy
for the glucose-intolerant dams.
Several studies have reported the presence of β-cell dysfunction postpartum clinically
after GDM [18–21]. Progressive β-cell dysfunction is likely the predominant factor that
drives the transition from impaired glucose tolerance to T2DM after GDM [38,39]. In
this study, LPP animals displayed glucose intolerance at PPD7 and PPD30 relative to
controls. We have previously shown that LPP animals exhibit β-cell dysfunction at late
gestation (GD18), resulting in reduced GSIS [6, Chapter 2 of this thesis]. A previous
clinical study classified β-cell dysfunction as the key factor in the development of
postpartum dysglycemia amongst non-obese patients [40]; insulin resistance, however,
was determined to be the driver of postpartum hyperglycemia in obese patients. Our
animal model of gestational glucose intolerance, which represents the non-obese
category, therefore accurately reflects the changes that occur during β-cell dysfunction
after GDM, rather than another underlying cause (such as insulin resistance as seen in
obese patients). Although pre-gestational obesity is a major driver of GDM, 20-30% of
women that develop GDM do not fall into this category. Therefore, this implicates
dysfunction at the level of the β-cell to GDM pathophysiology [12]. This study thus
proves useful for revealing underlying mechanisms of glucose intolerance postpartum
characterized by β-cell dysfunction. Since the animal model represents only a mild
hyperglycemia, the animals in this study were able to normalize blood glucose levels by
PPD90. Nonetheless, it is plausible that additional metabolic stress such as a second
pregnancy, or an age-related decline in β-cell function [41], could precipitate T2DM.
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Human studies of impaired glucose tolerance postpartum do not allow visualization of
histological changes occurring in endocrine pancreas. Previous studies of healthy mouse
pregnancy [7,8] report that offspring born to dams fed a control diet (CP) had a ~50%
reduction in BCM at PPD7 compared to GD18. In this study, CP females had a ~30%
reduction in β-cell fractional area at PPD30 compared to PPD7 and ~40% by PPD90
relative to PPD7, reducing β-cell fractional area to a level comparable to a non-pregnant
animal. These differences could be attributed to the use of fractional area in this study
instead of BCM. We used fractional area to exclude the effect of changes in exocrine
tissue mass postpartum. Prolactin can alter exocrine tissue mass during lactation in mice
[42] and we found differences in pancreatic weight postpartum in LPP mice. Thus, the
use of fractional area provides a more accurate representation of endocrine changes in
this study. These data support previous findings that β-cell apoptosis is occurring in
controls after parturition in order to facilitate normalisation of BCM. This occurs in part
due to a switch of β-cell serotonin receptor expression from HTR2B to HTR1D,
mediating an inhibitory signal and promoting regression of BCM via increased β-cell
apoptosis [9,43], in addition to higher levels of steroid hormones at late gestation which
block lactogen-induced β-cell replication [44]. Insulin/TUNEL staining was negative
when investigating the contribution of β-cell apoptosis at PPD7, suggesting that the
apoptotic processes likely occur earlier postpartum since BCM was already reduced by
PPD7. Nonetheless, a potential explanation for the retained β-cell fractional area at PPD7
in controls could be due to persistently higher expression of serotonin synthetic enzyme
tryptophan hydroxylase-1, Tph1, which normally increases during pregnancy in β-cells in
order to mediate BCM expansion. A previous study found that Tph1 expression remained
high at PPD7 until the end of lactation (PPD21) when levels returned to pre-pregnancy
levels [43]. Further regression of β-cell fractional area at PPD30 and PPD90 could be due
to regression of β-cell size, which was recently suggested as a contributor to BCM
regression after pregnancy, prior to subsequently being increased during lactation.
However, PPD30 and PPD90 mice in our study were not lactating, therefore, it is
plausible that regression of β-cell fractional at these timepoints does indeed occur due to
reduced β-cell size [45].
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In terms of changes in pancreatic α-cell abundance, fractional area was lower at PPD30
compared to PPD7 in CP females. Thus, it is evident that there is a prolonged effect of
pregnancy on the ontogeny of α-cells, as fractional area decreases to a level lower than
the non-pregnant control at PPD90. These findings prompt interesting questions for
future studies, especially concerning a second pregnancy and whether the pool of α-cells
would increase and expand as observed on GD18 in a healthy pregnancy? [6,46].
Furthermore, would the pool of α-cells take longer to replenish, or is the α-cell
complement fully depleted after a first pregnancy?
In contrast to CP females, β-cell fractional area was not further decreased postpartum in
LPP mice; the values instead remained at a similar level from GD18 to PPD90. There
were no differences in β-cell proliferation between dietary groups at PPD7 compared to
non-pregnant animals (Supplemental Fig. 3.1C). These data confirm previous findings
that lactogen-induced β-cell proliferation that normally occurs during pregnancy, which
is also functionally linked to increased levels of progesterone and estradiol as pregnancy
progresses [44], is arrested by PPD7. However, since levels of β-cell replication were
comparable in CP and LPP groups postpartum this excludes β-cell replication as a
mechanism for the sustained elevated fractional β-cell in LPP mice. As previously
mentioned, we found no evidence of β-cell apoptosis at PPD7. These findings support
clinical data that markers of β-cell loss were reduced in serum samples from women
postpartum after GDM and reached levels seen in non-pregnant women [47]. Thus, our
study is the first to provide histological evidence to support these clinical findings by
demonstrating that less β-cell loss is occurring postpartum after mild GDM.
When comparing healthy and hyperglycemic pregnancies, both α- and β-cell fractional
areas were lower in LPP mice at PPD7; a likely result of the insufficient endocrine
pancreas adaptation previously found to occur at GD18, appearing to persist at PPD7.
Importantly, α-cells have been identified as a target for serotonin action as a study in
human islets showed that β-cell-derived serotonin inhibited glucagon secretion in
response to high glucose [48]. Due to a reduced fractional β-cell area in LPP animals at
PPD7 in this study, it is plausible that α-cells receive a reduced serotonergic input from
β-cells and thus lose their ability to regulate glucagon secretion. This may result in
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uncontrolled glucagon secretion and could contribute to the hyperglycemia seen in LPP
animals at PPD7. This was shown to occur in vivo in women with GDM through a lack of
suppression of plasma glucagon at late pregnancy that persisted postpartum [49]. These
findings highlight an important role for pancreatic α-cells in pregnancy which has
previously been overlooked.
Despite the lack of a placental hormone stimulus to endocrine cell expansion postnatally,
the β-cell fractional area did not change in LPP mice. This might be a compensatory
mechanism in attempt to attain euglycemia. Size stratification of islets varied at PPD7
and PPD30 in both control and LP groups, but there were no differences between dietary
groups. This suggests that pregnancy itself causes re-modeling of islet populations after
parturition. Additionally, there were more small islets in LPP females compared to
controls found at PPD90, contributing to a recovered mean islet size comparable to that
of a control. Thus, these data support an additional adaptive response in endocrine cells
postpartum in LPP animals. These data could implicate β-cell neogenesis of small islets
to facilitate normalization of mean islet size at PPD90 as a compensatory mechanism,
thereby resulting in a rescue of glucose tolerance relative to controls. The LPP group had
a higher ratio of insulin relative to glucagon after parturition compared to controls which
provides further support of such an adaptive response.
Pro-inflammatory cytokines can modify insulin signaling pathways and can lead to β-cell
dysfunction [50]. Consequently, overexpression of cytokines can accelerate inflammation
and exacerbate insulin resistance. Women with GDM have been shown to have increased
circulating levels of the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 all of which
are associated with β-cell dysfunction [12,51]. Thus, it is plausible that prolonged glucose
intolerance or T2DM after GDM could involve persistent inflammation postpartum. Both
mouse and human placenta express multiple cytokines that contribute to the state of
insulin resistance that occurs during pregnancy; for instance, TNF-α induces IRS-1 serine
phosphorylation, which contributes to BCM expansion and insulin resistance in
pregnancy [52,53]. In women with GDM, the decrease in insulin receptor tyrosine kinase
phosphorylation does not improve postpartum as it does in women following a healthy
pregnancy [33,54]. In the present model, levels of TNF-α were relatively higher in the

139

LPP animals compared to controls after parturition which could contribute, in part, to the
glucose intolerance seen at PPD7 and PPD30. TNF-α levels in adipose increased with
time, as seen in non-obese women in a study investigating longitudinal changes in serum
pro-inflammatory markers across pregnancy and postpartum [55]. IL-6 has been found to
be significantly higher in women with GDM, independent of adiposity [56] as observed
in adipose samples from the non-obese animals used in this study where levels of IL-6
were higher in LPP mice at PPD7 compared to controls. Interestingly, IL-6 levels were
reduced in both CP and LPP groups by PPD90 concomitant with the return of glucose
tolerance to control values. Some studies have found that high concentrations of IL-6
could promote β-cell apoptosis and contribute to glucose intolerance [57]. However,
since β-cell area did not change at any timepoint after parturition in LPP mice it is more
likely that IL-6 is exerting effects on non-islet tissues. IL-6 has been shown to increase
lipolysis in adipocytes, damage mitochondria and Glut2 function, and as a result decrease
insulin sensitivity [58]. It is reasonable that higher IL-6 tissue levels contibuted to
increased insulin resistance postpartum in LPP mice [52]. IL-6 can also induce
production of IL-1 and TNF-α [59] further intensifying levels of pro-inflammatory
cytokines postpartum and contributing to β-cell dysfunction and glucose intolerance.
However, IL-1 levels in adipose tissue did not differ between dietary groups in the
present studies. Collectively, these findings implicate a potential contribution of
inflammation to insulin resistance postpartum in LPP mice, resulting in a maintaned βcell area resistant to apoptosis postpartum.
An increase in cytokine production occurs in healthy pregnancies. However, the activity
of PD-L1 also increases and attenuates the low-grade inflammatory immune response
[27], potentially protecting maternal β-cells from cytotoxic damage. In the present study,
levels of PD-L1 were relatively higher in LPP mice at PPD7 compared to controls. This
may have helped to enhance β-cell survival in the face of a higher cytokine environment,
as has been observed in autoimmune diabetes in NOD mice [29]. The PD-L1 ligand has
also been shown to be expressed in β-cells of individuals with type 1 diabetes as a
possible attempt to attenuate autoimmune attack [60]. However, PD-L1 was absent from
islets of non-diabetic controls. Furthermore, the same study showed that IFN induced
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PD-L1 mRNA expression in human pancreatic β-cells in vitro, potentially implicating
IFN at PPD7 in LPP mice in this study as a mechanism for increasing PD-L1 levels.
This pathway might also mediate β-cell neogenesis leading to a subsequent increase in
the number of small islets observed at PPD90. This inflammatory pathway may also
explain why β-cell fractional area remained elevated in LPP mice postpartum. Follow-up
experiments treating LPP and CP mice at PPD7/30/90 with a PD-L1 inhibitor would be
insightful to investigate potential differences in the ratio of serum insulin to glucagon.
Interestingly, PD-L1 levels increased from PPD7 to PPD90 in controls. As a multitude of
immunological changes involving both pro- and anti-inflammatory cytokines are
occurring throughout pregnancy to the postpartum period, it is plausible that serum PDL1 levels were elevated in controls in part to suppress maternal immunity, or, to mediate
a protective effect on β-cells against higher levels of TNF-α at postpartum. Interestingly,
since PD-L1 levels were ~25% lower in LPP mice at PPD90, perhaps these animals will
be more prone to cytoxic β-cell damage and could be on the trajectory to dysglycemia or
T2DM. PD-L1 has also been identified as a biomarker for GDM in humans [61] and our
findings support a potential role as a marker for prolonged glucose intolerance after
GDM.
In summary, we present novel findings of the ontogeny of α- and β-cell fractional areas
of islet morphology and glucose tolerance postpartum in normal and hyperglycemic
mouse pregnancies. The results demonstrate long-term pancreatic re-modeling after
parturition involving both pancreatic α- and β-cells, which was associated with changes
in the pro-inflammatory environment. These findings are informative in understanding
the pathophysiology involved in the progression from GDM to glucose intolerance and
T2DM.
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3.5

Supplemental Figures

Supplemental Figure 3.1. Metabolic and pancreas histology parameters after a
GDM and healthy pregnancy
A) Fasting blood glucose levels did not vary after parturition between dietary groups.
Values represented are mean ± SEM analyzed by two-way ANOVA, P>0.05.
B) Area under the glucose tolerance curve was higher in LPP animals at PPD7 compared
to controls. Values represented are mean ± SEM analyzed by unpaired two-tailed
Student’s t-test, ** P<0.01. C) There were no differences in proportion of beta-cell
proliferation (visualized by cell counting of dual-stained insulin and proliferation marker,
ki67, positive cells) found relative to all counted beta cells. Values represented are mean
± SEM analyzed by two-way ANOVA, P>0.05.
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The Increased Alpha and Beta Cell Mass during Mouse
Pregnancy is not Dependent on Transdifferentiation
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4.1

Introduction

Pregnancy is a physiological state characterized by relative maternal insulin resistance
[1]. This has been linked to the presence of placentally-derived hormones and cytokines
in the maternal circulation in the second half of pregnancy [2]. In preparation for the
increased demand for insulin, adaptive changes occur in the endocrine pancreas in order
to maintain euglycemia whilst also supplying the growing fetus with an adequate nutrient
supply. A reversible expansion of β-cell mass (BCM) has been documented in both mice
and humans and is maximal at late gestation (around gestational day (GD) 18.5 in mice)
[3–8]. In situations where BCM expansion is suboptimal, gestational diabetes mellitus
(GDM) can develop. This has been demonstrated in both clinical studies [9] and animal
models of GDM [3,8,10–13] implicating β-cell failure as a major driver to metabolic
pathogenesis. GDM is described as diabetes that first appears during pregnancy, which
regresses postpartum in most cases. Nonetheless, GDM is associated with adverse short
and long-term fetal and maternal health outcomes [14–18] necessitating the development
of effective methods of intervention. Current treatments for GDM, such as lifestyle
behavioural change or administration of insulin or metformin, aim to decrease
hyperglycemia but do not treat the underlying causes including a suboptimal BCM. Thus,
a better understanding of mechanisms of BCM expansion in pregnancy are needed in
order to effectively target potential therapeutic interventions.
The adaptive mechanisms of BCM expansion during mouse pregnancy have been shown
to involve a re-entry of normally quiescent pre-existing β-cells into cell replication,
mediated in part through prolactin receptor signaling in response to lactogenic hormones
[12,19,20], in addition to increased β-cell hypertrophy [10]. These processes are maximal
around mid-gestation in mice to prepare the pancreas for enhanced glucose-stimulated
insulin release in late pregnancy [7,8]. Additional mechanisms of BCM expansion are
likely to include the expansion and subsequent differentiation of a multipotent β-cell
progenitor pool expressing some insulin but low levels of glucose-transporter 2
(Ins+Glut2LO) [7]. Ins+Glut2LO cells are able to differentiate into mature β-cells under
metabolic stress [21,22]. Pregnant mice were shown to have a higher proportion of
proliferating Ins+Glut2LO cells at GD9.5, preceding maximal β-cell proliferation at
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GD12.5. This was concurrent with increased Pdx1 mRNA expression, marking endocrine
progenitor and mature β-cells, implicating this progenitor pool to BCM expansion during
pregnancy. The contribution of non-β-cell progenitors to gestational BCM expansion has
also been proposed and could contribute up to 25% of new β-cells in pregnancy [23,24].
An increase in the number of islets during mouse pregnancy has also been documented,
providing further support for a contribution of islet neogenesis [7,8,25]. Furthermore,
there were fewer small-sized islets throughout pregnancy in glucose-intolerant pregnant
mice, implicating a potential critical role for a deficiency of β-cell neogenesis in the
development of glucose intolerance [8, Chapter 2 of this thesis]. Although evidence exists
to support expansion of BCM in pregnant humans, due to the scarcity of human samples,
the mechanisms involved in BCM expansion remain unclear and controversial [6,26]. As
such, the scarcity of pregnant human pancreas implicates the reliance on animal models
of diabetes in pregnancy.
Although there is evidence that α-cells contribute to hyperglycemia in patients with type
2 diabetes mellitus (T2DM) via hyperglucagonemia [27–31], the dynamics of pancreatic
α-cells in pregnancy have only recently been explored [8,32]. The changes in α-cell
abundance during the endocrine adaptation to pregnancy were described with an
expansion in α-cell mass (ACM) at GD18.5 in mice [8,32] which was impaired in
glucose-intolerant pregnancies [8, Chapter 2 of this thesis]. One source of new β-cells
during pregnancy could derive from a molecular re-programming of glucagon-producing
α-cells as part of dynamic changes in the α-cell population. Previously it was shown that
α-cells can replenish β-cells following extreme β-cell loss or during β-cell stress by α- to
β-cell transdifferentiation [33,34]. Quesada and colleagues suggested that a negligible
amount of α- to β-cell transdifferentiation was occurring at GD18.5 in normal pregnancy
compared to non-pregnant mice, however genetic lineage tracing of α-cells was not
performed to confirm this, and earlier timepoints in pregnancy were not examined [32].
As this study was performed in normal pregnancy there remains a lack of information
about α-cell plasticity in the development of GDM. In this study, we aimed to address
these knowledge gaps by: (1) documenting changes in the balance of α- and β-cells in
control compared to glucose-intolerant mouse pregnancy, and (2) elucidating any
temporal changes in α- to β-cell transdifferentiation in normal mouse pregnancy using
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genetic lineage tracing. We hypothesized that one of the putative mechanisms related to
the endocrine adaptational increase in β-cells in pregnancy could be the
transdifferentiation of α-cells into β-cells and that any disbalance in this process will
predispose to GDM.

4.2

Methods

4.2.1. Animals and Sample Collection
All animal procedures were approved by the Animal Care Committee of Western
University in accordance with the guidelines of the Canadian Council for Animal Care.
Mice were housed in a temperature-controlled room with 12-h light:dark cycle at Lawson
Health Research Institute, London, ON, Canada. Water and food were given ad libitum.
Aim 1: Adult (6-week-old) C57BL/6 male and female (F0) mice were obtained from
Charles River Laboratories (Wilmington, MA, USA). Mice showing gestational glucose
intolerance at GD18.5 were generated using a previously described protocol involving a
dietary insult during early life [8, Chapter 2 of this thesis]. Briefly, F0 females underwent
estrous cycling and were time-mated with males. Dams were randomly assigned to either
a control (C, 20% protein, Bio-Serv, Frenchtown, NJ, USA) or a low protein (LP, 8%)
diet similar to that described by Snoeck et al. [35]. The two diets were isocalorific, the
deficiency in calories in the LP diet being compensated by additional carbohydrate [8].
F0 dams were fed either the LP or C diet throughout gestation and lactation, and female
offspring (F1) were weaned onto C diet. At maturity (postnatal day, PND, 42), female
offspring (F1) of LP and C diet-fed mothers were randomly allocated into two study
groups: pregnant or non-pregnant. All pregnant-grouped females were time-mated
(GD9.5, 12.5, 18.5) with C diet-fed males. Females (F1) were euthanized by CO2
asphyxia for comparison to non-pregnant age-matched F1 females. The pancreas was
removed at each assigned day of gestation (n = 4-6 C and LP animals for each timepoint
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during gestation and for the non-pregnant groups). The pancreas was fixed in 4%
paraformaldehyde for histology and embedded in optical cutting temperature compound.
Aim 2: Glucagon-CreiCre mice (stock #030663, Jackson Laboratories, Bar Harbor, Maine,
USA) that express Cre in 93-95% of α-cells, were crossed with a Rosa26-eYFP reporter
mouse strain (stock #006148, Jackson Laboratories) to produce double transgenic
Glucagon-Cre/Rosa26-eYFP (Gcg-Cre/YFP) mice. At maturity, double transgenic female
offspring were randomly separated into 2 study groups: pregnant and non-pregnant.
Pregnant-grouped females underwent estrous cycling in order to produce timed
pregnancies [36]. Individual double transgenic female and wildtype C57BL/6 male mice
(Charles River Laboratories, Wilmington, MA, USA) were housed together the morning
of pro-estrous for mating and were separated the following morning. Females in the nonpregnant group were age-matched to animals in the pregnant group (GD9.5, 12.5, and
18.5). Animals were euthanized by CO2 asphyxia and the pancreas was removed at each
assigned day of gestation (n = 4 animals for each timepoint during gestation and n = 8
animals for the non-pregnant group) and prepared for histology as described above.

4.2.2. Immunofluorescence Staining
Fixed pancreas tissue was prepared and sectioned as previously described [37]. At least
two 7 μm-thick cryosections (replicates) were cut from each pancreas for
immunohistochemical analysis. The interval between each section was >100 μm,
representing at least two longitudinal slices through the pancreas. Sections included both
the head and tail of the pancreas. For aim 1, immunofluorescence immunohistochemistry
was performed to localize insulin, glucagon and Ki-67 as described previously [7,8].
Antibodies against insulin (1:2000, anti-mouse, Sigma-Aldrich, St. Louis, MO, USA) and
glucagon (1:200, anti-rabbit, Santa Cruz Biotechnology, Dallas, TX, USA) were applied
to tissues and incubated overnight at 4°C. To investigate α-cell proliferation, antibodies
against glucagon (1:200, anti-rabbit, Santa Cruz Biotechnology) and Ki-67 (1:50, antimouse, Biosciences, Mississauga, ON, Canada) were applied to tissues and incubated
overnight at 4°C. The following day, secondary antibodies (1:500 Thermo Fisher
Scientific Waltham, MA, USA) were applied against the primary antibody using 555 and
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488 fluorophores, respectively, along with DAPI (1:500, Thermo Fisher Scientific) to
counterstain nuclei. ACM data was retrieved from our previous studies [8, Chapter 2 of
this thesis] and calculated by multiplying the fractional α-cell area (sum of all glucagonexpressing areas divided by the whole pancreas surface area) by pancreas weight. For aim
2, fluorescent immunohistochemistry was performed to localize insulin (phenotypic βcells), glucagon (phenotypic α-cells) and YFP (α-cell origin) for cell counting analysis.
Background Sniper (Biocare Medical, Concord, CA, USA) was applied to each tissue
section for 8 minutes to reduce non-specific background binding. Subsequently,
antibodies against insulin (1:50, anti-guinea pig, Abcam, Cambridge, UK), glucagon
(1:2000, anti-mouse, Sigma-Aldrich) and YFP (1:1000, anti-rabbit, Abcam) were applied
to tissue sections and incubated overnight at 4°C. The following day, secondary
antibodies (1:400 Thermo Fisher Scientific) were applied against the primary antibody
using 555, 647, 488 fluorophores, respectively, along with DAPI (4, 6-diamidino-2
phenylindole, dihydrochloride, 1:500, Thermo Fisher Scientific) to counterstain nuclei.

4.2.3. Cell Counting Analysis
Tissue sections were visualized by a blinded technician at 20x using a Nikon Eclipse
TS2R inverted microscope (Nikon, Minato, Tokyo, Japan) with the program NIS
elements (Nikon, Minato, Tokyo, Japan), and images were captured and analyzed using
cell counter on ImageJ software. Every insulin, glucagon, and YFP expressing cell was
imaged for each section and for each animal. In this study, an “islet” was considered to
contain >5 β-cells, and an extra-islet endocrine “cluster” as containing 1-5 β-cells [37].
For aim 1, manual cell counting analysis determined the percentage of Insulin+Glucagon+
(insulin and glucagon double-positive) cells as a marker for α- to β-cell transitional cells
[32,38–40]. Alpha-cell proliferation was determined by manually counting glucagon and
Ki-67 double-positive cells. For aim 2, manual cell counting analysis determined the
percentage of Insulin+YFP+Glucagon+ cells as a marker for a possible intermediate,
transitional cell type between an α-cell and a β-cell (Fig. 4.1). The percentage of
Insulin+YFP+Glucagon- cells was also determined to identify phenotypic β-cells arising
from an α-cell origin. These cells were further localized as either being in the islet core or
mantle. Co-localized cells that were part of the outermost layer of Insulin+ cells within
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each islet were classified as being part of the islets’ mantle. Any co-localized cells that
were closer to the middle of the islet, and therefore surrounded by this outer layer of
Insulin+ cells, were classified as being part of the islet core. While islets are large enough
to be able to break down into either core or mantle components, clusters were not. As
each cluster of cells is only made up of 1 to 5 Insulin + cells, no definitive outer layer of
cells exists within this structure. Therefore, the division of co-localized cells into core
and mantle layers was only feasible in “islets”, which are each composed of 6 or more
Insulin+ cells. The core and mantle analysis was completed for both
Insulin+YFP+Glucagon+ cells and Insulin+YFP+Glucagon- cells. For the core and mantle
calculations, the Insulin+YFP+Glucagon- or Insulin+YFP+Glucagon+ cells that fell within
either the core or the mantle were divided by the total number of Insulin+YFP+Glucagon+
or Insulin+YFP+Glucagon- counted for the tissue section.
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Figure 4.1. Representative images of islet populations
Representative images demonstrating staining for insulin (red), glucagon (yellow), YFP
(green) and nuclei (DAPI, blue) in pancreatic sections from GlucagonCre-YFP transgenic
female mice. The arrow in the non-pregnant islet represents a β-cell arising from an α-cell
that no longer expresses glucagon (Insulin+YFP+Glucagon-). The arrow in the GD12.5
islet represents an Insulin+YFP+Glucagon+ cell.
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4.2.4. Serum ELISA Assays
For aim 1, maternal (F1) blood was collected via cardiac puncture after euthanasia in
order to quantify serum insulin and glucagon using an Ultra-Sensitive Mouse Insulin
ELISA kit (Crystal Chem, Downers Grove, IL, USA) or Mouse Glucagon ELISA kit
(Crystal Chem), respectively. The insulin assay has a sensitivity of 0.05 ng/mL using a
5uL sample with precision CV ≤ 10.0%. The glucagon assay has a sensitivity of
1.1pg/mL using a 10uL sample with precision CV ≤ 10%. Samples were run in duplicate.
Data were collected using a BioRad iMark plate reader and analyzed using Microplate
Manager Software. Data throughout pregnancy was compared to non-pregnant animals,
as a previous study [32] found that mice showed hypoglucagonemia as they entered
pregnancy. Therefore, we compared the data as a percent change to non-pregnant
animals, to determine how the animals adapt pancreatic α-cells in response to pregnancy.

4.2.5. Statistical Analysis
The sample size of four to six animals per variable in either the LP or C groups was
calculated based on achieving a statistically significant difference with an expected
standard deviation around mean values for BCM and glucose tolerance of 15% or less
based on our previous studies [7]. Data are presented as mean ± SEM, with statistics
analyzed using GraphPad Prism software (Version 5.0). An unpaired two-tailed Student’s
t test, one-way ANOVA or two-way ANOVA were applied according to the set of groups
that were compared. A Tukey’s post-hoc test or a Bonferroni post-hoc test was performed
after one-way ANOVA or two-way ANOVA analysis, respectively. Non-parametric tests
were performed when data did not meet the assumption of normality. Significant outliers
were determined using Grubbs’ test for each parameter. Each animal presented as a single
unit of analysis (n). Statistical significance was determined as P < 0.05.
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4.3

Results

4.3.1. Glucagon presence and α-cell proliferation in control
vs. glucose-intolerant pregnancies
We examined the changes in α-cell presence and function during pregnancy, and
particularly the cells co-staining for insulin and glucagon, comparing normal pregnancies
and those previously shown by us to have impaired gestational glucose tolerance with a
decreased BCM [8, Chapter 2 of this thesis]. During pregnancy, both control and LP mice
exhibited hypoglucagonemia relative to non-pregnant animals (Fig. 4.2A). However, the
LP diet group showed a significantly greater serum glucagon presence (Fig. 4.2A) and
lower serum insulin (Fig. 4.2B) in late gestation compared to control-diet animals when
expressed relative to the values in treatment-matched non-pregnant animals. Nonetheless,
the overall serum insulin/glucagon ratio did not change during pregnancy between
treatment groups, although values were higher throughout pregnancy compared to nonpregnant animals (Fig. 4.2C). This indicates that an increase in both circulating insulin
and glucagon occurs during pregnancy but with relatively more insulin.
When the ontogeny of α-cell proliferation was examined during pregnancy, a significant
increase was seen at GD9.5 across the whole pancreas compared to pre-pregnancy in
control animals, although this subsequently declined (Fig. 4.3A). However, proliferating
α-cells were significantly reduced in extra-islet clusters at GD9.5 in the LP diet group
relative to controls (Fig. 4.3B). Alpha-cell mass changed across gestation in both control
and LP groups (P=0.01, Fig. 4.3C). However, ACM was significantly reduced in the LP
group compared to control animals at GD18.5 (Fig. 4.3C).
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Figure 4.2. Circulating levels of glucagon and insulin during control and LP
pregnancies, and changes in ratio of insulin to glucagon
(A) Serum glucagon and (B) insulin levels are shown as a percentage change relative to
non-pregnant animals for the gestational days indicated. (C) Serum insulin to glucagon
ratio throughout pregnancy. Samples were collected after euthanasia via cardiac puncture
following an intra-peritoneal glucose tolerance test. n = 4-6 C and LP animals, ***
P<0.001, ** P<0.01, * P<0.05, LP vs. C.
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Figure 4.3 Gestational α-cell proliferation measured by the nuclear presence of Ki67
in control and glucose-intolerant (LP-treated) mouse pregnancy
The percentage of proliferating α-cells in (A) whole pancreas and (B) extra-islet clusters.
is shown relative to all glucagon immunopositive cells. (C) α-cell mass in control and LP
pregnancy. n = 4-6 C and 4-5 LP animals, ** P<0.01, * P<0.05, LP vs. C.
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4.3.2. The balance of pancreatic α- and β-cells in control vs.
glucose-intolerant pregnancies
The frequency of insulin-staining cells that also contained glucagon was approximately
15% in non-pregnant control diet mice (Fig. 4.4A) but the abundance of such bihormonal
cells in whole pancreas, islets or extra-islet clusters did not change in control animals
during pregnancy, and also did not differ in the LP diet group (Fig. 4.4A-C). However,
the LP mice did enter pregnancy with a pre-existing reduction in the number of such cells
compared to controls. Furthermore, there was a trend towards fewer dual-stained cells at
GD12.5 in LP vs. control animals, suggesting that this potential lack of plasticity
remained throughout pregnancy (Fig. 4.4A, P= 0.087). Notably, there was a transient
decrease of ~50% of such cells in control pregnancies at GD9.5 (non-pregnant 16 ± 3%
to GD9.5 7 ± 1%) prior to replenishment of these cells by GD12.5/18.5, potentially
implicating a burst of α- to β-cell transdifferentiation at GD9.5. This relative decrease in
dual-stained cells was absent in LP dams at GD9.5 and could implicate α- to β-cell
transdifferentiation as a mechanism to increased BCM expansion gestation in control
animals that was impaired in LP females.
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Figure 4.4. Ontogeny of bihormonal cells containing both glucagon and insulin in
control and glucose-intolerant (LP-treated) pregnancies
The percentage of bihormonal cells is shown in (A) whole pancreas, (B) islets, and (C)
extra-islet clusters relative to the total insulin immunopositive cells. n = 4-6 C and 4-5 LP
animals, * P<0.05, LP vs. C.
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4.3.3. The contribution of α- to β-cell transdifferentiation to
new β-cells in control pregnancy
To address this question, we investigated the contribution of α- to β-cell
transdifferentiation to BCM expansion in the pancreas during pregnancy by
immunostaining histological sections of Gcg-Cre/YFP mouse pancreata for YFP,
glucagon and insulin. By using Gcg-Cre/YFP transgenic mice, we were able to accurately
lineage trace changes in the fate of glucagon-expressing pancreatic α-cells during the
course of pregnancy to determine if some cells transdifferentiate to express insulin but
not glucagon. First, co-localization of YFP with insulin in cells that did not contain
glucagon (Insulin+YFP+Glucagon-) was examined within the pregnant mouse pancreas at
various timepoints throughout pregnancy. Co-localization was seen in a minority of cells
in both islets and small extra-islet endocrine clusters. In non-pregnant mice
approximately 8% of insulin-staining cells also expressed YFP and this did not alter
significantly throughout pregnancy when examined for the whole pancreas (Fig. 4.5A) or
considering islets (Fig. 4.5B) or extra-islet clusters alone (Fig. 4.5C). Furthermore, the
pattern for fold change relative to non-pregnant animals was also negligible in whole
pancreas (Supplemental Fig. 4.1). Whilst the relative number of insulin-YFP dual stained
cells in islets did not change during pregnancy the distribution did alter, with a relative
reduction being seen in late gestation in the outer mantle of the islets relative to the islet
core (Fig. 4.5D).
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Figure 4.5. Alpha to β-cell transdifferentiation expressed as the percentage of
phenotypic β-cells (Insulin+YFP+Glucagon-)
Alpha to β-cell transdifferentiation in non-pregnant mice and at various gestational ages
during normal pregnancy as expressed by the percentage of phenotypic β-cells
(Insulin+YFP+Glucagon-) relative to the total insulin immunoreactive cells. The
percentage of such cells in (A) the entire pancreas, (B) islets and (C) clusters are shown.
(D) Localization of Insulin+YFP+Glucagon- cells to the islet mantle vs. the core. n = 8
non-pregnant and 4 pregnant animals, * P<0.05, core vs. mantle.
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4.3.4. Cells in a transitional stage of α- to β-cell
transdifferentiation increase in the islet mantle at GD18.5
In addition to insulin-staining cells expressing YFP in the absence of glucagon
(Insulin+YFP+Glucagon-) an approximately equal number of cells co-stained for insulin,
YFP and glucagon in non-pregnant animals (Fig. 4.6A). As observed above with the C
and LP-diet animals, the relative abundance of these cells did not change during
pregnancy in either islets or extra-islet clusters (Fig. 4.6B-C), but their relative
anatomical distribution within islets did alter in late gestation with significantly more
being observed in the islet mantle (Fig. 4.6D).
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Figure 4.6. Presence of Insulin+YFP+Glucagon+cells in the pancreas of non-pregnant
and pregnant mice at gestational days 12.5 and 18.5
The percentage of cells present in (A) whole pancreas, (B) islets and (C) clusters is
shown relative to all insulin immunoreactive cells. (D) Localization of
Insulin+YFP+Glucagon+cells to the islet mantle vs. the core. n = 4 non-pregnant and 4
pregnant animals, ** P<0.01, core vs. mantle.
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4.4

Discussion

Pregnancy displays a remarkable reversible adaptation of BCM in order to maintain
euglycemia, otherwise, pathologies such as GDM can arise. Although β-cells make up the
majority of the islet, α-cells are the next most abundant cell type in the pancreas. These
two endocrine cells play a critical role in maintaining glucose homeostasis by functioning
in an antagonistic manner, whereby the intra-islet hypothesis states that insulin inhibits
glucagon secretion [41]. The contribution of α-cells to hyperglycemia in patients with
T2DM via hyperglucagonemia has been well-documented [27–31]. However, much less
is known regarding the plasticity of pancreatic α-cells in pregnancy and this has yet to be
investigated in glucose-intolerant pregnancy. Since α-cells can act as a reservoir to
increase β-cell regeneration via α- to β-cell transdifferentiation in non-pregnant animals
[42], it was also important to elucidate the role of this transdifferentiation in pregnancy.
We first investigated changes in pancreatic α-cells in glucose-intolerant pregnancy using
a previously established mouse model involving a dietary (LP diet) insult [8, Chapter 2 of
this thesis]. Both dietary groups (LP and C) exhibited hypoglucagonemia during
pregnancy. This supports findings from a previous study that showed that pregnant mice
exhibited hypoglucagonemia and impaired glucagon secretion at GD18.5 [32]. This likely
occurs as a protective effect to prevent hyperglycemia in the presence of insulin
resistance at late pregnancy. Although, in our study there was less suppression of serum
glucagon in LP mice at GD18.5, contributing to glucose intolerance in these animals as
has been shown to occur at late pregnancy in women with GDM [43,44]. Importantly,
higher glucagon levels persisted after parturition in women with GDM and it has been
shown that this can contribute to dysglycemia and eventual development of T2DM.
While treatment for GDM currently focuses on administering blood glucose lowering
agents, such as insulin, management of uncontrolled glucagon secretion in GDM could
theoretically also serve as a mechanism to reverse blood glucose levels in hyperglycemic
women, by means of suppressing these levels. In contrast, levels of insulin were lower in
LP mice at GD18.5, further contributing to glucose intolerance in these animals,
occurring due to reduced BCM and insulin secretion [8, Chapter 2 of this thesis]. These
findings demonstrate the sophisticated integrative islet communication between
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pancreatic α- and β-cells, functioning to balance levels of insulin and glucagon to
accommodate metabolic homeostasis in pregnancy, which becomes dysregulated in
GDM.
To further elucidate the role of pancreatic α-cells in control and glucose-intolerant (LPdiet mice) pregnancies, the ontogeny of α-cell proliferation throughout pregnancy was
assessed. We found that α-cell proliferation was highest at GD9.5 in controls and
subsequently declined. The decline in α-cell proliferation likely follows similar
progesterone-mediated inhibition that has been shown to occur in β-cells at late
pregnancy [32,45]. A previous study determined that α-cell proliferation is mediated by
placental lactogens and prolactin, similarly to what has been observed in β-cells [32].
However, earlier timepoints were not examined in this study [32] which could have
provided crucial information as pregnancy hormones have been shown to mediate
changes in pancreatic β-cells at GD9.5 to prepare the pancreas for adaptive BCM
expansion at GD18.5. Thus, our results demonstrate an earlier onset of α-cell
proliferation during gestation in control diet animals at GD9.5, which is a significant
temporal difference that could have important implications for therapeutics. This
provides histological evidence that α-cells follow similar temporal dynamics to β-cells in
early pregnancy, which also reach maximal proliferation early in gestation [7,8].
Proliferating α-cells were subsequently also localized to islets or clusters within the
pancreas, as it has been shown that Ins+Glut2LO β-cell progenitors are enriched in clusters
[37]. In contrast to control-diet animals, glucose-intolerant animals (LP) exhibited less αcell proliferation in clusters at GD9.5. These data could implicate a contribution for α-cell
neogenesis from small endocrine clusters to the adaptive expansion of ACM at GD18.5,
which has also been shown to be a mechanism of BCM expansion [7,8,25]. However, our
data suggest that adaptive α-cell mechanisms were impaired in GDM.
Interestingly, we noted a high percentage of proliferating α-cells at GD9.5 relative to a
non-pregnant animal (4.15% vs. 0.63%), providing speculation for a process of α- to βcell transdifferentiation in pregnancy requiring subsequent α-cell renewal mechanisms.
This represented a 6.6-fold increase in α-cell proliferation, in comparison to the 3.6-fold
increase in β-cell proliferation that occurs at the same time during pregnancy in mouse
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(3.5% vs. 1%) [7,8]. This data brings into question the purpose of such a high level of αcell proliferation, which is greater than necessary simply to achieve the ACM expansion
observed, which is only 2-fold higher at GD18.5 relative to a non-pregnant animal. In
comparison, a 4-fold increase in BCM is achieved at GD18.5 with less β-cell
proliferation [8, Chapter 2 of this thesis]. However, studies suggest that α-cells may serve
as a reservoir for β-cell regeneration [42]. For example, GABA has been shown to cause
α- to β-cell transdifferentiation and induces replacement of α-cells from duct-lining
precursor cells that develop an α-cell identity prior to conversion into β-cells [46]. An
additional study in mice with experimental type 1 diabetes mellitus found an increase in
the proportion of glucagon+ cells that were positive for insulin or β-cell specific
transcription factor Pdx1 [39]. Together, these findings suggest that increased pancreatic
α-cell renewal mechanisms are a strategy to replenish and maintain the α-cell reservoir
and/or to increase β-cell regeneration via α- to β-cell transdifferentiation.
Consequently, we co-localized insulin and glucagon double-positive cells whose presence
outside of pregnancy has been demonstrated previously [32,38–40]. Although insulin and
glucagon double-positive cells have been suggested to be bihormonal cells in previous
studies, better characterization of this population of cells would be important for future
experiments. Data regarding secretion of insulin, glucagon or both by localization of
hormones to granules using immune transmission electron microscopy would be
insightful. It would also be interesting to determine if there is heterogeneity of function in
bihormonal cell populations. Furthermore, additional questions remain, such as whether
these bihormonal cells are a transitory type of cell, or a dedifferentiated type. A minority
(~15%) of β-cells were bihormonal in non-pregnant, control-diet females suggesting that
these cells are present as a normal feature of pancreas morphology and could represent
functionally immature cell types. However, there was a transient decrease of bihormonal
cells in controls at GD9.5 that was absent in LP dams, potentially implicating a burst of
α- to β-cell transdifferentiation as a mechanism to increase BCM expansion during
gestation in C animals that was impaired in LP females. Transdifferentiation may be
reduced in these mice due to fewer Insulin+Glucagon+ cells being present in the nonpregnant LP animal. Therefore, this dietary insult in utero may impair the plasticity of the
α- and β-cell endocrine lineages and reduce α- to β-cell transdifferentiation [47].
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However, there were also fewer Insulin+Glucagon+ cells at GD12.5 in LP animals vs.
controls, potentially implicating a deficit of α- to β-cell transdifferentiation in glucoseintolerant pregnancy specifically at this time.
Accordingly, to elucidate the role of α- to β-cell transdifferentiation to BCM expansion in
pregnancy, we used transgenic mice to lineage track α-cells. Our data suggested that α- to
β-cell transdifferentiation does not significantly contribute to BCM expansion in
pregnancy. Interestingly, a minority (~8%) of β-cells in non-pregnant females expressed
an α-cell label (Insulin+YFP+) suggesting that these cells are present as a normal feature
of pancreas morphology. These findings are in contrast to studies that investigated α- to
β-cell transdifferentiation in unchallenged mice, where baseline values for
transdifferentiation were only around 1% [33,48,49]. However, it is important to
acknowledge that these studies used an inducible method for tagging α-cells that was
initiated after pancreatic development, which would not take into account the significant
pancreatic remodeling that occurs during postnatal development [50]. Importantly,
studies suggest that it is possible that some β-cells undergo a bihormonal, glucagonexpressing progenitor stage during embryonic/postnatal development. One study used
Gcg-Cre/YFP mice and reported that 10% of β-cells expressed an α-cell label at postnatal
day 5, and 20% at postnatal day 21, which is comparable to values reported in the present
study. Likewise, an additional study found comparable values, where 5-10% of β-cells
were tagged with an α-cell label at postnatal day 1, and 12% at postnatal day 7-14, in a
similar model using Gcg-Cre/YFP mice where α-cells were also labelled during pancreas
development [51]. Although direct lineage tracing of transdifferentiated β-cells from an
α-cell lineage would not be feasible in human samples, clinical data also suggests that it
is possible that some β-cells undergo a bihormonal, glucagon-expressing progenitor stage
during embryonic/postnatal development as bihormonal cells were also found in the
developing human pancreas [52–54]. Since our model is a conditional Cre that is present
from conception, the higher baseline values in our study compared to what has been
published in many α- to β-cell transdifferentiation studies could be explained by the
different lineage tracing models used. One way to address this discrepancy to elucidate
the effects of the pregnancy time window would be to use an inducible Gcg/CreER model
[55]. Alternatively, using the model in the present study the fold change can be calculated
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and compared to baseline in the non-pregnant animals. As we found no temporal
differences in the percentage of β-cells that underwent transdifferentiation, the pattern for
fold change was unsurprisingly also negligible.
Although the relative number of Insulin-YFP dual-stained cells did not change during
pregnancy, we found that there were fewer of these cells in the islet mantle compared to
the core at GD18.5. Previous studies have suggested that the mantle of the islet of
Langerhans (where α-cells predominantly reside in mouse) contains a neogenic niche of
-cell progenitors [49]. It is suggested that this group of cells is persistent throughout life
and could represent a transitional cell type between an α-cell and a β-cell phenotype,
perhaps within a process of α- to β-cell transdifferentiation. If so, then it does not appear
that the metabolic stress of pregnancy enables a further differentiation of these cells to
become unihormonal insulin-expressing. Using the lineage tracking molecule YFP,
subpopulations of cells were also identified within this model that co-expressed both
insulin and glucagon. While their relative abundance did not change during pregnancy
their anatomical distribution did. In contrast to phenotypic β-cells
(Insulin+YFP+Glucagon-) that were predominantly located in the islet core at GD18.5, the
Insulin+YFP+Glucagon+ cells were found predominantly in the mantle. This supports
previous findings that lineage-flexible α-cells may be most abundant in the mantle of the
islets of Langerhans [49], and that they are present during pancreatic remodeling and
endocrine adaptation in pregnancy. It has been previously reported that β-cell maturation
begins from the islet mantle and propagates to the islet core, being coordinated by islet
vascularization [56]. Our data would support the notion that transitional endocrine cell
types originate at the islet mantle and then likely propagate towards the centre of the islet
once lineage committed. This process occurs as pregnancy progresses, in order to
coordinate optimal islet function and facilitate cell-to-cell communication at GD18.5
when metabolic stress is highest [57].
In summary, we present novel data showing that there is an early onset of α-cell
proliferation during pregnancy in controls, contributing to ACM expansion. This was
impaired in glucose-intolerant pregnancies (LP) resulting in reduced ACM expansion and
possibly fewer α-cells for α- to β-cell transdifferentiation to occur. However, using
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lineage tracing, the process of transdifferentiation did not appear to dynamically alter
during pregnancy. Nonetheless, both cell phenotypes examined (Insulin+YFP+Glucagon-,
Insulin+YFP+Glucagon+) underwent anatomical changes in distribution within the islets
in late gestation and in opposing directions. These data provide support for a potential
transitional cell type in a pancreatic neogenic niche.

174

Supplemental Figures

% YFP+Ins+Gluc- total
fold change relative to NP

4.5

2.0
1.5
1.0
0.5
0.0

N

P
G

5
9.
D
G

.5
12
D

G

.5
18
D

Day of Pregnancy

Supplemental Figure 4.1. Transdifferentiation expressed as fold change relative to
baseline
The fold change of β-cells arising from α-cells that no longer express glucagon
(Insulin+YFP+Glucagon-) relative to the baseline (non-pregnant animals). n = 8 nonpregnant and 4 pregnant animals. P>0.05.
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Chapter 5

5

Strategies to Improve Glucose Tolerance in Pregnancy

5.1

Introduction

Pregnancy presents as a physiological state of insulin resistance that requires
compensatory adaptations in maternal endocrine pancreas to maintain euglycemia [1]. If
this compensation fails, gestational diabetes mellitus (GDM) can develop, implicating
pancreatic β-cell failure as a major driver to metabolic pathogenesis. GDM is described
as diabetes that first appears during pregnancy, which regresses postpartum in most cases.
Nonetheless, GDM is associated with adverse short and long-term health outcomes to the
mother (birthing difficulties, T2DM) and offspring (pre-term birth, respiratory distress
syndrome, obesity, type 2 diabetes mellitus, T2DM) necessitating the development of
effective methods of intervention [2–6]. Current treatments for GDM, such as lifestyle
behavioural change or administration of insulin or metformin, aim to decrease
hyperglycemia but do not treat the underlying causes including a suboptimal β-cell mass
(BCM). Thus, a better understanding of mechanisms of BCM expansion in pregnancy are
warranted in order to effectively target potential therapeutic interventions.
In both mice and humans, a reversible expansion of pancreatic BCM and α-cell mass
(ACM) has been documented and is maximal at late gestation (gestational day (GD) 18.5
in mice) [7–13]. In mice, these changes have been shown to be mediated by increased
levels of placental lactogen and prolactin, initiating proliferation of pre-existing β- and αcells [13,14]. Additional placental peptides, such as apelin and apela which signal
through the apelin receptor (APJ), have been shown to alter β-cell number and function in
non-pregnant animals and could also influence β-cell adaptations during pregnancy [15].
Although evidence exists to support expansion of BCM in pregnant humans, the
mechanisms involved remain unclear and controversial due to limited samples [10,16].
An additional source of new β-cells during pregnancy could derive from
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transdifferentiation of α-cells. Previous studies in non-pregnant animals reported that αcells can replenish β-cells during metabolic stress by α- to β-cell transdifferentiation
[17,18]. The use of structural analogs of artemisinins, a class of anti-malarial drugs, has
been shown to stimulate α- to β-cell conversion in vivo and in vitro [19] and improve
glucose tolerance in non-pregnant animal models of diabetes [20,21]. In rodent and zebra
fish models, treatment with artemisinins increased GABAA signaling which led to
transdifferentiation of α-cells into β-cells [19]. The increased BCM resulted in improved
glucose homeostasis, which suggests a therapeutic effect of treatment with artemisinins in
animal models of diabetes. Furthermore, based on studies investigating the safety of these
compounds in pregnancy, the World Health Organization has deemed artemisinins as safe
to be used during pregnancies complicated by malaria [22,23]. Some data in animals
suggests that artemisinins are embryotoxic during first trimester and the use is thus
discouraged in first trimester [23,24]. Nonetheless, recent human studies have found no
adverse pregnancy outcomes when artemisinins were used in the first trimester [22] and
additional studies are now recommending re-assessment of this guideline as the benefits
of artemisinin use in the first trimester exceed any potential risks [25].
GDM severely impacts healthcare costs around delivery due to pregnancy complications
and admission to NICU, as well as long-term health resources due to future T2DM in
both the mother and offspring. Therefore, a safe method of prevention is needed.
Replacement of β-cells as a strategy for diabetes treatment is limited by the shortage of
islet supply from deceased donors, and the use of immune-suppressive drugs would not
be safe during pregnancy [26]. Current data suggests antidiabetic effects of artemisinins
in non-pregnant animals, however, no data exists in pregnant animals. In this study, we
investigated the potential therapeutic effects of artemisinin treatment in an animal model
of gestational glucose intolerance during and following pregnancy, and elucidated the
underlying potential mechanisms involved leading to improved glucose tolerance.
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5.2

Methods

5.2.1. Animals, Treatment, and Sample Collection
All animal procedures were approved by the Animal Care Committee of Western
University in accordance with the guidelines of the Canadian Council for Animal Care.
Mice were housed in a temperature-controlled room with 12-h light:dark cycle at Lawson
Health Research Institute, London, ON, Canada. Water and food were given ad libitum.
Adult (6-week-old) C57BL/6 male and female (F0) mice were obtained from Charles
River Laboratories (Wilmington, MA, USA). Mice showing glucose intolerance at
GD18.5 were generated using a previously described protocol involving a dietary insult
during early life [12, Chapter 2 of this thesis]. Briefly, F0 females underwent estrous
cycling and were time-mated with males. Dams were fed a low protein (LP, 8% protein,
Bio-Serv, Frenchtown, NJ, USA) diet similar to that described by Snoeck et al. [27]
throughout gestation and lactation. Female offspring (F1) were weaned onto a control
diet (C, 20% protein) for the remainder of the study. At maturity (postnatal day, PND,
42), female offspring (F1) of LP diet-fed mothers were randomly allocated into two study
groups: pregnant (GD18.5 or postpartum day (PPD) 7.5) or non-pregnant. We chose
GD18.5 based on previous findings that this was the timepoint where glucose intolerance
and reduced BCM were present. We also investigated mice after parturition at PPD7.5
due to a previous study showing that glucose intolerance persisted until 1 month
postpartum [6, Chapter 3 of this thesis]. These animals were subsequently separated into
an artemisinin-treated group, acetone vehicle group or non-treated group (non-treated
non-pregnant and GD18.5 data retrieved from [12, Chapter 2 of this thesis], non-treated
PPD7.5 data retrieved from [6, Chapter 3 of this thesis]). All pregnant-grouped females
were time-mated with control diet-fed males. Initial experiments followed a protocol
diluting the artemisinin, artesunate, in dimethyl sulfoxide vehicle (DMSO) [28].
However, pregnant mice treated with this mixture presented with pregnancy
complications including preterm birth and embryolethality (Supplemental Fig. 5.1).
Therefore, we adapted the protocol from an additional study where mice were treated
with artesunate in an acetone vehicle diluted in drinking water daily [19]. A stock
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solution of 250mg/ml artesunate (Cayman Chemicals, Ann Arbor, MI, USA) in acetone
(Sigma-Aldrich, St. Louis, MO, USA) was prepared daily, 40 l of which was diluted
daily in 10mL drinking water for a final concentration of 1mg/mL artesunate. An equal
concentration of acetone was used in the control group, and drinking water was provided
ad libitum. Water bottles were covered with aluminum foil to prevent light penetration
[19]. Vehicle or treatment was replaced daily from GD0.5-6.5, after which the solution
was replaced with tap water for the remainder of the experiment (Fig. 5.1). Females were
euthanized by CO2 asphyxia at their assigned day for comparison to non-pregnant agematched females. Maternal pancreatic samples were fixed in 4% paraformaldehyde for
histology and embedded in optical cutting temperature compound. Maternal serum
samples were collected via cardiac puncture. Placenta samples were collected in 1mL of
RNAlater RNA Stabilization Reagent and frozen at -20°C (Qiagen, Hilden, Germany).
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Figure 5.1. Animal model of treating glucose intolerance in pregnancy
F0 dams were fed a LP diet (8% protein) during gestation and lactation. Offspring
(F1) were weaned onto control diet (C, 20% protein). At maturity, pregnant-grouped
F1 females were time-mated with C-fed males. Artesunate-grouped pregnant females
were treated (1mg/mL) via drinking water from gestational day (GD) 0.5-6.5 vs. vehiclegrouped females which were treated with the acetone vehicle alone, and non-treated
females which were given regular tap water. The artesunate/acetone treatment group is
represented by the pink bar, the acetone vehicle alone is represented by the black dashed
bar. Non-pregnant animals were age-matched to females in the pregnant group. Stars
indicate timepoints where an intraperitoneal glucose tolerance test was performed prior to
euthanasia and the pancreas was removed for fluorescence immunohistochemistry. The
blue box represents the F1 pregnancy experimental timepoints.
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5.2.2. Intra-peritoneal Glucose Tolerance Test
Prior to euthanasia, an intra-peritoneal glucose tolerance test (2g glucose/kg body weight,
IPGTT) was performed on all animals. Mice were fasted for 4 h. Blood glucose was
measured from the tail at 0, 5, 15, 30, 60, 90 and 120 minutes using a One Touch Ultra2
glucometer.

5.2.3. Immunohistochemistry and Endocrine Pancreas
Morphometry
Fixed pancreas tissue was prepared and sectioned as previously described [29]. At least
two 7 μm-thick replicate cryosections were cut from each pancreas with an interval
between each section >100 μm representing at least two longitudinal slices through the
pancreas. Sections included both the head and tail of the pancreas. Immunofluorescence
immunohistochemistry was performed to localize insulin and glucagon as described
previously [12]. Antibodies against insulin (1:2000, anti-mouse, Sigma-Aldrich) and
glucagon (1:200, anti-rabbit, Santa Cruz Biotechnology, Dallas, TX, USA) were applied
to tissues and incubated overnight at 4°C. The following day, secondary antibodies
(1:500 Thermo Fisher Scientific Waltham, MA, USA) were applied against the primary
antibody using 555 and 488 fluorophores, respectively, along with DAPI (1:500, Thermo
Fisher Scientific) to counterstain nuclei.
Tissue sections were visualized at 20x using a Nikon Eclipse TS2R inverted microscope
(Nikon, Minato, Tokyo, Japan) with the program NIS elements (Nikon, Minato, Tokyo,
Japan), and images were captured and analyzed using cell counter on ImageJ software.
Every insulin and glucagon expressing cell was imaged for each section and for each
animal. Manual cell counting analysis determined the percentage of bihormonal
Insulin+Glucagon+ cells as a marker for α- to β-cell transitional cells [13,30–32].
To determine BCM and ACM, morphometric analysis was performed by manually
measuring the total pancreas area for each tissue section, and the relative area of β-cells
and α-cells [12,33]. BCM and ACM was calculated by multiplying total β or α-cell area
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(sum of entire β or α-cell area/surface area of entire tissue section) by the pancreas
weight. Islets were counted per tissue section and further separated by size into small
(<5000 μm ), medium (5000–10,000 μm ), or large (>10,000 μm ) islets as previously
2

2

2

described [12,33].

5.2.4. Serum ELISA Assays
Maternal (F1) blood serum was used to quantify insulin and glucagon using an UltraSensitive Mouse Insulin ELISA kit (Crystal Chem, Downers Grove, IL, USA) and Mouse
Glucagon ELISA kit (Crystal Chem), respectively. The insulin assay has a sensitivity of
0.05 ng/mL using a 5uL sample with precision CV ≤ 10.0%. The glucagon assay has a
sensitivity of 1.1pg/mL using a 10uL sample with precision CV < 10%. Data were
collected using a BioRad iMark plate reader and analyzed using Microplate Manager
Software.

5.2.5. Quantitative Polymerase Chain Reaction
Placenta samples (3-5mg) were minced with scissors in lysis buffer and Qiashredder spin
columns (Qiagen) prior to total RNA extraction according to the RNeasy Plus Micro kit
manufacturers’ specifications (Qiagen). Sample yield and purity was quantified by
absorbance at 260 and 280 nm (value 1.7-2) using a NanoDrop 2000c Spectrophotometer
(ThermoFisher Scientific, Mississauga, ON). Total RNA (<1 μg) was extracted and
reverse transcribed to cDNA using iScript Reverse Transcription Supermix (Bio-Rad
Laboratories, Hercules, CA, USA). Quantitative PCR (qPCR) experiments were
accomplished using the 2-ΔΔCT method after confirmation of parallel PCR amplification
efficiencies. The mRNA levels of apelin receptor and apela were quantified using the
TaqMan gene expression assay and the TaqMan Fast Advanced Master Mix (Invitrogen,
Carlsbad, CA, USA) with the following Taqman primers: apelin receptor
(Mm00442191_s1, Applied Biosystems, Forest City, CA, USA), apela
(Mm04278372_m1, Applied Biosystems), with Cyclophilin A (Mm02342429_g1,
Applied Biosystems) as the housekeeping gene. qPCR reactions were performed on
triplicate samples with 20ng cDNA added per reaction using the QuantStudio Design and
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Analysis Software. QuantStudio 5 Real-Time PCR System (Applied Biosystems) was
programmed with the following thermal-cycling profile: polymerase activation step at
95ºC for 20 seconds, followed by 40 cycles of denaturation at 95ºC for 3 seconds, and
annealing/extension at 60ºC for 30 seconds. Levels of mRNA expression were calculated
relative to those of the housekeeping gene cyclophilin A.

5.2.6. Statistical Analysis
Data are presented as mean ± SEM, with statistics analyzed using GraphPad Prism
software (Version 5.0). An unpaired two-tailed Student’s t test, one-way ANOVA or twoway ANOVA were applied according to the set of groups that were compared. A Tukey’s
post-hoc test or a Bonferroni post-hoc test was performed after one-way ANOVA or twoway ANOVA analysis, respectively. Each animal presented as a single unit of analysis
(n). n = 4 – 7 animals per treatment per timepoint. Statistical significance was determined
as P < 0.05.

5.3

Results

5.3.1. Artesunate treatment in mid-gestation and pregnancy
outcomes
Our hypothesis was that treatment with artesunate would improve glucose tolerance
during pregnancy, as was observed in previous studies in non-pregnant diabetic mice
[34]. We initiated these experiments by treating animals with artesunate in an acetone
vehicle via drinking water between GD8.5-14.5. Artesunate/acetone treatment caused a
reduction in weight gain (Supplemental Fig. 5.2A), food consumption (Supplemental Fig.
5.2B), and altered water consumption (Supplemental Fig. 5.2C) at the onset of treatment
compared to a non-treated animal. However, fetal resorptions were observed implicating
substantial embryonic lethality. Similar findings were observed in rats treated with
artemisinins during organogenesis [23]. Nonetheless, in this study embryolethality was

190

only observed during organogenesis and not when the rats were treated during
blastogenesis/pre-implantation (GD0.5-6.5) or during the fetal period (GD14.5-20.5).
Thus, subsequent experiments were modified to treat mice with the artesunate/acetone
intervention from GD0.5-6.5.

5.3.2. Artesunate treatment in early gestation and
pregnancy outcomes
Weight gain was significantly reduced in both artesunate/acetone and the acetone vehicle
group compared to non-treated animals (Fig. 5.2A). However, artesunate/acetone treated
animals had a higher food consumption relative to non-treated animals (Fig. 5.2B). Both
treatment groups drank an average of 4mL of solution a day during treatment (Fig. 5.2C),
which is comparable to values for non-treated mice of 3-4mL depending on body weight
[35]. There was no difference in the number of fetuses at GD18.5 (Fig. 5.2D). There were
no significant differences in placental weight (Fig. 5.2E) or fetal weight between
treatment groups at GD18.5 (Fig. 5.2F). However, artesunate/acetone treated animals
trended to weigh more compared to non-treated animals (P=0.0618).
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Figure 5.2. Pregnancy and model characteristics between treatment groups
A) Both treated groups gained less weight during pregnancy, and B) food consumption
was higher in artesunate/acetone treated animals. C) Water consumption did not differ
between treatment groups. There were no differences in (D) number of fetuses at
GD18.5, E) placental weight, or F) fetal weight between treatment groups. n = 4-6
animals per treatment group. *** P<0.001, * P<0.05, non-treated vs. treatment group. ##
P<0.01 non-treated vs. vehicle.
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5.3.3. Both artesunate-treated and acetone vehicle-treated
animals have improved glucose tolerance vs. non-treated
females
Animals in both the artesunate/acetone and acetone vehicle group had significantly lower
blood glucose levels at 5, 15 and 30 minutes during the IPGTT relative to non-treated
mice at GD18.5 (Fig. 5.3A). At 120 minutes, the acetone vehicle-treated mice had
significantly higher blood glucose levels compared to non-treated mice. Furthermore, the
area under the glucose tolerance curve was significantly lower in the acetone vehicle
group (Fig. 5.3B). IPGTT curves/glycemic curves were similar (as shown for those
groups at GD18.5), and not significantly different between the artesunate/acetone vehicle
and acetone vehicle alone for non-pregnant and PPD7.5 animals. This led us to postulate
that the acetone vehicle was primarily responsible for improved glucose tolerance.
Therefore, artesunate/acetone and acetone vehicles animals were pooled for further
analysis. Blood glucose levels were significantly lower in non-pregnant acetone-treated
animals compared to non-treated animals (Fig. 5.3C/D). Blood glucose levels were also
lower in acetone-treated animals compared to non-treated animals at PPD7.5 (Fig.
5.3E/F).
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Figure 5.3. Artesunate-treated and vehicle animals have improved glucose
tolerance vs. non-treated females
A) Artesunate/acetone and acetone vehicle-treated females had significantly reduced
blood glucose levels compared to non-treated animals at GD18.5. B) Area under the
glucose tolerance curve was significantly lower in acetone vehicle-treated animals vs.
non-treated LP females at GD18.5. Similar trends were observed in non-pregnant (C, D)
and PPD7.5 (E, F) animals. n = 4 animals at GD18.5 per treatment group, n = 4-7 animals
per treatment in non-pregnant and PPD7.5 animals. *** P <0.001, ** P<0.01, * P<0.05,
non-treated vs. treatment group. ## P<0.01, # P<0.05 non-treated vs. vehicle.
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5.3.4. Acetone treatment alters pancreas histology during
and after pregnancy
Again, there were no differences in BCM between artesunate and vehicle-treated animals,
thus data was combined. Beta-cell mass was significantly higher in non-pregnant
acetone-treated animals compared to non-treated animals (Fig. 5.4A). There were no
significant differences in ACM (Fig. 5.4B) or mean islet size (Fig. 5.4C) between
treatment groups over time. Islet sizes did not vary between treatment groups in nonpregnant (Fig. 5.4D) or GD18.5 (Fig. 5.4E) animals. However, acetone-treated animals at
PPD7.5 had significantly more medium and large-sized islets compared to non-treated
animals (Fig. 5.4F).
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Figure 5.4. Acetone treatment alters BCM in non-pregnant animals but not
during or after pregnancy
A) BCM, B) ACM, and C) mean islet size. Islet sizes did not differ in D) non-pregnant
or E) GD18.5 animals. F) However, there were more medium and large islets at PPD7.5
in treated animals. n = 4-8 animals per treatment group. * P <0.05, acetone-treated vs.
non-treated.
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5.3.5. Acetone treatment causes hyperglucagonemia
during and after pregnancy
Serum insulin and glucagon were quantified from blood collected via cardiac puncture at
the end of the IPGTT (120 mins). There were no significant differences in serum insulin
between treatment groups over time (Fig. 5.5A). However, serum glucagon levels were
significantly higher at GD18.5 and PPD7.5 in acetone-treated animals compared to nontreated animals (Fig. 5.5B). There were no significant differences in serum insulin to
glucagon ratio between treatment groups over time (Fig. 5.5C).
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Figure 5.5. Acetone treatment alters glucagon levels during and after pregnancy
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5.3.6. Acetone treatment increases bihormonal transitional
cell number in islets
To investigate a potential mechanism of new β-cells observed in non-pregnant acetonetreated animals, we quantified the percentage of Insulin+Glucagon+ (insulin and glucagon
double-positive, Fig. 5.6A/B) cells as a marker for α- to β-cell transitional cells [13,30–
32]. Acetone-treated non-pregnant animals had significantly more bihormonal cells
compared to non-treated animals (Fig. 5.6C). However, there were no significant
differences in the percentage of bihormonal cells between treatment groups at GD18.5 or
PPD7.5.
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Figure 5.6. Representative micrographs and quantification of bihormonal cells
A) Bihormonal (Insulin+Glucagon+) cell of a non-treated non-pregnant animal. B)
Bihormonal cell of an acetone-treated GD18.5 animal. C) Total percentage of
bihormonal cells relative to all insulin + cells. n = 5-8 animals per treatment group. ** P
<0.01, * P <0.05, acetone-treated vs. non-treated.
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5.3.7. Acetone treatment leads to increased expression of
the placental apelinergic system
To investigate a potential mechanism of improved glucose tolerance in pregnant acetonetreated animals, we analyzed the placenta, since placental weight was relatively higher in
acetone-treated animals and body weight was recovered in acetone-treated animals
despite reduced weight gain during treatment (Fig. 5.2E). Since the placenta secretes
apelin, and it is known to alter both β-cell number and function we looked at the
apeligneric system. Both APJ (Fig. 5.7A) and apela (Fig. 5.7B) mRNA levels were
significantly higher in acetone-treated animals compared to non-treated animals.
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Figure 5.7. Acetone treatment increases placental apelinergic system
Placental mRNA expression of both A) apelin receptor, and B) apela were
significantly higher in acetone-treated vs non-treated animals at GD18.5. The fold
change in expression was measured relative to housekeeping gene cyclophilin A. n = 5
non-treated animals and 4 acetone-treated animals. ** P<0.01, * P<0.05, acetone-treated
vs. non-treated.
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5.4

Discussion

GDM is associated with adverse health consequences for both the mother and her child,
implicating the need for an effective method of treatment. The initial experiments in this
study sought to treat mice with gestational glucose intolerance with the artemisinin,
artesunate via drinking water. Artemisinins have been shown to increase BCM via α- to
β-cell transdifferentiation and improve glucose homeostasis in non-pregnant animal
models of diabetes [19], although these findings are controversial and have been rebutted
by some studies [28,36]. Our experiments revealed a high consumption of artesunate
within drinking water and no indications of fetal resorptions to implicate embryolethality.
Nonetheless, the initial objective of testing artesunate was negated as we noted that
multiple parameters investigated in our study demonstrated similar findings between the
treatment group (artesunate diluted in the acetone vehicle) and the vehicle (acetone
alone). This led us to conclude that our findings could be primarily due to the use of the
acetone vehicle. Thus, we rejected our initial hypothesis and suggest that artesunate had
no effect on multiple parameters in this study, as compared to the vehicle alone.
Subsequently, we re-adjusted our focus to determine the effects of acetone on glucose
homeostasis and pancreas histology.
Weight gain was lower in acetone-treated animals during treatment, although body
weight recovered by the end of the experiment. Acetone-treated animals consumed a
comparable amount of food as non-treated animals, bringing into question whether there
could have been a transient effect of acetone on nutrient uptake via the villi in the small
intestine, resulting in reduced weight gain in treated animals. Although we did not collect
gastrointestinal tissues in our studies, other studies have found that acetone abolished
adhesion of F18-fimbriated (F18R) E. coli to isolated porcine intestinal villi in vitro,
concluding F18R was a glycolipid [37]. Since glycosphingolipids (GSL) are a major
component of intestinal enterocytes, it is possible that acetone could be breaking down
these villi and preventing nutrient absorption. In an animal model with genetic deletion of
the gene for the enzyme that catalyzes the initial step of GSL biosynthesis (Ugcg),
newborn mice presented with growth retardation and loss of body fat deposits, due to a
severe disturbance in uptake of nutrients [38]. The same study showed that adult mice
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presented with a drastic decrease in body weight, as was observed in animals in our study
during treatment with acetone. It was concluded that GSLs in the intestinal epithelium are
essential for intestinal endocytic function to effectively absorb nutrients. These findings
could provide an explanation for the reduced weight gain observed in acetone-treated
animals in our study at a time where food consumption was unchanged. It is worth noting
that reduced nutrient and glucose uptake for the time period of the treatment in our study
could mimic a situation of fasting, which has been suggested to have protective effects on
reducing oxidative stress and protects against many diseases in both rodents and humans
[39,40]. Intermittent or periodic fasting has also been shown to improve glucose tolerance
in part via adipose tissue remodeling [41,42], which could explain why glucose tolerance
was improved in non-pregnant, GD18.5 and PPD7.5 acetone-treated animals in our study.
Thus, acetone abolition of glycolipids on enterocytes could have affected nutrient
absorption, mimicking a situation of fasting which led to improved glucose tolerance in
the treated-mice in our study. It is important to note that the data for untreated controls
used in this chapter were retrieved from chapter 2 and 3. Thus, we acknowledge the use
of historical controls as a potential weakness in design which could be strengthened with
an additional group of untreated animals.
Next, we sought to investigate a mechanism of improved glucose tolerance in acetonetreated animals and investigated changes in endocrine pancreas. BCM was higher in nonpregnant acetone-treated animals but this did not correlate with higher serum insulin
levels. Serum glucagon levels were higher at the end of the IPGTT at both GD18.5 and
PPD7.5, despite no differences being observed in ACM. The high glucagon levels at
GD18.5 likely contributed to hyperglycemia in the acetone-treated animals compared to
non-treated animals at the end of the IPGTT. In contrast, there were no differences in
serum insulin levels at GD18.5 and PPD7.5. However, with the half-life of insulin being
relatively short (~4-6 minutes) in comparison to the time span of the IPGTT and blood
collection via cardiac puncture (~120 minutes), it is possible that there could have been
differences in serum insulin levels at earlier timepoints (0, 5, and 15 minutes) when
insulin secretion is highest (i.e. first phase insulin secretion). Indeed, analysis of the
IPGTT curves of acetone-treated animals might implicate improved insulin secretion, as
shown by the blunted blood glucose curve in response to the glucose bolus. Furthermore,
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the L-cells in the distal ileum and colon secrete glucagon-like peptide 1 (GLP-1), an
incretin hormone that is released in response to nutrient ingestion. GLP-1 increases
insulin secretion and inhibits glucagon secretion [43]. Thus, a mechanism for improved
glucose tolerance could also involve a regenerative response of the enteroendocrine cells
post acetone treatment, resulting in greater GLP-1 production and improved insulin
secretion. Therefore, acetone could be resulting in increased insulin secretion, although
improved insulin sensitivity in peripheral tissues also remains to be explored.
Interestingly, the finding of hyperglucagonemia at the end of the IPGTT at GD18.5 and
PPD7.5 was not observed in non-pregnant animals which was likely due to BCM being
higher and maintaining glucose homeostasis. There is much convincing data that α-cells
play an essential role in regulating insulin secretion from β-cells [44]. For example, one
study reported that insulin secretion was higher in response to glucose in paired α- and βcells compared to single β-cells alone [45]. Furthermore, it was shown that α-cells were a
target for serotonin in human islets, whereby β-cell-derived serotonin inhibited glucagon
secretion in high glucose conditions [46]. Since BCM was higher in non-pregnant
animals in our study, it is plausible that α-cells received an increased serotonergic input
from β-cells to regulate glucagon secretion. However, BCM did not increase in acetonetreated animals at GD18.5 and was lower than BCM levels observed in a healthy
pregnancy (~2mg). Thus, a potential explanation for the hyperglucagonemia observed at
GD18.5 could be due to decreased serotonergic input from β-cells, resulting in
hypersecretion of glucagon. Overall, these findings demonstrate the importance of the
sophisticated integrative islet communication between pancreatic endocrine cells in order
to effectively manage glucose homeostasis.
To investigate a potential mechanism for the generation of new β-cells resulting in an
increased BCM in non-pregnant acetone-treated animals, we quantified bihormonal
(insulin and glucagon double-positive) cells as a marker for possible α- to β-cell
transitional cells. There was an increased percentage of bihormonal cells in non-pregnant
acetone-treated animals compared with non-treated animals. Since the acetone ingestion
in our study may mimic a situation of short-term fast, these findings agree with those
observed following transient fasting where a greater number of transitional α- to β-cells
were observed upon re-feeding [47]. In these non-pregnant mice, transient fasting
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resulted in β-cell regeneration and rescue from type 1 and type 2 diabetes [47]. In this
study, non-pregnant animals were fasted for 4 days followed by up to 10 days of refeeding. This is comparable to our study where we postulate that the animals are fasted
for at most 6 days, dependent on the length of time required for acetone to destroy villi
and impair nutrient uptake.
In terms of pregnancy and fasting, clinical studies on the effects of fasting on pregnancy
outcomes are inconsistent. Some studies suggest that fasting during pregnancy results in
adverse fetal outcomes [48] and a higher incidence of developing GDM [49], while
others found no differences in pregnancy and fetal outcomes in fasting women [50–52].
A number of these studies also reported lower birth weight or intrauterine growth
restriction. However, in our study there were no indications of growth restriction in
acetone-treated animals. Therefore, because of the short duration of the treatment during
the first week of pregnancy it is plausible that deleterious effects would not be observed.
Nonetheless, to our knowledge, this has not been investigated in pregnancy in mouse and
we are the first to show a beneficial effect of a likely pathologically-induced functional
fasting in early gestation to improved glucose tolerance in mice with GDM at GD18.5
and glucose intolerance at PPD7.5 without adversely affecting fetal parameters.
Given that there were no differences in bihormonal cells or BCM in pregnant or lactating
animals to account for the improved glucose tolerance observed, we investigated if a
placental-specific mechanism might exist. To investigate a mechanism for improved
glucose tolerance in acetone-treated animals during and after pregnancy, we analyzed the
placenta for compensatory mechanisms since placental weight was relatively higher in
acetone-treated compared to non-treated animals. For example, previous studies have
shown increased deposition of glycogen in GDM placentas with the placenta acting as a
buffer for excess glucose and thereby lowering blood glucose levels in the mother [53].
Interestingly, the apelinergic system was shown to promote transplacental transport of
glucose from mother to fetus in rat dams injected intravenously with apelin-13 without
changes to the expression of placental glucose transporters Glut1 and Glut3 [54]. Rather,
it was reported that at mid to late gestation, apelinergic signaling increased vasodilation
of fetal arterioles and glucose transport to the fetus. In the present study, acetone-treated
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animals expressed increased placental apela and APJ at GD18.5 compared to non-treated
animals. Therefore, transfer of glucose from mother to fetus in our study could be
increased by the placental apelinergic system, resulting in improved glucose tolerance in
the mother. The trend of higher fetal weight in acetone-treated animals further supports
this hypothesis, as excess glucose is transferred to the fetus and subsequently stored in
fetal tissues. Apelin has been linked to placental growth and efficiency due to
observations that fetal apelin levels were reduced in studies with maternal food restriction
during gestation [54]. In the present study, high levels of apelingeric system in the
placenta could be responsible for the relatively larger placenta observed in acetone
compared to non-treated animals. Apelin has also been shown to be involved in the
regulation of food intake [55] and could explain the hyperphagia seen in acetone-treated
animals at late gestation (GD17.5). Interestingly, apelin is a beneficial adipokine with
anti-obesity and diabetic effects [55]. Despite reduced weight gain upon acetone
treatment, the treated animals in this study recover in body weight. The subsequent
hyperphagia could result in adipogenesis, and thus it could be insightful to determine
levels of apelin in adipocytes in future studies to investigate if apelin is also secreted
from adipocytes and causing an anti-diabetic effect in acetone-treated animals.
In conclusion, artesunate had no effect on multiple parameters investigated in this study.
However, acetone treatment improved glucose tolerance in non-pregnant, GD18.5 and
PPD7.5 LP-treated animals. In non-pregnant animals, improvements in glucose tolerance
were due to an increased BCM, possibly involving α- to β-cell conversion. However,
pregnant/lactating animals demonstrated overall improved glucose tolerance likely due to
compensatory mechanisms in the placenta involving upregulation of placental apelinergic
system, resulting in vasodilation and increased glucose transfer decreasing maternal
blood glucose levels, and/or better insulin release dynamics during an IPGTT. Our
findings provide a potential therapeutic glucose-lowering effect of acetone via mimicking
a situation of short-term fasting to improve glucose tolerance, including a model of
gestational glucose intolerance. Potential mechanisms include beneficial changes in
pancreas histology and placental function.
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Supplemental Figure 5.1. The effects of artesunate intervention in a DMSO vehicle
on a GD18.5 LP animal treated GD0.5-6.5
A) Weight gain was reduced in DMSO vehicle animals compared to non-treated animals.
B) Food consumption during treatment did not vary between treatment groups. C)
Treatment solution consumption in artesunate/DMSO was lower compared to non-treated
animals throughout gestation.
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6

Summary and Perspectives

6.1

Summary of Major Findings

GDM is an increasingly prevalent pathology in pregnancy that is associated with adverse
maternal and fetal health outcomes, necessitating the need for interventional strategies.
There is currently no reliable method of prevention for GDM. Thus, we sought to better
understand the mechanisms of impaired endocrine adaptability in GDM by creating a
mouse model that can be used to establish novel therapeutics.
We hypothesized that a dietary LP insult during early development in mice would impair
β-cell adaptability in pregnant offspring, resulting in glucose intolerance during
pregnancy, which could be reversed with treatment. Within this thesis, we addressed four
major objectives: first, we established a novel mouse model for study of suboptimal
endocrine adaptations during pregnancy. Using this model, we then determined the longterm effects of GDM following parturition and mechanisms of suboptimal endocrine
mass expansion. Finally, we used this model and our knowledge of impaired mechanisms
in GDM from our previous work to propose a therapeutic intervention for GDM through
the manipulation of BCM.

6.1.1 A mouse model of gestational glucose intolerance
through exposure to a low protein diet during fetal and
neonatal development
To implement targeted therapeutics, a better understanding of suboptimal endocrine
adaptations in GDM is needed. However, as pancreatic samples from GDM patients are
scarce, and no safe in vivo imaging modalities for endocrine cells in pregnancy exist at
the present time, initial experiments involved the development of a novel mouse model of
gestational glucose intolerance. This was accomplished using a dietary insult (LP diet)
during fetal and neonatal development, previously shown to program impaired endocrine
pancreas plasticity in offspring [1–3]. This model produced female offspring with glucose
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intolerance restricted to GD18.5, as is observed in late pregnancy in human GDM.
Glucose intolerance was attributed to reduced β-cell proliferation, leading to reduced
BCM expansion and GSIS at GD18.5 relative to a healthy pregnancy. We also presented
novel findings of reduced ACM at GD18.5 in glucose-intolerant mice, revealing the
significance of the often overlooked pancreatic α-cell population to glucose homeostasis
in GDM. A major strength of these findings was the ability to reproduce glucose
intolerance in pregnancy that was restricted to late gestation, as other animal models of
diabetes in pregnancy demonstrate pre-gestational obesity and/or diabetes [4–7], which is
not comparable to a diagnosis of clinical GDM [8].

6.1.2 Altered pancreas remodeling following glucose
intolerance in pregnancy in mice
GDM increases the risk of T2DM after parturition by up to 90% [9], yet no histological
data existed comparing endocrine pancreata after healthy and GDM pregnancies. Next,
we sought to use our animal model of gestational glucose intolerance to determine the
long-term effects of GDM on glucose tolerance and pancreas histology after pregnancy.
Analysis of pancreata at PPD7.5 revealed suboptimal pancreatic maladaptations in
glucose-intolerant mice that persisted from GD18.5, resulting in prolonged glucose
intolerance until 1 month postpartum. By 3 months postpartum, a compensatory increase
in the number of small islets and a higher insulin to glucagon ratio likely enable
euglycemia to be attained in the previously glucose-intolerant mice. Our findings
demonstrated long-term pancreatic re-modeling after parturition involving both α- and βcells, which were potentially associated with changes in the pro-inflammatory
environment. These findings are important to understanding the mechanisms involved in
the progression from GDM to T2DM after parturition.
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6.1.3 The increased alpha and beta cell mass during mouse
pregnancy is not dependent on transdifferentiation
It was evident that impaired endocrine adaptations during GDM were one of the key
determinants of glucose intolerance not only during pregnancy, but also after pregnancy,
resulting in long-term metabolic impairments. In order to prevent these adverse health
outcomes through therapeutic interventions, it is essential to target the underlying causes
of a suboptimal BCM in GDM. To provide some mechanistic insights of reduced BCM in
GDM, we looked at the contribution of α- to β-cell transdifferentiation to BCM in
pregnancy, and also α-cell plasticity in healthy vs. glucose-intolerant pregnancies. Alphacell proliferation was maximal at GD9.5 and resulted in increased ACM expansion at
GD18.5 in control animals, but this was reduced in glucose-intolerant (LP) mice.
However, LP mice displayed hyperglucagonemia at GD18.5 contributing to glucose
intolerance at late gestation in GDM. Notably, hyperglucagonemia has also been
observed in women with GDM which persisted after parturition, contributing to glucose
intolerance [10]. Although there were trends in bihormonal transitional
(Insulin+Glucagon+) cells in LP vs. control pregnancy, lineage tracing in control
pregnancy revealed a negligible amount of α- to β-cell transdifferentiation contributing to
BCM expansion. These findings further emphasized the importance of other islet cell
types, other than just β-cells, to glucose homeostasis in pregnancy, a subject area that has
previously been overlooked. Importantly, the dynamic changes in ACM that occurred
during normal pregnancy were altered in glucose-intolerant pregnancies, providing an
additional potential avenue for therapeutics by targeting hyperglucagonemia to reduce
hyperglycemia in pregnancy.

6.1.4 Strategies to improve glucose intolerance in
pregnancy
As the development of an effective intervention for GDM is clinically important, we
sought to explore the use of artemisinins, which have been shown to increase BCM and
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improve glucose tolerance in non-pregnant animal models of diabetes [11]. Importantly,
artemisinins are safe for use in pregnancy as they are used to treat women suffering from
malaria [12]. Glucose-intolerant animals were treated with the artemisinin, artesunate.
While an improved glucose tolerance was found in non-pregnant, GD18.5 and PPD7.5
animals, this was shown to primarily result from the use of the acetone vehicle. In nonpregnant acetone-treated animals, this was attributed to a higher BCM, possibly involving
α- to β-cell conversion. BCM did not differ between acetone-treated and non-treated
animals at GD18.5. Instead, glucose tolerance in pregnant animals was improved possibly
due to an upregulation of the placental apelingeric system [13], and/or improved insulin
secretion. Additionally, acetone-treated animals in these studies demonstrated reduced
weight gain during treatment despite unaltered food consumption. These findings could
implicate a transient state of fasting, which could additionally be contributing to
improvements in glucose tolerance through glucose uptake mechanisms in peripheral
tissues. Thus, transient fasting could be particularly beneficial in preventing glucose
intolerance during pregnancy.
Collectively, the data presented throughout this thesis implicate the importance of
endocrine adaptations to successfully counter relative maternal insulin resistance during
pregnancy. Although most research has focused on the importance of pancreatic β-cell
adaptation in pregnancy, we presented many findings revealing the role that pancreatic αcells simultaneously play in regulating glucose levels during pregnancy and demonstrated
how this is altered in GDM. Although a therapeutic potential of artemisinins was not
demonstrated, a mimicked state of fasting induced by dilute acetone treatment yielded a
potential therapeutic, glucose-lowering effect. Nonetheless, further research is needed
before the mechanisms of impaired endocrine adaptability presented in this thesis, and
therapeutic effects of acetone in GDM, can be transferred to a clinical setting.
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6.2

Limitations and Future Directions

The purpose of this section is to discuss some limitations of the experiments presented
throughout this thesis and discuss potential future experiments that can strengthen our
findings.

6.2.1 Use of animal models to study diabetes in pregnancy
in humans
The rationale for establishing an animal model of gestational glucose intolerance was due
to the very limited access to pregnant human pancreas samples, and samples from GDM
women would be even more scarce. Although having human samples would be preferred,
if samples were retrieved it would be highly likely that data from multiple gestational
timepoints would need to be combined which could lead to inaccurate conclusions if
time-specific physiological changes occur, as has been observed in mice. As such, studies
thus far have highly relied on animal models of diabetes in pregnancy. Although mice are
powerful models that recapitulate many aspects of human pregnancy, they are not
without limitations. For example, it is difficult to directly demonstrate the multi-factorial
nature of GDM pathogenesis in an animal (i.e. including both polygenetic and
environmental factors). Of relevance to the findings in this thesis are the differences in
the context of endocrine adaptations in humans compared to mice. The most
controversial studied difference between mouse and human pregnancy is in regard to βcell neogenesis and proliferation, as human β-cells are thought to rarely divide [14]. The
role of β-cell proliferation in human pregnancy is unclear, as the only study investigating
this phenomenon in humans showed a lack of replication from pre-existing β-cells [15].
However, these findings need to be taken with extreme caution, as samples were pooled
over multiple gestational timepoints potentially diluting an effect of proliferation
occurring in a timing-specific manner. Further contributing to a potential difference
regarding β-cell replication as a major driver of BCM expansion in mouse pregnancy is
the influence of lactogenic hormones to this process. In mice, strong evidence supports
that β-cell replication is driven by PRLR signaling [16]. However, human studies report
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conflicting results on the influence of lactogen treatment on mitogenic activity of β-cells
[17,18] which could be due to lower PRLR expression on human β-cells than in mice
[19]. Although it is premature to confirm that there are species differences in mechanisms
of pancreas adaptations in pregnancy based on a reliance of in vitro data, it is important
to acknowledge that studies support the presence of endocrine mass expansion in human
pregnancy [15,20]. Furthermore, both mouse and human gestation implicate β-cell
dysfunction and insulin resistance as a key driver to metabolic dysfunction in human and
animal models of diabetes in pregnancy [21]. Therefore, these findings provide strong
rationale for continued research efforts in this field.
An exciting methodology to deciphering these mechanisms would be non-invasive in
vivo imaging to monitor BCM in humans. Indeed, many sophisticated studies have
performed in vivo imaging of endogenous β-cells in humans and small and large animals
using positron emission tomograph (PET), single photo emission computed tomography
(SPECT) and magnetic resonance imaging (MRI) [22,23]. Each methodology presents
with both strengths and limitations in terms of resolution and sensitivity, and specificities
of radiotracers for β-cells. These studies are also limited by the small size and density of
β-cells relative to the remainder of the exocrine pancreas, and/or potential uptake of
tracers in peripheral tissues. Undeniably, important additional considerations in the
context of pregnancy would involve technical issues as pregnancy progresses and the
abdomen enlarges, as the pancreas is located deep in the abdomen. Furthermore, the
requirement for non-toxic contrast agents that are safe for the fetus are of paramount
importance. Thus, these considerations need to be elucidated in non-pregnant humans
first, before implementation can be safely suggested to pregnant women.
In conclusion, it remains to be investigated whether the maladaptations in endocrine
pancreas presented in this thesis occur in human GDM. As such, additional caution must
be considered before extrapolating data in mice directly to humans. Further studies would
need to be performed in a clinical setting to elucidate whether these mechanisms could
provide new therapeutic opportunities to promote generation of new β-cells.
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6.2.2 Influence of cytokines to β-cell dysfunction after GDM
Cytokines released from adipose tissue and from placenta influence metabolism during
pregnancy, which often becomes dysregulated in GDM. GDM is characterized as an
inflammatory state [24–26] which can impact successful β-cell adaptation during
pregnancy. Imbalanced levels of cytokines can contribute to glucose intolerance in GDM
by contributing to β-cell dysfunction [27,28] and insulin resistance via impaired insulin
receptor signaling [29,30]. We showed that increased levels of the pro-inflammatory
cytokine, IL-6, in adipose tissue could have contributed to glucose intolerance after
parturition in GDM mice (Chapter 3). Since cytokines can act in a paracrine/autocrine
manner, it would have also been valuable to measure levels of cytokines in the pancreas
in order to elucidate if there was a local effect on the histomorphometric changes
observed in fixed pancreas sections. Some preliminary qPCR experiments were
performed in whole pancreas preparations; however, most values were below the levels
of detection. Cytokines in serum samples were also quantified, but most samples were
also below the levels of detection. In order to draw more precise conclusions, future
experiments could quantify cytokines in isolated islets at postpartum, as levels of
cytokines could be diluted by exocrine pancreas in whole pancreas samples since the
endocrine portion only compromises 2% of the pancreas. Importantly, IL-6 has been
shown to be involved in α-cell growth and function in rat neonates during suckling [31].
In the context of the LP model, undernourished rat neonates had impaired glucagon
production and secretion. However, there could be species differences and these findings
could differ in adult mice, such as the animals used in the present study. Nonetheless,
these experiments further reinforce the importance of elucidating the impact cytokines,
and specifically IL-6, on the endocrine pancreas in LP compared to control-diet exposed
mice. It is also important to consider that the animal model of gestational glucose
intolerance presented in this thesis presents with only a mild glucose intolerance. Thus, it
is also plausible that these animals present with a mild pro-inflammatory state and
therefore we might not anticipate observing elevated levels of pro-inflammatory
cytokines in the pancreas implicating a potentially negligible effect on pancreatic
endocrine cells in our model. Therefore, the low cytokine values in both serum and
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pancreas samples could simply implicate a low level of inflammation in our model of
GDM.

6.2.3 Discovering the contribution of non-β-cell endocrine
cells in pregnancy
Despite the significant influence that pancreatic α-cells have on regulating glucose
homeostasis by working antagonistically with β-cells, very little was known about the
contribution of these cells in pregnancy. We investigated α-cell plasticity in healthy
pregnancies and concluded that α- to β-cell transdifferentiation was negligible. However,
it is important to acknowledge that the amount of β-cell loss can influence the extent of
α- to β-cell transdifferentiation. Previous studies have reported that with mild β-cell
ablation, less α-cell reprogramming occurred, and near-total β-cell ablation was required
to trigger reprogramming [32]. In the case of the healthy animals in our study, there was
no loss of β-cells, rather an adaptive increase in BCM expansion was observed in
pregnancy. Therefore, the metabolic stress of pregnancy was likely insufficient to trigger
reprogramming of α-cells and without the stressor of β-cell loss, α- to β-cell
transdifferentiation will likely not occur. Nevertheless, it is plausible that in a situation of
higher metabolic stress in pregnancy, such as in GDM, α- to β-cell transdifferentiation
could occur. In our animal model of gestational glucose intolerance, we observed a ~50%
reduction of BCM (Chapter 2). These findings provide rationale for genetic tagging of
α-cells to provide mechanistic insights into whether α- to β-cell transdifferentiation could
be occurring as a compensatory mechanism in GDM pregnancies with mild
hyperglycemia. These studies would involve the combination of our established animal
model of gestational glucose intolerance via dietary LP insult (Chapter 2) and transgenic
Gcg-Cre/YFP mice (Chapter 4). Although BCM was reduced in GDM compared to a
control, β-cell proliferation was also reduced. Thus, α- to β-cell transdifferentiation could
be occurring at a larger scale in GDM mice than in controls to contribute to the
suboptimal BCM expansion that was still higher than in a non-pregnant animal.
At the same time, it is important to consider that our animal model of gestational glucose
intolerance presented with only a mild glucose intolerance, which might not pose a high
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enough metabolic stress to trigger conversion of α-cells into β-cells. Pregnancies with an
additional metabolic stress, such as in obese mothers, are an example of where there
could be a high enough metabolic stress to trigger transdifferentiation. Although, some of
these models are limited by the presence of pre-gestational glucose intolerance [7]. An
additional experiment that could be performed in subsequent studies would involve
treating LP mice with a mild STZ intervention before mating, to only partially reduce
BCM. This could theoretically ensure that glucose tolerance is maintained before mating
and in early pregnancy. Additionally, future examination of subsequent pregnancies using
our model could also provide an additional metabolic stress to trigger α- to β-cell
transdifferentiation. GDM recurs in an estimated 30-69% of subsequent pregnancies
following a pregnancy with GDM [33]. In our animal model of gestational glucose
intolerance, glucose intolerance persisted until 1 month postpartum and normalized by 3
months postpartum (Chapter 3). Nonetheless, it is plausible that an additional metabolic
stress such as a second pregnancy, could pose a large enough metabolic demand on the βcells, triggering α- to β-cell transdifferentiation. Our findings provide a strong rationale
for investigating a subsequent pregnancy, as we identified that α-cell fractional area was
lower at 3 months postpartum in control diet mice relative to a non-pregnant animal.
These findings prompt interesting considerations as to whether an adaptive expansion of
ACM would occur in a subsequent pregnancy, or if perhaps the α-cell reservoir would be
fully depleted after the first pregnancy. The investigation of subsequent pregnancies
would be an invaluable area of future study. Bihormonal cells (Insulin+Glucagon+) have
been identified in human pancreas sections, where it was reported that de-differentiation
of β-cells into α-cells contributed to loss of BCM in patients with T2DM [34]. These
findings suggest endocrine plasticity is possible in humans, however further studies are
required to elucidate this in humans, which is limited with lineage tracing technology.
As our studies showed the critical contribution of pancreatic α-cells to endocrine
adaptations in pregnancy, especially in the context of maladaptations of α-cells
contributing to hyperglycemia in GDM, these findings provide a strong rationale to
investigate additional endocrine islet cell types. An additional mechanism that could be
contributing to hyperglucagonemia in GDM and would be worth exploring in future
studies would be to assess -cell function. Eloquent studies have started to reveal the
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precise mechanisms of somatostatin secretion from -cells, as was previously discussed
(Chapter 1) [35–37]. It is postulated that defective somatostatin secretion can occur in
diabetes [36]. Indeed, a recent study showed that reduced -cell function resulted in
reduced inhibition of insulin and glucagon secretion, contributing to hyperglucagonemia
in mice fed a high fat diet [38]. In pregnant mice, a novel contribution for -cells in early
compensatory adaptations during pregnancy was also suggested [39]. Delta-cells were
shown to reprogram to a β-cell identity, increasing insulin secretion to counter relative
insulin resistance in pregnancy, mediated via less somatostatin-mediated inhibition.
Therefore, it would be interesting to investigate whether this process is altered in GDM
pregnancies using our animal model of gestational glucose intolerance. Maladaptations in
-cells in GDM could be possible, contributing to reduced GSIS or hyperglucagonemia,
however further studies are required to elucidate this. Evidently, continued research
efforts to elucidate the integrative communication between multiple endocrine islet cell
types in pregnancy are important, as the pathology of hyperglycemia in GDM could be
much more complex than initially presumed if multiple endocrine cell types are involved.

6.2.4 Reversing glucose intolerance in pregnancy
Our findings in animals treated with artesunate/acetone present convincing data that the
acetone vehicle was responsible for improvements in glucose tolerance. Although we
posit some mechanistic insights to these improvements (Chapter 5), definitive
mechanisms underlying the improved glucose tolerance remain elusive. As we postulate
that acetone could be impairing nutrient intake in intestinal villi, subsequent studies
examining histology or nutrient uptake of enterocytes would be of value to provide more
precise conclusions about whether nutrient intake is indeed impaired. If proven to be true,
these findings would provide strong evidence that a transient fast-mimicking situation
could be contributing to improved glucose tolerance in our study. Because the IPGTT
curve is drastically improved in acetone-treated animals, as shown by significantly
reduced areas under the curve (Chapter 5), it would also be important to collect blood
samples from animals at earlier timepoints during the IPGTT to assess if there is
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improved insulin secretion. Finally, should acetone impair nutrient intake in enterocytes,
it would be essential to follow animals to a longer time post-treatment to ensure longterm safety of this compound. Assessment of peripheral tissues could also prove
insightful to assess for potential effects of toxicity. Moreover, long-term effects of
acetone exposure in utero on parameters of health in the offspring, and even
transgenerational effects, would be of interest to elucidate the safety of this compound in
pregnancy.

6.3

Concluding Remarks

β-cell dysfunction has been described as a major driver of GDM, although based on the
data presented in this thesis, the importance of α-cells has also come to light. Evidently,
effective regulation of glucose homeostasis relies on sophisticated communication
amongst both of these endocrine cell types. As such, effective treatments for GDM
regulating both hormones could be pertinent. In summary, the work presented in this
thesis advances our understanding of mechanisms involved in suboptimal endocrine
adaptability and glucose intolerance in pregnancy (Fig. 6.1). While we were limited by
the lack of GDM human pancreas samples for experimentation, the development of
sophisticated endocrine pancreas imaging modalities to provide non-invasive monitoring
of BCM/ACM in GDM would be essential to validate our findings. For the time being,
the animal model and mechanisms explored in this thesis could lay the groundwork for
evaluating new therapeutic opportunities to safely prevent and/or treat glucose
intolerance in GDM.
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Figure 6.1. Summary of endocrine adaptations in a healthy pregnancy and
maladaptations in GDM
A) Healthy Pregnancy: Alpha and BCM expansion occurred in response to increased
insulin demand during the insulin resistant state of pregnancy. Endocrine mass expansion
occurred due to increased replication of both α- and β-cells. Euglycemia was maintained
during insulin resistance due to increased endocrine mass and increased insulin secretion.
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There was a negligible contribution of α- to β-cell transdifferentiation to BCM expansion
during pregnancy.
B) GDM Pregnancy: i). Both reduced α- and β-cell replication contributed to reduced
ACM and BCM expansion. Insufficient compensatory endocrine adaptations, including
decreased insulin secretion, led to glucose intolerance at late gestation which persisted
until 1 month postpartum. Hyperglucagonemia also contributed to glucose intolerance at
late gestation. The role of α- to β-cell transdifferentiation in GDM pregnancy remains to
be determined via lineage tracing of α-cells during pregnancy.
ii). Treatment with acetone improved glucose tolerance at late gestation without
increasing BCM, although these animals presented with hyperglucagonemia.
Improvements in glucose tolerance persisted until 1 week postpartum. It remains to be
determined whether nutrient uptake is reduced in intestinal villi, mimicking a transient
state of fast, and/or whether insulin secretion is increased.
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Appendix A 2. Animal Use Protocol Ethics Approval: Transgenics and Artemisinin Study

AUP Number: 2018-027
PI Name: Arany, Edith
AUP Title: Control of regeneration in the endocrine pancreas
Approval Date: 12/01/2018
Official Notice of Animal Care Committee (ACC) Approval:
Your new Animal Use Protocol (AUP) 2018-027:1: entitled " Control of
regeneration in the endocrine pancreas"
has been APPROVED by the Animal Care Committee of the University Council
on Animal Care. This approval, although valid for up to four years, is subject
to annual Protocol Renewal.
Prior to commencing animal work, please review your AUP with your
research team to ensure full understanding by everyone listed within this
AUP.
As per your declaration within this approved AUP, you are obligated to
ensure that:
1) Animals used in this research project will be cared for in alignment
with:
a) Western's Senate MAPPs 7.12, 7.10, and 7.15
http://www.uwo.ca/univsec/policies_procedures/research.html
b) University Council on Animal Care Policies and related
Animal Care Committee procedures
http://uwo.ca/research/services/animalethics/animal_care_and_use_policies
.htm
2) As per UCAC's Animal Use Protocols Policy,
a) this AUP accurately represents intended animal use;
b) external approvals associated with this AUP, including
permits and scientific/departmental peer approvals, are complete and
accurate;
c) any divergence from this AUP will not be undertaken until
the related Protocol Modification is approved by the ACC; and
d) AUP form submissions - Annual Protocol Renewals and Full
AUP Renewals - will be submitted and attended to within timeframes
outlined by the ACC.
e)
http://uwo.ca/research/services/animalethics/animal_use_protocols.html
3) As per MAPP 7.10 all individuals listed within this AUP as having any
hands-on animal contact will
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a) be made familiar with and have direct access to this AUP;
b) complete all required CCAC mandatory training
(training@uwo.ca); and
c) be overseen by me to ensure appropriate care and use of
animals.
4) As per MAPP 7.15,
a) Practice will align with approved AUP elements;
b) Unrestricted access to all animal areas will be given to ACVS
Veterinarians and ACC Leaders;
c) UCAC policies and related ACC procedures will be followed,
including but not limited to:
i) Research Animal Procurement
ii) Animal Care and Use Records
iii) Sick Animal Response
iv) Continuing Care Visits
5) As per institutional OH&S policies, all individuals listed within this AUP
who will be using or potentially exposed to
hazardous materials will have completed in advance the appropriate
institutional OH&S training, facility-level training, and reviewed related
(M)SDS Sheets,
http://www.uwo.ca/hr/learning/required/index.html
Submitted by: Copeman, Laura
on behalf of the Animal Care Committee
University Council on Animal Care
AUC Chair Signature
Dr.Timothy Regnault,
Animal Care Committee Chair
The University of Western Ontario
Animal Care Committee / University Council on Animal Care
London, Ontario Canada N6A 5C1
519-661-2111 x 88792 Fax 519-661-2028
[auspc@uwo.ca]auspc@uwo.ca ï¿½
http://www.uwo.ca/research/services/animalethics/index.html
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Appendix A 6. Permission to reproduce Figure 1.1.
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Appendix A 7. Permission to reproduce Figure 1.3.
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Appendix A 8. Permission to reproduce Figure 1.4.
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